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GENERAL INTRODUCTION 
 
 
 
SUMMARY 
This thesis deals with new insights on the role of  tumor suppressor proteins p53, p16, and 
p14 in (pre)malignant epidermal tumors of renal transplant recipients (RTRs) and 
immunocompetent individuals (ICIs).  Expression of these tumor suppressor proteins in 
relation to important etiologic factors in cutaneous carcinogenesis, such as sun exposure, 
immune status, and Human Papilloma Virus are studied in epidermal skin tumors of both 
patient groups.  Furthermore, the use of mutation analysis for p53 and INK4a-ARF is 
investigated in case of multiple primaries in patients with metastatic cutaneous squamous 
cell carcinoma.  
The last part of the thesis deals with systemic retinoid treatment in skin (pre)cancer in RTRs. 
Retinoids are known to influence proliferation and differentiation.  The effects of systemic 
retinoids on expression of  markers for differentiation, proliferation and tumor suppressor 
protein expression are studied in these transplant recipients. 
The introduction comprises a review on cutaneous squamous cell carcinogenesis in renal 
transplant recipients,  and on the role of the tumor suppressors p53 and INK4a-ARF in 
cutaneous  carcinogenesis.  The main features of systemic retinoid treatment in skin 
malignancies will be reviewed. 
These three topics will each be discussed in a separate part of the introduction. 
 
 PART I 
 
SQUAMOUS CELL CARCINOGENESIS IN 
RENAL TRANSPLANT RECIPIENTS 
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1.1.1 
Introduction 
 
Transplant recipients have an increased incidence of cancers that arise de novo after 
transplantation.  The prevalence in several large series ranges from 4% to 18%, with an 
average of 6% 149. 
In transplant recipients a variety of uncommon tumors, such as Kaposi sarcoma, occurs 
which are seldom encountered in the general population.  Of the malignancies that are also 
frequently seen in the general population, cancers of the skin and lips are the most commonly 
encountered de novo cancers in organ allograft recipients comprising 37% of all newly 
presented tumors.  Within the group of organ allograft recipients, the largest group of patients 
is formed by renal transplant recipients (RTRs).  Since the incidence of skin cancer increases 
with the number of years after transplantation, skin cancers are especially a problem in these 
RTRs because of their longer survival after transplantation when compared to for instance 
heart transplant recipients.  
At present, RTRs account for a still growing patient population visiting the dermatology 
department and attribute significantly to the workload for the dermatopathologist in hospitals, 
harboring a renal transplantation center.  The multiplicity of skin cancers in these patients, 
their more aggressive behavior and also the difficulties in clinical assessment of skin lesions 
in these RTRs leads to frequent and often multiple biopsies of clinically suspect skin lesions.  
Several  large epidemiological studies have been performed in the past which all implicate  
sun exposition, immunosuppressive treatment, and Human Papilloma virus as important 
etiological factors.  However, until now, the exact mechanism for the enhanced cutaneous 
carcinogenesis in this specific patient group is still unknown. 
Histopathological, immunohistochemical and molecular pathological studies of skin lesions 
in RTRs can be expected to yield important mechanistical information on the pathogenesis of 
skin cancer in these patients.  
In this part, the epidemiology and etiology of skin (pre)cancer in RTRs will be addressed, 
with focus on squamous cell neoplasia. 
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1.1.2 
Epidemiology of skin cancer in RTRs 
 
Warts and keratotic lesions are the most frequently encountered epithelial neoplasms in RTRs 
30; they affect up to 48% to 100% of the renal transplant recipients 5,6,8,50,171 and are localized 
on sun-exposed areas, such as the face, forearms and back of the hands. When compared to 
the general population the warts are more numerous and more resistant to therapy.  RTRs 
with high sun exposure are found to have significantly more warts than those with normal sun 
exposure 30. The incidence of warts increases with time after transplantation; Barr et al. found 
warts in 20% of RTRs with graft survival below 5 years, compared to 77% in patients with 
graft survival of 5 years or more.  Bouwes Bavinck et al. found a comparable mean interval 
from transplantation to the development of warts of  6.6+/-3.6 years.  Warts preceded the 
development  of the first skin cancers by 2-3 years 8.  Ramsay et al. found presence and large 
number of viral warts associated with SCCs risk and numbers 154 
Figures on the incidence of actinic keratoses (AKs) in renal transplant recipients are scarce 
and most are based on relatively small groups of RTRs with diagnosis of AK often only 
based on clinical grounds without histological confirmation.  Boyle reported an incidence of 
AKs of 7.4% in 94 RTRs with lesions being confined to recipients with a previous history of 
high sun exposure 30; Seckin described an incidence of 5% for AKs in 80 RTRs 171; in both 
studies there was a short mean follow-up period of less than 5 years. Barr et al. found up to 
38% keratoses in RTRs with graft survival above 5 years, although they often experienced  
difficulties in clinically separating keratoses and viral warts 6.  
In the past 3 decades several often large retrospective studies16,26,82,86,94,117,154,210 and reviews 
11,50,60,64,111 on the incidence and pathogenesis of skin cancer in RTRs and organ transplant 
recipients have been performed and published (Table 1A).  
These studies and reviews yield the following features characteristic for cutaneous 
carcinogenesis in RTRs: 
1. There is an increase in the overall incidence of skin cancer, both squamous cell carcinoma 
(SCC) and basal cell carcinoma (BCC), when compared to the general population, in organ 
and renal transplant recipients. 
2. The increase in incidence of SCC by far outnumbers the increase  in BCCs, and as a 
consequence a reversal of the BCC:SCC ratio is seen, varying from 2:1 to 3:1,when 
compared to the general population in which BCCs outnumber SCCs by a ratio of 5:1 64,149. 
The relative risk of developing carcinomas seems to increase linear for BCCs, and 
exponentially for SCCs 210. 
3. The overall risk to develop skin cancer  increases with time after transplantation, affecting 
half of the patients within 20 years posttransplantation 26,64,210. In the Netherlands, a 770-fold 
rise of incidence of SCC was found in RTRs with more than 15 years graft survival, while the 
risk in the group of RTRs as a whole was 250-fold increased compared to the general 
population 82. 
4. SCCs in RTRs tend to be multiple.  About half of the patients have more than one SCC and 
one third also has BCCs 63. Carcinomas are usually associated with warts, premalignant 
keratoses, Bowen’s disease and keratoacanthomas 179. 
5. SCCs are more aggressive than in non immunosuppressed patients.  In 12% local 
recurrences and in 8% metastatic disease occur 64. The primary site of metastasis is the lymph 
node, as in the general population 125. 
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6. The distribution of SCCs differs considerably from that of BCCs. SCCs occur on sun-
exposed areas with a preference for the backs of the hands and the face, while BCCs 
frequently occur on the upper chest but not on the back of the hands 82 
7. There is a strong race effect with series from Western countries only mentioning Caucasian 
recipients being at risk for developing non-melanoma skin cancer (NMSC) after 
transplantation 77,210. 
8.Transplant recipients are affected by NMSCs at an average age 30 years below that of the 
general population in which NMSCs mainly occur in people in their 60s and 70s 149. 
9. The percentage of transplant recipients with skin cancer increases with decreasing latitude.  
In Australia 45% develop skin cancer within 10 years after transplantation, compared to 10-
15% in for instance the Netherlands 82. 
The  number of patients with premalignant and malignant epidermal cutaneous neoplasms 
shows considerable variation between the studies listed in Table 1A.  This is attributable to 
differences in mean follow-up of patients, variability in the UVB exposure of the investigated 
populations, changes in long term immunosuppressive therapy, rejection treatment, and in 
development in  HLA-matching of donors with recipients.  The latter three factors can be 
expected to have a continuing impact on the skin cancer incidence in these patients and 
demand up-to-date cancer registration in RTRs. 
 
In conclusion, these epidemiological data indicate that skin problems and especially skin 
cancer is a major cause of morbidity and even mortality in the population of RTRs. Insight 
into the pathogenesis of the enhanced cutaneous carcinogenesis in these patients might 
attribute to better future preventive and therapeutically treatment modalities. 
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1.1.3 
Etiological and risk factors of skin cancer in RTRs 
 
1.1.3.1 Sunlight and UVB exposure 
 
Epidemiologic evidence  
Exposure to sunlight is believed to be one of the most important risk factors for the 
development of both warts and skin cancers in RTRs as suggested by the location of warts 
and carcinoma on sun-exposed areas of Caucasian transplant recipients 6,30,82,133. In the non-
immunosuppressed population sunlight is also a major factor in the development of non 
melanoma skin cancers, but in contrast to renal recipients, relation between sunlight exposure 
and development of warts in immunocompetents has not been reported. 
Several investigators have compared the incidence of skin cancer in transplant recipients with 
high and low sun exposure and they all showed an increase of  skin cancer in the first. For 
instance, Bouwes Bavinck et al. reported a relative risk of 4.3 for developing skin cancer after 
renal transplantation in Queensland, Australia, when compared with the Netherlands: after 20 
years of immunosuppression in the Australian cohort the cumulative skin cancer incidence 
increased to  70%, while in the Dutch patients the incidence 20 years post-transplantation 
increased to 41% 26,82. In the Dutch population 97% of the SCCs occurred on sun-exposed 
areas of the skin. In another separate study in Dutch renal transplant recipients, exposure to 
sunlight before the age of 30 was found to contribute more to the risk of skin cancer 
development  than exposure after the age of 30 8. Barr et al. studied  202 renal allograft 
recipients in Scotland and in all but 1 of the 10 recipients with skin cancer, sun exposure was 
high. Furthermore all cancers occurred on sun-exposed skin 6. 
Boyle et al. reported only AKs and SCCs in RTRs with a history of high sun exposure 30. 
 
 Mutagenic effects of ultraviolet radiation 
Skin cancers are due to a complex of simultaneous and sequential biochemical events, 
caused, and promoted by UV-radiation of varying wave length (UVB 280-320nm, UVA 320-
400nm, and perhaps visible light and infrared).  These radiations produce DNA lesions, that 
may if not repaired lead to mutations in proto-oncogenes and tumor suppressor genes 168.  
UVA gives rise to lesions probably by production of oxygen activated species (ROS), while 
UVB (main factor in sun exposure) is directly absorbed by DNA. 
UVB exposure induces predominantly DNA lesions between two adjacent pyrimidine bases 
(TT, CT, TC, CC) on the same DNA strand, forming essential 2 mutagenic dimers 
(cyclobutane-pyrimidine dimers and (6-4) pyrimidine-pyrimidones) between these bases, that 
give rise to mutations mainly characterized by C to T or CC to TT transitions always located 
at the sites of pyrimidine-pyrimidine sequences 42,54,168.  These mutations are now considered 
as a true signature of sun exposure.  The CC to TT tandem transitions is absolutely specific of 
UV radiation. 
The pyrimidine dimers caused by solar DNA damage, can enzymatically be repaired by 
nucleotide excision repair (NER) 74,168.  Xeroderma Pigmentosum (XP) patients lack this type 
of repair and have a strongly increased risk of skin cancers 42.  
UV-type mutations have been found in for instance p53, more recently in INK4A-ARF, ras 
oncogenes, and PTCH tumor suppressor genes 74,168,219.  The first two will be discussed in 
more detail in PART II of this thesis. 
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In NMSC the p53 gene appears to bear point mutations with features of UVB induced 
mutations, i.e., association with di-pyrimidinic sites, mostly C to T transitions and 5-10% CC 
to TT tandem mutations 42.  
Giglia-Mari et al. analyzed mutational hot spots in skin cancers, malignant melanomas, and 
NMSCs.  One hot spot was common to all skin cancers, the Arg248.  In skin SCCs a hot spot 
at codon 278 seems specific 74.  
 
Immunosuppressive effects of UV 
Ultraviolet radiation might predispose to skin cancer by down regulation of local immune 
response of the skin.  Langerhans’ cells (LCs) are a major component of the skin’s immune 
system.  They are a population of antigen presenting cells that recognize and transport 
antigen to the local lymph node where it is presented in a processed form to antigen specific 
T-lymphocytes and it has been suggested that they participate in immune response to viral 
and tumor antigens 156.  The skin must have an adequate density of Langerhans’ cells 
otherwise an immune response is not generated. 
As reviewed by Meunier, UVB has been shown to deplete epidermal Langerhans’ cells 135.  
After severe sunburn, LCs are replaced by circulating bone marrow derived precursors and by 
DCs migrating from hair follicles that have a partial deficiency of molecules important for T 
cell costimulation.  
Mechanisms underlying the LC depletion after UVB radiation are still unknown.  Chronic 
UVB radiation may cause deficiency of growth factors for LCs or abrogate cytokine 
responsiveness of DCs by down regulating the expression of surface receptors for growth 
factors.  UVB radiation may trigger apoptosis of resident epidermal LCs, or cause LCs to 
migrate to the lymph node.  UVB irradiation of human LCs decreases their capacity to induce 
proliferation of CD4 and CD8 T cells.  Furthermore UVB inhibits the antigen presenting 
capacity of LCs by interfering with antigen processing 135 
Some investigators found marked depletion of Langerhans’ cells in benign, premalignant and 
malignant skin lesions of RTRs when compared to normal skin 72, although no significant 
differences in Langerhans’ cell numbers could be demonstrated between normal skin of 
RTRs and immunocompetent controls.  
Galvao et al. found in transplant recipients a decrease in CD4 and CD8 positive T 
lymphocytes in exposed and non-sun exposed skin in the subset of the RTRs with a long 
interval post-transplantation 69.  In RTRs the CD1a+ dermal cells were reduced in sun-
protected skin, and the CD1a epidermal cells were reduced in number and had small 
dendrites in sun-exposed skin, when compared to controls 69.  
 
In conclusion, both epidemiologic data as well as molecular data on UV type mutations in 
skin cancers indicate that sun exposition is a major factor in the development of skin cancer 
in both RTRs and ICIs.  In addition UVB might act carcinogenic by lowering local skin 
immunity by causing Langerhans’ cell depletion. 
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1.1.3.2 Immunosuppressive treatment 
 
Immunosuppression can increase carcinogenesis by direct carcinogenic effect of the 
immunosuppressive agents, or by creating a state of decreased immune surveillance and 
insufficient eradication of malignant cells.  Direct carcinogenic effects are reported for 
azathioprine and cyclosporine as reviewed by Berg et al 11.  
Clinical studies comparing azathioprine and cyclosporine based regimens yield conflicting 
results with respect to effects on skin cancer incidence.  Some report greater proportion of 
skin cancers among azathioprine–treated patients, explained by its photosensitizing effects 
11,150,154,181, while others found no differences 95, or a reduced risk compared to regimen which 
included cyclosporine 159.  Studies on newer medications such as tacrolimus suggest that the 
skin cancer risk continues to exist, but need to be established in the future since skin cancers 
take several years after transplantation to develop 11. 
The incidence of skin cancer is correlated to immunosuppression levels.  
Comparative epidemiologic study of premalignant and malignant epithelial neoplasia in 
kidney and heart transplant recipients implicate that the effects of immunosuppressive 
treatment are dosage dependent.  Heart transplant recipients, who generally receive higher 
levels of immunosuppression, develop skin cancers earlier after transplantation and at a 2-3-
fold higher rate when compared to RTRs 63. 
Several studies have shown that patients on triple or multi-drug therapy have a higher 
cumulative risk for developing SCC than RTRs on double therapy 86,94,212.  
A 5–year randomized, prospective study showed that low-dose cyclosporine regimen was 
associated with fewer malignant disorders, though rejections were more frequent 41.  
 
In conclusion, skin cancer rate in RTRs is influenced by type and degree of 
immunosuppressive treatment.  The continuing development in immunosuppressive treatment 
modalities, can expect to have impact on skin cancer development in these patients.  Search 
for immunosuppressive treatment, which causes less secondary tumor development post 
transplantation, is of great importance for the group of RTRs being at risk for morbidity and 
mortality due to these secondary cancers. 
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1.1.3.3 Human Papilloma virus 
 
Virology and Pathology of HPV infection  
Human Papilloma viruses (HPVs) are increasingly recognized as pathogens in the 
development of specific human cancers.  For instance, HPV is strongly implicated in the 
development of human uterine cervical cancer 53,85,192.  HPVs are non-enveloped, double 
stranded DNA viruses.  Molecular cloning of viral nucleic acids and more recently 
polymerase chain reaction (PCR) amplification and sequencing have demonstrated that 
multiple HPV types exist with more than 100 HPV types now described 151,192.  HPVs can be 
classified on the base of specific tissue tropism, resulting in two main HPV groups: cutaneous 
and mucosal 151,192,201.  The cutaneous HPVs are found in cutaneous warts (HPV-1 in plantar 
warts and HPV-2 and 4 in common warts), and there is a large group of 20 or more HPV 
types that are associated with the rare disease Epidermodysplasia Verruciformis (EV), 
namely HPV types 5,8,9,12,14,15,19-25,36-38 and 47) 25.  The mucosal HPVs predominate 
in cervical and anogenital lesions, like condylomata accuminata, and are broadly classified 
into those with a low risk (HPV-6 and 11 predominantly) and those with a moderate-to-high 
risk for cancer development (HPV-16 and 18) 85,192. 
All HPVs contain 2 functional groups of genes, the early genes that function primarily in 
episomal replication (E1 to E7) and late (L1 and L2) genes that encode the viral capside 
proteins 4,36,85. 
HPVs are strongly epitheliotropic viruses and can be found in all human squamous epithelia 
and only basal replicating cells can be infected by HPVs. How the virus gains access to basal 
epithelial cells is not known and a viral receptor on host cells has not been identified to date, 
though recent data suggest that integrin complexes containing 6 integrin complexed with 
either 1 or  4 integrins may act as a receptor for papillomavirus binding and entry in 
epithelial cells65.  
Interestingly, although host-cell infection must occur in undifferentiated dividing (basal) 
cells, viral replication can only occur in cells committed to differentiation.  Therefore in 
benign lesions only a low number of viral genomes are present in basal and suprabasal layers.  
Amplification of viral genomes occurs in stratum spinosum and granulosum with a high 
number of HPV copies in the superficial epithelial layers.  It is in these terminally 
differentiated cells, that  HPV gene expression (L gene expression)  and protein synthesis ( 
capsid protein expression ) lead to histological visible cytopathogenic effects  of HPV in 
epithelial cells with koilocytosis, nuclear enlargement, dyskeratosis and multinucleation 
being the most prominent 192.  In benign lesions, the viruses are episomal, located outside the 
host chromosomes, and eventually shed at the surface.  In contrast to this permissive non-
transformable HPV infection, HPV infection can also be non-permissive and transformable; 
in this situation viral replication and vegetative viral production do not occur, but viral DNA 
persist within the cells either as an extra-chromosal element or by integration into the host 
genome 4,85,98,192. This persistence in cells is strongly associated with cellular transformation  
and implicated in the genesis of cervical dysplasia and cancer.  Within the group of mucosal 
HPVs, especially HPV types 16, 18, 31 and 33, are classified as high risk viruses with respect 
to cervical cancer development 93. 
Among viral infections in the epidermis, HPVs are of major importance 49.  Clinical 
infections (warts) are the most common in children and young adults, with an estimated 
incidence of 10%.  The exact prevalence in the adult population is not known, however 
serological and DNA hybridization techniques suggest that viral exposure at this age with 
subclinical and latent infection might be very common. Although some warts spontaneously 
regress, warts in some adults and immunocomprised persons can persist for years 49. 
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The earliest link between warts and skin cancer was noted in the rare genetic disorder EV83.  
In these patients widespread skin warts occur from  an average age of onset of six years and 
SCCs develop on light exposed sites in 30-60% of affected  patients by the fourth decade, and 
specific HPV types, predominantly HPV-5 and HPV-8 , are found in more than 90% of the 
tumors 83.  With respect to the co-occurrence of often multiple warts and SCCs, RTRs 
resemble these EV-patients.  
  
Model for HPV-related cervical neoplasia 
Approximately 80% of high-grade squamous intraepithelial lesions (HSILs) and cervical 
cancers contain  a restricted spectrum of just four  HPV types (16,18, 31,33 and 45) and these 
HPV DNAs become integrated into host chromosomes4,192.  Integration typically occurs 
within the viral E1 or E2 genomes and disruption of these E1 or E2 genes allows for 
deregulated/enhanced expression of E6 and E7, which are consistently expressed in HPV 
associated cervical cancers4,192.  The E6 and E7 oncoproteins of these so called high risk HPV 
types interfere with two important pathways involved in cell cycle control: the retinoblastoma 
protein (pRb) pathway (E7) and the p53 pathway (E6).  The E6 protein inactivates the p53 
tumor suppressor protein, the functional equivalent of mutational inactivation.  P53 is a prime 
regulator of cell proliferation and has been shown to regulate programmed cell death or 
apoptosis in response to DNA damage. By abrogating p53-related effects on cell proliferation 
and apoptosis upon DNA damage, E6 promotes chromosomal instability and unrestrained 
cell growth causing malignant progression. The high risk E7 oncoprotein, can complex with 
pRb, leading to functional inactivation of pRb and release of an active host transcription 
factor E2F , causing enhanced cell proliferation4,192. Presence of high risk HPV in cervical 
cancers, leads through the respective actions of the two oncoproteins E6 and E7, to typical 
immunohistochemically detectable changes in the expression profiles of important tumor 
suppressor proteins involved in the above mentioned Rb and p53 pathways. 
For instance p16, involved in the p16-CDK4/6-RB pathway ( for more detail see part II),  is 
strongly overexpressed in almost all HPV-related cervical cancers with preserved pRb 
immunoreactivity99,100,167. This seems to be an E7-related effect, causing an overexpression of 
E2F,  which in turn induces the transcription of p16 100.  
 
HPV in cutaneous neoplasia 
In contrast to cervical neoplasia, in skin tumors harboring HPV DNA, the steps of 
progression from benign lesions to malignancy are not known. 
So far, the kinetics of HPV in the epidermis is not well understood,  and despite in vitro 
studies  the virus cycle of HPV in keratinocytes remains unknown. HPV infection probably 
starts in basal cells which are reached by infecting virus particles probably through skin 
defects and so far no HPV cell receptors have yet been identified 98, although alpha-6 integrin 
specifically expressed on basal keratinocytes is suggested to function as possible HPV 
receptor 65.  
As described above , the viral proteins crucial for tumorigenesis in the uterine cervix are E6 
and E7 oncoproteins of high risk HPVs. The mechanism of action of E6 and E7 of oncogenic 
EV HPVs is not known. It was shown that E6 oncoprotein does not degrade p53 protein. 
Only recently, in vitro studies, showed that HPV-38 ( an EV-HPV type) E7 was able to 
inactivate the tumor suppressor pRb with induced loss of G1/S transition control, and that E6 
and E7 of HPV-38 were able to increase the life span of human cultured keratinocytes. In 
contrast to E6 of HPV-16, E6 of HPV-38 was unable to promote p53 degradation 34. Since 
p53 is often mutated in skin cancers, in contrast to HPV induced cervical cancers, these data 
might suggest that E6-mediated p53 degradation is unnecessary in skin carcinogenesis, since 
UV-radiation has already lead to p53 inactivation. 
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In addition, in skin HPV E6 might prevent apoptosis in a p53-independent manner. In fact, it 
was reported that E6 of HPV-5, 10 and 77 in vitro were able to target and promote 
proteolysis of bak protein, a pro-apoptotic protein. This E6 induced elimination of Bak 
protein, could lead to decreased apoptosis in UV irradiated cells which might enhance tumor 
formation 92. 
Both E6 and E7 are expressed in EV cancers but integration of HPV-5 DNA into the host 
DNA is an exception and occurs only in metastases121, while in cervical and anogenital HPV 
associated cancers HPV DNAs are integrated in the genome 192. 
 
In conclusion, the role in which HPVs are involved in skin carcinogenesis needs further 
elucidation. The role of HPV in skin cancer is most likely different from the role of HPV in 
cervical cancers, with UV induced p53 mutation rather than p53 inactivation by E6 
oncoprotein playing a role. This might be expected to be reflected in different 
immunohistochemical profiles for important tumor suppressors involved in the p53 and RB 
pathways,  in HPV induced skin neoplasia compared to cervical neoplasia. Therefore, in the 
present thesis immune expression profiles of three important oncoproteins, p53, p16, and 
p14,  in (pre)malignant skin lesions in relation to HPV and other risk factors will be studied.  
 
Role of HPV in cutaneous neoplasia of renal transplant recipients 
A variety of HPV types can be detected in benign, premalignant, and malignant proliferations 
of RTRs (Table 1B) . In RTRs the most frequent HPV types are benign cutaneous types 
1,2,4,  EV-associated HPV types or possibly potentially oncogenic cutaneous types (HPV 
types 5,8,9,12,14,15,17,19-25,36-38 and 47) and mucosal HPV types, partially benign (6/11) 
or potentially oncogenic (HPV types 16,18). In many instances more than one HPV type in a 
single lesion is found. 
The listed studies show considerable variation in the prevalence and types of HPV detected. 
These discrepancies are likely to reflect the different detection methods used. The early 
studies employed DNA hybridization based techniques that tend to be less specific and 
sensitive than later methods based on PCR. Furthermore DNA was extracted from frozen or 
formalin fixed specimen and of the large number of  known HPV types especially earlier 
studies tested only a few. Some studies were performed on small series of lesions.  
Even with the introduction of PCR-based techniques for HPV-detection, discrepancies in data 
continue to arise. This is also likely to be a methodological phenomenon with different 
investigators using different primer sets. Meyer et al, compared 4 PCR assays for detection of 
HPV in SCCs and found that the rate of HPV-DNA positive specimen increased with 
addition of nondegenerate primers derived from HPV-5 and 8 to 69% compared to PCR 
assays using only degenerate primers for broad range HPV detection (50% HPV positivity) 
136. Furthermore an increasing number of novel HPV sequences have been detected in 
NMSCs from RTRs in the past few years using PCRs with consensus primers that target the 
gene region of the L1 capside protein of HPV14,172,173. 
  
18  Chapter 1 
General Introduction  19 
Also in ICIs, HPV DNA is frequently detected, also with sometimes reported differences 
between studies with regard to HPV-types and frequencies found in skin tumors. For 
instance, Meyer et al reported prevalence of HPV DNA in 75% of SCCs of OTRs, and 47% 
of SCCs in ICIs. In warts and premalignant skin tumors comparable HPV prevalence were 
present in both patient populations137. HPV types 5 and 8 were more frequent in SCCs (26%) 
than in benign and premalignant lesions and all HPV 5 and 8 positive SCCs were from OTRs. 
Recently, positive serologic positive findings for HPV type 8 proved associated with SCC 
occurrence in ICIs, independently from other risk factors as sun-exposure and positive family 
history of skin cancer126. Comparable to Meyer et al, Rübben et al also reported the same 
distribution of HPV types in common warts from ICIs and immunocomprised patients 164. 
Iftner et al. reported presence of HPV DNA in 90.9% of warts, 60.4% of premalignant lesions 
and 59.7% of SCCs in ICIs. High risk mucosal HPV types ( e.g. HPV 16 and 31) were 
present in skin tumors of these ICIs and linked to NMSC 89. Shamanin et al also found more 
frequently HPV DNA in SCCs of RTRs compared to ICIs and the spectrum of HPV types 
differed substantially. High risk mucosal types were only present in malignant skin tumors 
from RTRs, while in ICIs low risk mucosal types were found 173. 
In conclusion, with the development of degenerate PCR methods a high prevalence and broad 
spectrum of HPV types has now been found in premalignant and malignant skin lesions from 
both immunosuppressed and immunocompetent individuals. The different spectrum of HPV 
types reported in malignant lesions from immunocomprised patients and RTRs and 
association of NMSC occurrence in ICIs with high risk HPV types, both suggest that viral 
infection acts as a cofactor in tumor development, along with solar radiation and other 
environmental exposures, although at present mechanistic data are lacking. 
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 PART II 
 
 
CURRENT KNOWLEDGE ON THE ROLE 
OF P53 AND  INK4A-ARF (P16-P14) IN 
CUTANEOUS SQUAMOUS CELL 
CARCINOGENESIS 
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1.2.1 
p53 and INK4A-ARF in the cell cycle control 
 
Cell growth is controlled by two main pathways, one involving the retinoblastoma protein 
(pRb), regulating exit from the G1 phase of the cell cycle, and one involving the p53 protein 
that induces growth arrest or apoptosis in response to cellular stress. Crosstalk between the 
p53 and pRb pathways are provided by MDM2, by p21 and an additional important bridge is 
provided by the INK4a-ARF locus located on human chromosome 9p21 (see Figure 2A). 
This locus, by alternative transcripts encodes for two proteins p16INK4a (exons 1, 2 and 3), 
and p14ARF (exons 1 and 2). 
 
 
FIGURE  2A  pRb is inactivated by phosphorylation, and inactivation of RB releases the E2F1 transcription 
factor from the RB complex. This factor regulates the expression of many genes involved in entry and 
progression through the S phase of the cell cycle. Overexpression of p16 inhibits entry and progression into the 
S phase of the cell cycle by inhibition of  CDK4 and 6, thereby preventing phosphorylation of RB and release of 
E2F. Loss of p16 may allow excessive activity of CDKs, promoting RB phosphorylation and proliferation of 
tumor cells. 
P14 interacts directly with MDM2 and sequesters MDM2 in the nucleolus and enables p53 stabilization. Also 
E2F1-induced activation of p53 is mediated by p14, which is transcriptionally activated by E2F1 and functions 
in p53 activation and stabilization by negating the effects of MDM2 on p53.  
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The p16-CDK4/6-RB pathway 
P16 is a member of the INhibitor of cyclin-dependent Kinase 4 (INK4) family of proteins, 
which are capable of binding to and blocking the activity of cyclin dependent kinases 
(CDKs)4 and 6. CDK4/6 kinases associate with type D cyclins and these complexes are 
responsible for phosphorylation of pRb at G1 of the cell cycle. Sequential phosphorylation of 
pRb by CDK4/6 complexes followed by CDK2 complexes is thought to be critical for 
progression through G1 and entry into S-phase of the cell cycle. RB phosphorylation leads to 
release of E2F, which transactivates many genes important for mitosis. 
By binding to CDK4/6, p16 can inhibit the phosphorylation of pRB with subsequent 
inhibition of E2F release and arrest of the cell cycle in G1 phase and suppression of cell 
proliferation. Functional or structural loss of p16, could therefore lead to cell cycle 
propagation of potential genetically damaged cells and subsequent risk of tumor 
development. Links between the p16 and p53 pathways are present and mediated by p14, 
which is formed by an alternative reading frame in the INK4a gene, which is shared by p16 
and p14 163. Therefore, loss of the INK4a gene disrupts two cell control pathways, one 
through p16 /CDK4/6/pRB and the other through p14 /MDM2/p53.  
Expression of p16 does not displace type D cyclins from already preformed cyclin D/CDK 
complexes, but type D cyclins have a very rapid turnover allowing p16 to out complete the 
cyclins for binding to CDK4/6. The p16/CDK complexes have a long half-life.  
The expression of pRb is essential for transducing p16’s signal to cause a cell cycle arrest. In 
absence of pRb, forced induction of p16 does not cause cell cycle arrest. 
A negative feedback loop exists between pRb and p16. Transcription of p16 is repressed by 
pRb 91,163,174.  
 
The p14-MDM2-p53 pathway 
The human (p14) form of ARF is capable of inducing cell cycle arrest at the G2/M as well as 
at the G1/S phase91,163,174. Unlike p16, ARF does not bind to CDKs. ARF interacts with 
MDM2, an oncoprotein that negatively regulates p53 by (a) binding within the transcriptional 
domain of p53, inhibiting its transcriptional activity, and (b) acting as an E3 ubiquitin ligase, 
thereby promoting p53 proteolysis through the ubiquitin/proteasome pathway and it shifts 
MDM2 from the nucleus to the nucleolus. Transcription of MDM2 itself is controlled by p53 
in response to cellular stress. Thus p53 and MDM2 form a loop creating a tight check over 
p53 protein level and function54. 
P14 interacts directly with MDM2 and sequesters MDM2 in the nucleolus and enables p53 
stabilization.  
Also E2F1-induced activation of p53 is mediated by p14, which is transcriptionally activated 
by E2F1 and functions in p53 activation and stabilization by negating the effects of MDM2 
on p53 54,174. This responsiveness of p14 to E2F1 makes p14 an important nexus between the 
pRB and p53 pathways. The p14-E2F1 interplay enables the cell to sense oncogenic stimuli 
transduced through the RB-pathway, such as p16 inactivation or cyclin D overexpression. 
P14 is also induced by typical oncogenes such as myc and ras, and some viral oncogenes.  
Furthermore, a negative feedback loop exists between ARF and p53 193. Thus p14 plays a 
central role in cell cycle control, by integrating all these stimuli and by targeting at least two 
of the key pathways in control of cell cycle, namely the p53 and RB pathway. 
P53 is a transcription factor that enhances the rate of transcription of several genes among 
which are  p21 and MDM2.  Normally in a cell the p53 protein level is low due to a relatively 
short half life (20 min). Several different types of DNA damage can activate p53 ( for 
instance UV radiation), leading to a rapid increase in p53 level of the cell and activation of 
p53 as a transcription factor. The downstream events mediated by p53 activation take place 
by two major pathways : cell cycle arrest and apoptosis 116.  
24  Chapter 1 
P53 activation turns on the transcription of its downstream genes, for instance p21. P21 binds 
to a number of cyclins and CDK-complexes, and binding of 2 molecules of p21 per complex 
inhibits kinase activity and blocks cell cycle progression. P21 also binds to PCNA and these 
complexes are thought to block the role of PCNA as a DNA polymerase processing factor in 
DNA replication. Thus p21 can act on cyclin-cdk complexes and PCNA to stop DNA 
replication (G1 arrest). 
P53 plays a role in triggering apoptosis under several physiological conditions and p53 can 
also initiate apoptosis in response to the expression of a viral or cellular oncogene or the 
absence of a critical tumor suppressor gene product (Rb).  
In conclusion, p53,  p16, and p14, all act as  proliferation and growth inhibitors in normal cell 
cycle control and therefore alteration in one of these ( tumor suppressor) genes or proteins 
could lead to enhanced carcinogenesis. In addition, alteration in only one of these three tumor 
suppressors will have influences on both others, since p14 forms a nexus between the 
p16/pRB and p53/MDM2 pathways.  In the present chapter the current knowledge on the role 
of these three tumor suppressors in cutaneous squamous cell carcinogenesis will be reviewed. 
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1.2.2  
p53 in cutaneous squamous cell carcinogenesis of 
immunocompetent individuals and renal transplant recipients  
 
 
1.2.2.1 TP53 mutations 
In table 2A the frequencies of p53 mutations in ICIs and RTRs in CSCCs as previously 
reported in the literature are summarized. Reported frequencies in RTRs range from 8-43%, 
in ICIs from 18-50%. In most studies patient numbers are relatively small. 
McGregor et al. detected mutations in p53 in 43% (9/21) of SCCs in RTRs and in 50% (3/6) 
of SCCs in ICIs. In 75% of the transplant tumors and 100% of the non transplant tumors p53 
mutations were consistent with damage caused by UV radiation 129. Mc Gregor concluded 
that both the type and frequency in p53 mutations, predominantly of an UV-related nature, 
was similar in transplant NMSC when compared to sporadic NMSC. Furthermore, in both 
groups they found that p53 mutations were present irrespective of HPV status. This latter 
finding is in contrast to anogenital cancer in which concurrent presence of high risk HPV and 
p53 mutation is uncommon, due to efficient binding and thereby functionally inactivating of 
p53 and RB by E6 and E7 proteins respectively, both encoded by the high risk HPV. 
Bennett et al. and O’Connor et al. detected a much lower mutation frequency in SCCs of 
RTRs, with only 8% (2/25 cases) 10 and 11% (1/9 cases) p53 mutations respectively 144.  
Soufir et al. reported p53 mutations in 5/21 (24%) of sporadic SCCs 187, in one case with 
associated p16 mutation. 
Bolshakov et al. analyzed p53 mutations in aggressive SCCs with aggression being defined 
as tumor size above 2 cm, invasion in muscle, bone or cartilage or regional or distant 
metastasis. In aggressive SCCs 35% (28/80 cases) contained p53 mutations, while in non-
aggressive SCCs 50% (28/56 cases) contained p53 mutations 23. In  both aggressive and 
nonaggressive SCCs most p53 mutations were C to T and CC to TT transitions at 
dipyrimidine sequences, suggesting induction by UV radiation ( 71% of all NMSCs studied 
contained UV-signature mutations). Whether tested SCCs were all sporadic or partly derived 
from special patient groups as for instance RTRs in this study is not mentioned. 
Boldrini et al. found p53 mutations in 2/11 (18%) SCCs, probably sporadic tumors 22. 
 
Table 2A. Reported p53 mutation frequencies in the literature in CSCCs in renal transplant recipients 
(RTRs) and immunocompetent individuals (ICIs) 
Reference RTR ICI/sporadic Exons p53 
129 43% 50% 2-11 
187  24% 4-9 
10 8%  5-8 
23  35-50% in aggressive vs. non-
aggressive SCCs* 
4-9 
22  18% * 4-9 
144 11%  5-8 
*Most probably sporadic 
 
In special patient groups, other than RTRs, most studies report higher frequencies for p53 
mutations compared to frequencies reported in CSCCs of immunocompetent individuals.  In 
addition, tumors more often have multiple p53 mutations: for instance Stern et al. reported 
61% p53 mutations in 51 CSCCs in PUVA treated (psoriasis) patients 191.  Of these 
mutations, 41% were PUVA type and 44% UV type.  In Epidermodysplasia Verruciformis 
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(EV), 62.5% (5/8 cases) of CSCCs contained p53 mutations.  Mutations were also present in 
2 AKs (40%), 3 Bowen’s disease (33.3%) and in 1 benign lesion.  In 5/9 (55%) cases, 
mutations characterized by sequencing proved C->T transitions and were considered as UV-
signature 147. 
Soufir et al. found 44% (8/18 cases) p53 mutations in exons 4 through 9 of the p53 gene in 
Xeroderma Pigmentosum (XP) patients (contrasting to 24% in sporadic tumors); of these 
tumors 58% also had an INK4a-ARF mutation 187.  XP is an autosomal recessive disorder 
associated with a germ line nucleotide excision repair defect.  This defect prevents removal 
of a wide array of DNA lesions, including those induced by UV radiation.  This leads to a 
high frequency of sunlight induced skin cancers in these patients.  The DNA repair defect, 
forms an explanation for the increase in mutational frequencies in p53 and also INK4A-ARF 
in skin cancers from these patients compared to sporadic skin cancers 187. 
 
In conclusion, there are a limited number of studies on the incidence of p53 mutations in 
CSCCs in RTRs, which show a wide variation in the frequency of p53 mutations that might 
be at least partially attributable to differences in the number of p53 exons, tested.  
Frequencies seem lower or comparable to those in ICIs.  UV-related mutations in p53 are 
common in both patient groups (range 71-100%). 
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1.2.2.2 p53 protein expression  
Immunohistochemistry has been used to detect modified p53 protein, because many of the 
mutations in the p53 coding region result in a structurally altered, inactive protein that is 
more stable than its wild type counterpart, resulting in higher levels of protein detectable by 
antibody. 
Findings on p53 expression in (pre) malignant squamoproliferative lesions in ICIs reported in 
the literature are listed in Table 2B.  In all studies p53 staining was nuclear.  As can be read 
from the listed studies variable results are reported, with p53 expression in AKs varying from 
69-92%, in BDs from 9.1%-100%, and in SCCs from 50% to 100%.  But as also can be read 
from the table different antibodies and dilutions have been used and varying quantitative 
scoring systems. 
P53 staining in normal skin was reported as either absent 90,128,214, or as having low detectable 
expression throughout the epidermis in sun-exposed skin 214.  
 
Table 2B. Reported frequency of p53 protein expression in (pre) malignant squamoproliferative lesions in 
the general population. 
Reference P53 antibody AK MB SCC 
113 Pab1801, (Oncogene 
Science, Cambridge, 
MA 
 9.1% >10% p53 +  
214 DO-7, DAKO  80% moderate to 
strong + 
100% moderate to 
strong + 
120 DO-7, Novocastra, 
UK 
79.2% moderate to 
strong + 
100% + 38% >50% tumor 
cells p53 + 
90 BP53-12, Japan 
Tanner, Kobo, Japan 
1:20 
  50% moderate to 
strong + 
157 DO-7, DAKO, 
Denmark 1: 200 
Up to 69% + 55.6% + 69.1% + 
183 CM1 1:1000-1:8000  57.7%+  
177 DO-7, DAKO Japan 
1:100 
  75% + 
146 DO-7, Novocastra, 
England 1:100 
92% + 71% + 55% + 
128 DO7, Novocastra, 
UK 1:50 
  94% + 
 
 
Literature is sparser on p53 expression in tumors of RTRs. 
Ferrandiz described more prevalent accumulation of p53 protein (used antibody DO-7, 
Novocastra, UK) in AKs and SCCs of RTRs, percentages of 82% and 85% respectively, 
when compared to equivalent lesions in ICIs with 40% p53 positivity in both actinic 
keratoses and SCCs 66. 
McGregor et al. found no difference in the overall prevalence of p53 staining in transplant 
and non-transplant associated skin tumors: 43% p53 immunostaining in SCCs of RTRs and 
55% of SCCs in the general population.  57% of verrucous keratoses in RTRs and 62% of 
AKs in the general population were p53 positive.  In this study none of the lesions contained 
oncogenic HPV (PCRs for HPV types 16,18,31,33,5 and 8 were performed), suggesting that 
p53 mutation rather than p53 inactivation by HPV-encoded E6 oncoprotein plays a role in 
carcinogenesis of both patient groups 130. 
  
O’Connor et al. found p53 expression in 70% (7/10) of SCCs of RTRs, compared to 40% 
(2/5 cases) p53 expression in ICIs.  Only one of all p53 positive SCCs contained a p53 
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mutation.  The number of positive tumor cells varied from >30% to 80%.  In 8 of all 15 cases 
HPV was present (EV-HPV types), in 6 RTRs and 2 ICIs, not related to p53 expression.  
Viral warts from both ICIs and RTRs contained p53 in 5/15 cases, and in most cases staining 
was weak (<10%) in a few isolated cells, located basal or suprabasal 144. 
In conclusion, p53 expression in (pre) malignant skin lesions of RTRs is reported frequently 
(range 43-70%) with most studies reporting less prevalent p53 overexpression in equivalent 
lesions in ICIs.  P53 overexpression is not synonymous with p53 mutations, and in skin 
lesions thus far no correlation of p53 expression with presence of oncogenic HPVcould be 
demonstrated. 
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1.2.3 
INK4A-ARF in cutaneous squamous cell carcinogenesis of 
immunocompetent individuals and renal transplant recipients 
 
Inactivation of p16 and p14 can occur by a variety of genetic mechanisms including 
mutations and deletions.  In addition to genetic mechanisms, hypermethylation of the CpG 
islands of the separate p16 and p14 promotors, is a significant means of transcriptional 
silencing 143,163,182.  There is now compelling evidence that DNA methylation errors in cancer 
cells can alter the expression of critical genes and contribute to carcinogenesis 163.  In chapter 
2.3.1 an update on INK4A-ARF mutations in cutaneous carcinogenesis will be given, and 
only briefly mention other genetic events concerning INK4A-ARF, since these were not 
further studied in the present thesis. 
 
1.2.3.1 INKA-ARF mutations 
So far there is a restricted number of studies on INK4A-ARF mutations in skin carcinomas: 
see Table 2C.  
Reported frequencies of p16 mutations in sporadic CSCCs varies from 0% (0/6 cases) 35 to 
20% (resp. 4/20 CSCCs 188 and 8/42 cases of CSCCs 187).  P14 mutations in the sporadic 
CSCCs have a reported frequency of 17% (7/42 cases) 187.  
Chang et al. found no p16 mutations in 6 SCCs, including 2 with metastases.  Only exons 1 
and 2 of p16 were amplified 35.  
Kubo et al. found INK4A-ARF mutations in 3/21 (14%) sporadic CSCCs, all in exon 2 
affecting both p16 and p14.  The two SCCs arising from sun-exposed skin, contained a CC-
>T mutation at a dipyrimidine site and a deletion of 21 base pairs.  Both types of mutations 
were not specific and uncommon to UV mutagenesis.  The third mutation was a C->T 
transition, occurring at a dipyrimidine site, but this SCC originated in a scar in a non-sun 
exposed site 110. 
Soufir reported 66% UV-type mutations in sporadic CSCCs ( two tandem CC:GC to TT:AA 
transitions and two C:G to T:A transitions at dipyrimidic sites) 188, with only 5% (1/21 cases) 
of sporadic SCCs having combined p16 and p53 mutation 187.  In addition methylation 
analysis of p16 was performed, and was present in 8/20 SCCs (40%), three of which 
harboring a p16 mutation188. 
At the moment only one previous study was  concerned with INK4A-ARF mutations in 
iatrogenically immunosuppressed patients, which were not further specified 32.  A total of 40 
SCCs was studied, 30 samples from immunosuppressed patients and 10 from ICIs.  In 4/40 
(10%)  SCCs, INK4A-ARF mutations were present.  All mutations were C to T nucleotide 
changes or double substitutions CC to TT, consistent with UVB fingerprint type of mutation 
(100% UV type).  In ICIs 3/10 SCCs contained mutations, 2 combined p16/p14 mutations, 1 
mutation affected only p16.  In immunosuppressed only 1/30 SCCs contained a combined 
P16/p14 mutation.  In this study, LOH for 9p21 was found in 13/40 (32.5%) of the tumors.  
No samples showed microsatellite  instability for this locus.  Methylation of the p16 promotor 
was found in 13/36 (36%) of cases, for the p14 promotor in 16/38 (42%) cases, and 4 samples 
were methylated for both the p16 and p14 promotor. 
So in this study genetic/epigenetic events ( mutation, methylation, immunohistochemical 
expression) for p16 and p14 were found to be more common in ICIs compared to 
immunosuppressed patients.  An overall frequency of 76% 9p21 alterations was found for 
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both p16 and p14, with promotor methylation being the most common mechanism of gene 
inactivation.  
Studies on INK4A-ARF mutations in RTRs so far have not been performed. 
In special patient groups, other than RTRs, reported frequencies for INK4A-ARF mutations 
in CSCCs are higher than those reported in the general population. 
In SCCs form PUVA-treated psoriasis patients, 42% (11/26) SCCs contained 19 INK4a-ARF 
mutations: 10 mutations affected p16, 6 affected p14, and 3 affected both.  UV-type 
mutations were present in 58%, three (16%) were ultraviolet and/or PUVA type 109. 
In Xeroderma Pigmentosum (XP) patients, p16 and p14 mutations both have a reported 
frequency of 33%  (6/18 cases); all tumors in these patients with mutations in p16 also had 
mutations in p14 187.  Furthermore tumors in XP patients often contained multiple mutations 
in p14, p16 and p53 and  tumors with INK4a-ARF mutations almost all also had one or more 
mutations in the p53 gene (7/8, 88%).  
54% of INK4a-ARF mutations in XP tumors (basal cell carcinomas included) were of UV-
signature.  Statistically positive associations were present between the frequency in p53 and 
p16 and between the frequency in p53 and p14.  
 
Table 2C. Studies on INK4A-ARF mutations in SCCs 
Ref Freq. p16 
mutations 
Freq. p14 
mutations 
Patient characteristics Analyzed exons 
of INK4a-ARF 
35 0% (0/6)  Not done Sporadic SCCs 1,2 
110 14% (3/21) 14% (3/21) Sporadic SCCs 1,2,3 
188 20% (4/20)  Sporadic SCCs 2,3 
187 19% (8/42) 17% (7/42) Sporadic SCCs 1, 1, 2 
30% (3/10) 20% (2/10) Sporadic SCCs  32 
3% (1/30) 3% (1/30) Immunosuppressed patients 
1, 1, 2 
109 50% (13/26) 35% (9/26) SCCs from PUVA treated psoriasis patients 1, 1, 2, 3 
187 33% (6/18) 33% (6/18) SCCs from XP patients 1, 1, 2 
 
 
In conclusion, so far the frequency of INK4a-ARF mutations in RTRs is not studied.  In 
sporadic CSCCs INK4a-ARF mutations are reported in up to 30% of cases with often-
combined p16 and p14 mutations.  In immunosuppressed patients less epigenetic and genetic 
events in INK4a-ARF are described when compared to the general population with promotor 
methylation of p14 and p16 being the most frequent mechanism of gene inactivation (42%). 
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1.2.3.2 p16 protein expression 
So far only a few studies have evaluated p16 immunoexpression in SCCs and precursors, 
mostly in ICIs.  Hodges et al. recently described p16 positivity in all 10 (100%) probably 
sporadic AKs, SCC in situ lesions, and SCCs studied.  They used  the monoclonal p16 
antibody G175-405 (Pharmingen, San Diego, CA (dil.1:25) and a semi quantitative scoring 
system.  Normal skin was negative.  AKs stained positive in the lower one third or lower one 
half of the epidermis.  Transepidermal staining was only present in SCC in situ.  100% of the 
SCCs exhibited moderate to strong staining of the invasive component 87. 
In contrast, Mortier et al.  140 found p16 expression in 66% of AKs (12 AKs studied) and only 
10% of SCCs (10 SCCs studied ), probably sporadic tumors, without specification of the used 
scoring method.  The lower number of p16 positive SCCs in this study correlated with an 
increase of LOH at the p16 coding region 9p21 from 21% (3/14) AKs to 46% (17/37) SCCs, 
although for immunohistochemistry and LOH different samples were used.  In contrast, they 
also describe p16 expression in normal skin with the use of the same antibody as Hodges et 
al. (G175-405, Pharmingen). 
Combined mutation analysis with immunohistochemistry for p16, so far was only performed 
by Chang 35 et al. though on a very small number of probably sporadic SCCs (6 cases): 2/6 
SCCs showed positive nuclear staining for p16 (anti-p16 antibody, C-20, Santa Cruz 
Biotechnology), and 4/6 SCCs were negative.  In all cases wild type p16 was present and no 
mutations could be demonstrated, implicating that immunohistochemical findings cannot 
directly be correlated to underlying molecular alterations. 
Nindl et al. studied p16 expression in relation to presence of HPV in normal skin (3), 
psoriasis (2), verrucae vulgares (VVs) (2), AKs (5), SCCIS 4), and SCCs (7) with the use of 
the monoclonal antibody E6H4 (MTM laboratories, Heidelberg, Germany; dil. 1:200) and a 
semi quantitative scoring system.  P16 expression was absent in normal skin, psoriasis, and 
VVs.  All AKs, SCCISs and SCCs showed p16 expression, with the highest percentage of 
positive lesional cells in SCCIS (>70%) and in all AKs, SCCIS and SCCs either EV-
associated HPV types (20,24,5,14,15,17,25,8) or mucosal HPV types (16,6) were detected. 
At present only Brown et al. 32 studied p16 expression in SCCs of both ICIs and 
immunosuppressed patients, which were not further specified.  The monoclonal antibody 
p16INK4A/MTS1 Ab-7 (16PO7) (Neomakers, Fremont, California, dil. 1:100) was used, and 
only nuclear staining was considered positive.  A semi quantitative scoring system was used.  
P16 staining was present in 20/40 (50%) of SCCs, of which 75% showed less than 25% 
positive tumor cells.  In Immunosuppressed 16/30 cases (53%) were p16 positive, in ICIs 
4/10 (40%).  In 64% of cases there was concordance between the presence/absence of p16 
protein expression and genetic results (mutation, methylation).  In 70% of tumors with 
biallelic events, p16 protein expression was absent. 
Summarizing,  results with respect to p16 staining in SCCs of skin and precursors are 
conflicting and seem partly related to usage of different p16 antibodies, often-small patient 
numbers, and different immunohistochemical scoring methods.  At this moment no studies 
regarding p16 protein expression in epidermal neoplasia of RTRs are available.  Further 
studies with larger sample size are needed to clarify the relationship between p16 
overexpression, etiological factors (HPV, sun exposition) and NMSC. 
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1.2.3.3 p14 protein expression 
At this moment only 1 study has been performed regarding p14 protein expression in (pre) 
malignant squamoproliferative skin lesions.  Brown et al. 32 studied p14 expression in 40 
SCCs, 30 from immunosuppressed patients and 10 from immunocompetent persons.  They 
used a goat polyclonal antibody  p14 ARF (C-18)(sc-8613) (Santa Cruz Biotechnology, Inc.) 
in a 1:100 dilution, a semi quantitative scoring method and considered only nuclear staining 
as positive. 
P14 expression was seen in 17/40 (43%) of cases: 12/30 (40%) p14 positive samples in 
immunosuppressed, and 5/10 (50%) p14 positive SCCs in ICIs.  In 62% there was 
concordance between the presence/absence of protein expression and genetic events.  In all 
tumors with biallelic events, p14 expression was absent. 
So far studies on p14 expression in premalignant squamoproliferative lesions of specifically 
RTRs are lacking. 
 
 PART III 
 
 
SYSTEMIC RETINOID TREATMENT IN 
SKIN CANCER 
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1.3.1  
Retinoid effects on the epidermis 
 
Retinoids are a class of compounds that includes the natural and synthetic analogues of 
retinol or vitamin A. Vitamin A has long been known for its importance in promoting general 
growth, in regulating proliferation and differentiation of epithelial tissues, and in maintaining 
visual function and reproduction 170.  
Retinoids have a broad range of effects on the epidermis, and the most important and relevant 
to the studies described in this thesis will be mentioned here.  First, I will briefly mention 
normal keratinisation in the epidermis and in benign and (pre) malignant epidermal neoplasia 
since retinoids have a profound effect on epidermal keratinisation and the effect on 
keratinisation of retinoids in epidermal tumors was one of the study objectives in this thesis. 
 
 
1.3.1.1 Keratins in normal epidermis 
 
Epithelial keratins comprise a heterogeneous group of acidic (type I) and neutral-to-basic 
(type II) proteins.  As a general rule, they are coexpressed in specific pairings, each pair 
consisting of a type I keratin and II.  For instance, in the normal adult skin, keratin pairs 
K5/K14 (46 and 58-kD resp.) predominate in the basal layer and larger keratins K1/K10 (67 
kD and 56.5 kD resp.) in the suprabasal compartment 28,185.  
The type I keratins K13 and K19 (52 kD and 40kD resp), are usually expressed separately in 
adult epithelia.  Combined expression occurs only in fetal skin ( see Figure 3A).  Both 
keratins are absent in normal skin of adults except for certain body sites such as penile 
foreskin that still contains K13.  Furthermore, K13 in adults is abundantly present in internal 
stratified epithelia (for instance the esophagus) and associated with terminal differentiation or 
suprabasal expression 114,139,185,200.  K19 expression in adults is found in simple epithelia, such 
as most glandular epithelia. 
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Figure  3A  Expression of the different keratins during the development of the epidermis. Keratin expression at 
15 weeks of gestational age (GA), at 22-24 weeks of GA, and  in adult skin are depicted. Keratin 13 (K13) is 
only  present  in fetal skin.  
 
 
1.3.1.2 Keratinisation in warts, premalignant and malignant skin 
tumors 
 
Proby et al. assessed the profile of keratin expression in benign warts, dysplastic skin lesions 
and SCCs in RTRs and compared expression patterns with identical lesions in 
immunocompetent controls (ICIs)153. 
In warts, besides also normally present suprabasal keratins K1 and K10, immunoreactivity 
for hyperproliferative keratins K6 and K16 was seen usually throughout the suprabasal 
compartment.  Suprabasal K17 expression was found.  Simple epithelial K7, K8, and K18 
were not expressed in warts.  Findings were similar in warts of RTRs and ICIs.  
Dysplastic lesions frequently showed marked delay in suprabasal immunoreactivity for K1/10 
with marked expansion of basal cell marker LH8.  In addition, a combination of basal and 
suprabasal K17 expression was seen.  Simple keratins K7 and 8/18 were not expressed in 
dysplastic lesions. 
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The profile of keratin expression of SCCs from RTRs did not differ from SCCs of ICIs.  
Expression of K1/10 was lost.  In SCCs extensive K17 positivity was seen with panepithelial 
staining throughout areas of invasive tumor. K8/18 was only detected in the least 
differentiated SCCs, as was K19. 
K13 was negative in all lesions. 
Malecha and Kuruc also reported absent K13 expression in SCCs of the skin 114,122.  
Markey et al. and Ichikawa et al. found comparable keratin expression in epidermal dysplasia 
and in situ carcinomas as described above 88,123. Both reported in situ lesions a few 
K7/K8/K18 and K19 positive cells. In well differentiated SCCs K5 and 14 staining was 
preserved, while poorly differentiated ones showed widespread loss of both K14 and K5 and 
loss of other basal markers. All SCCs showed K1/10 loss, and no alternative terminal 
differentiation such as oral/esophageal (K4/13) or corneal (K3/12) keratin expression could 
be demonstrated. In all SCCs widespread expression of keratins normally present in simple 
epithelia, like K7/K8/K18 and K19, was present 123.  
In conclusion, cutaneous malignant transformation is heralded by a switch from production of 
larger MW keratins normally present in the epidermis (K1/10) to smaller MW keratins (K8, 
18 and 19) characteristic of fetal skin and simple epithelia and that the extent of shift 
correlates with the histological grade of the tumor as already stated by Smack et al. 185. K13 
expression is reported to be absent in (pre) malignant epidermal tumors. 
 
1.3.1.3 Effects of retinoids on epidermal keratinisation, 
differentiation, and proliferation 
 
With respect to keratinisation and differentiation, retinoids influence expression of 
cytokeratins. In skin, retinoids induce keratins that are normally not present in normal adult 
human skin, but are present only in embryonic skin. Data from animal and in vitro studies 
with cultured human keratinocytes have indicated that retinoids repressed expression of 
epidermal differentiation-specific keratins (K1/K10) and strikingly reinduced expression of 
two lower molecular weight keratins, corresponding to K13 and K19 respectively 55,106,107,202. 
Since these two keratins are coexpressed in fetal skin 139,200, this type of retinoid-induced 
differentiation is also termed embryonic differentiation. Furthermore retinoids in vitro 
increase the keratins K4, K15, and K6/K16 in keratinocyte cell cultures 185. Keratinocytes in 
vivo, when exposed to topical retinoids in healthy volunteers, display an increase in K13 and 
K6/16 synthesis, but no alterations in K1/10 and K14 expression 161. Interestingly, in contrast 
to normal keratinocytes, in psoriatic skin systemic retinoid treatment seems to reverse the 
enhanced K6/16 in psoriasis, with restoration of suprabasal K1/10 expression. This illustrates 
that retinoid response of keratinocytes in vivo and in vitro do not always correlate and that 
normal keratinocytes respond differently to retinoid than diseased keratinocytes 119,185. 
Epidermal proliferation is also influenced by retinoids. Some have reported that topical 
retinoids increase the uptake of tritiated thymidine in human epidermis and pilosebaceus 
follicles, while others noted decreased numbers of mitotic figures after oral administration of 
vitamin A, suggesting that local irritation may explain the increased labeling after topical 
application of retinoids as reviewed by Elias 57.  Furthermore oral retinoids were reported to 
produce acanthosis and increased epidermal labeling index in mice, although this proved only 
a temporally effect with reversion to normal after 2 weeks. Light microscopy after topical and 
systemic retinoid therapy also demonstrated only temporally acanthosis or psoriaform 
hyperplasia 57. Hyperplasia of epidermis after retinoid stimulation is also accompanied by an 
increased shedding of corneocytes. This shedding is probably at least partially attributable to 
dyshesion, which correlates with the loss of desmosomes and the formation of intracellular 
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and extracellular amorphous materials in the upper dermis. Ultrastructural studies 
demonstrated that retinoids reduced the size of desmosomes and increased the number of 
gap-junctions, reduced the density of tonofilaments and induce the formation of gaps in the 
epidermal basement membrane 56,57,197. 
Retinoids are thought to induce growth or inhibit growth dependent on the cell type and state 
of the studied tissue. With regard to cell type, for instance the sensitivity of various type of 
cultured keratinocytes to retinoids appears to reflect the degree of cornification of the tissue 
of origin in vivo: conjunctival keratinocytes proved more sensitive to retinoid than epidermal 
keratinocytes, probably due to either divergence of differentiation program in these 
keratinizing epithelia and/or different sensitivity to vitamin A.   
Regarding cell state, in normal epidermis retinoids are reported to induce DNA synthesis and 
increase proliferation with increased desquamation. This contrasts with growth inhibition by 
retinoids in hyperproliferative states, for instance psoriatic skin 197. 
These pluripotent effects of retinoids have made them an established treatment for various 
skin disorders such as psoriasis, acne, and keratinisation disorders 170. In addition, retinoid 
treatment has been employed in the prevention and treatment of skin ageing and skin cancer 
46,118, the latter being the subject of investigation in the present thesis. 
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1.3.2  
Retinoid receptors in skin  
 
The ability of retinoids to modulate gene expression is the most plausible mechanism by 
which they can modulate differentiation and growth of malignant cells or suppress the 
progression of premalignant cells to frank neoplastic lesions by redirecting their 
differentiation 119. 
To modulate gene expression, retinoids must transmit signals to the nucleus.  Both 
cytoplasmic and nuclear retinoid binding proteins have been identified.  Cytoplasmic retinoid 
binding proteins, like cellular retinol-binding protein (CRBP) and cellular retinoic acid-
binding protein (CRABP), have been identified in human skin and (un) differentiated 
cultured keratinocytes.  These proteins probably function in transport of retinoids to the cell 
nucleus.  
Nuclear retinoic acid receptors are members of a large family of nuclear receptors for 
steroids, vitamin D, and thyroid hormones.  There are three Retinoic-Acid-Receptor (RAR) 
subtypes (RAR-, and ) and three Retinoid-X-Receptor (RXR) subtypes (RXR-, and ) 
and each subtype has different tissue distribution. 
Human epidermis expresses RAR-, RAR-, RXR- and RXR-. Total RXR protein levels 
are fivefold greater than RAR levels.  RXR- is the skin’s predominant RXR, accounting for 
90% of the RXR protein in skin, while RAR- is the most predominant RAR accounting for 
87% of RAR protein in skin 67,119,215. The RXRs form heterodimers with RARs, and therefore 
it is highly likely that the RAR-/RXR- heterodimer is the principle transducer of the 
retinoid signal in human skin. 
Different retinoids have different receptor specificity.  At present there are three generations 
of synthetic retinoids 170. The first generation is the group of non-aromatic retinoids.  One of 
these, all-trans retinoic acid (ATRA), is used topically for a variety of dermatologic 
conditions and also in prevention of skin cancer.  Of the second generation of mono-aromatic 
retinoids, the compounds etretinate and acitretin, both have been employed in systemic 
prevention and treatment of skin (pre)cancers.  ATRA especially binds to RAR receptor 
subtypes.  Acitretin does not bind, but activates RAR receptors.  Bexarotene is an example of 
the third generation of polyaromatic retinoids or arotinoids, and binds especially to RXR 
receptors47. 
During squamous cell carcinogenesis decrease in nuclear retinoid receptors is reported : 
RXR- was relatively more decreased in AKs, and RAR- relatively more in SCCs, 
suggesting that suppression of RXR- may be an earlier event in skin carcinogenesis than 
RAR- suppression 215 
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1.3.3  
Oral/systemic retinoid treatment in prevention and treatment of 
skin (pre)cancer in RTRs 
 
Several studies have suggested a beneficial effect of systemic retinoid treatment in RTRs and 
other high-risk patients with skin cancer 27,46,73,132,180,203 ( Table 3A). Most of these studies are 
open studies in small groups of patients with different follow-up periods and variable 
treatment regimens.  Most studies suggest a beneficial effect of systemic retinoid treatment 
with either etretinate or acitretin on the development of new skin (pre)cancers, but after 
discontinuation of the treatment report recurrent tumors 46,180,203. Because retinoids only seem 
to work temporarily, long-term treatment seems indicated.  Long-term retinoid therapy 
however has been associated with side-effects 47,118,196. Therefore it seems advisable to restrict 
its use to RTRs actively developing large numbers of skin cancers 46. 
 
Table 3A. Studies on systemic retinoid treatment in RTRs 
Ref retinoid dose duration Patient 
no. 
Effect Type 
180 etretinate 1mg/kg/day 6 mo 6 Resolution in 4/6 patients. 
Recurrent tumors in 2/6 
after 6 months. 
Open 
132 acitretin 0.3mg/kg/day 5 yr 16 Significant reduction in 
tumors excised in 12/16 
patients.  Two patients lost 
due to side effects. 
Open 
27 acitretin 30 mg/day 6 mo 44 Reduction of SCCs and 
keratotic lesions in treated 
patients. 
Double blind, 
placebo-
controlled 
160 Etretinate 
& topical 
tretinoin 
0.025% 
10 mg/day 6 mo 11 After 6 mo 50% decrease 
lesions in 6/8 patients, 
including 2/3 patients on 
tretinoin alone 
Open 
203 acitretin 0.5 
mg/kg/day 
15 mo 1 No new dysplastic lesions 
during treatment and 
disappearance of existing 
verrucosities.  Return 
verrucous lesions 4 mo 
after discontinuation 
Single case 
73 etretinate 0.3 
mg/kg/day 
17 mo 11 Significant reduction of 
skin cancers compared to 
pretreatment.  
Improvement in 
hyperkeratotic lesions and 
in viral warts 
Open 
102 etretinate 50mg/day 8-13 
mo 
4 During treatment 
considerable reduction in 
number of SCCs. Rapid 
and accelerated tumor 
formation after treatment 
cessation in 2 patients 
open 
 
 
So far, only one study was randomized, double blind, placebo-controlled.  It concerned RTRs 
with more than 10 keratotic skin lesions, in which 6 months treatment with acitretin 
30mg/day lead to a significant reduction of new skin cancers in the treated group.  There was 
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also a relative decrease in keratotic skin lesions in this group.  Patients with a prior history of 
skin cancer benefited most 27. McKenna et al demonstrated that patients with five or more 
tumors prior to treatment, benefited most from acitretin treatment132. 
Kelly et al. 102 found marked reduction in SCC incidence in 4 RTRs treated with oral 
etretinate ( 50mg/d); these patients developed 23 SCC in the 12 months before treatment, 6 
SCCs on etretinate, and 34 lesions in the 12 months post-treatment. In 1 patient a rapid return 
and accelerated tumor development was noted with 21 SCCs in the 12 months after treatment 
cessation.  So there was a rapid loss of chemopreventive benefit after discontinuation of 
retinoid treatment, which implicates that long-term treatment is necessary.  
 
In none of these studies concerning systemic retinoid in RTRs, histology of (lesional) skin 
was evaluated.  Furthermore no immunohistochemical markers for keratinisation, 
proliferation, or apoptosis were applied on skin biopsies during oral retinoid treatment in 
RTRs.  Therefore in what way systemic retinoids act chemopreventive in skin (pre)cancer 
still needs further elucidation. 
Regarding topical retinoid treatment with tretinoin cream ( all-trans-retinoic acid) for 
photodamaged skin and actinic keratoses in ICIs, there are studies including histological and 
immunohistochemical changes in skin biopsies during treatment.  Most studies concerning 
topical retinoids in photoaging report an increased epidermal thickness, increased granular 
cell layer thickness, decreased melanin content and stratum corneum compaction.  
Furthermore a bluish mucin-like material was noted in the stratum corneum75,78,145,207,211,213. 
Diminished or disappearance of dysplasia and atypia was found 78,105,213. Some reported no 
clear dermal changes like for instance severity of inflammation or elastin and collagen 
content with light microscopy75, while others found reduced elastosis, increased thickness of 
papillary dermis and decreased perivascular inflammation 15. 
Immunohistochemistry was only performed in one study in which topical retinoic acid 
treatment in normal volunteers showed an induction of K6 and K13 expression, while K1, 
K10 and K14 retained a normal expression pattern 161. 
 
  
 PART IV 
Outline of the thesis 
 
Epidemiologic and etiological studies support an important role for UV radiation, 
immunosuppression, and HPV in squamous cell carcinogenesis in RTRs.  There is a need for 
improved insight in the enhanced and more aggressive squamous cell carcinogenesis in renal 
transplant recipients.  The role of the different risk factors in the enhanced carcinogenesis in 
RTRs needs further elucidation.  In addition mechanistic data on the role of HPV in skin 
cancer development are currently lacking, although currently available data suggest its role is 
different from the role in cervical cancers.  The influence of UV and HPV can expected to be 
reflected in immunohistochemical profiles for important tumor suppressors like p53 and 
INK4a-ARF.  At this moment no studies regarding p16 and p14 protein expression in 
epidermal neoplasia of RTRs are available.  
In RTRs, CSCCs tend to behave more aggressive with more frequent metastases.  At the 
moment studies on p53 and INK4a-ARF mutations in metastatic skin tumors are not 
available.  Since skin cancers are often multiple in RTRs, correct identification of the primary 
tumor responsible for metastasis is important in order to get more insight in what tumors 
behave aggressive in this patient group.  
Systemic retinoid treatment is currently applied in RTRs actively developing skin cancers, 
but so far no studies have been performed to study effects of this treatment on markers for 
keratinisation, proliferation and apoptosis in skin in order to get insight in the way retinoids 
act chemopreventive. 
 
Regarding the above, we developed the following research aims: 
1. Is the influence of risk factors for cutaneous carcinogenesis (sun exposure, HPV, and 
immune status) different in RTRs compared to ICIs? 
2. Can molecular tools aid in identifying the correct primary cutaneous squamous cell 
carcinoma in case of metastases in patients with multiple primary skin cancers? 
3. How exert retinoids their chemopreventive effect in skin tumor development? 
 
In order to address these research aims, the following research designs were formulated in 
this thesis: 
1. Immunohistochemical studies for p53, p16, and p14 were performed in order to compare 
profiles for these markers in epidermal tumors from RTRs and ICIs, in order to get insight 
in the respective roles of the different etiological factors (HPV, sun exposition, immune 
status) in cutaneous carcinogenesis of both patient groups.  By comparing profiles with 
data in the literature on profiles in HPV induced cervical neoplasia the role of HPV in skin 
cancer development of these patients might become clearer.  In addition PCR for mucosal 
HPV types was performed and related to the expression of these markers. 
2. Molecular study regarding the usefulness of p53 and INK4a-ARF mutation analysis in 
identifying primary CSCCs in case of metastases and multiple primaries was performed. 
3. To elucidate the mechanisms of action of retinoids in (pre) malignant skin disorders in 
RTRs, immunohistochemical studies with markers for keratinisation and expression of 
cell-cycle associated proteins were performed in RTRs during retinoid treatment and after 
cessation of this therapy. 
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2.1 
 
P16 and p53 Expression in (Pre)Malignant Epidermal Tumors 
of Renal Transplant Recipients and Immunocompetent 
Individuals  
 
 
Abstract 
Ultraviolet (UV) radiation is a prevailing factor implicated in the etiology of keratinocytic 
intraepidermal neoplasia (KIN) and squamous cell carcinomas (SCCs), as evidenced by the 
high frequency of UV-related mutations in the p53 and p16 tumor suppressor genes.  In renal 
transplant recipients (RTRs), immunosuppression is considered another important risk factor 
in the enhanced carcinogenesis in these patients.  So far, effects of UV and immune status on 
p53 and p16 immunoexpression in SCCs and precursors have not been studied. 
The aims of this study were to assess (1) the relation between risk factors for carcinogenesis, 
sun-exposure, and immune-status, and p16 or p53 expression, and (2) to assess differences in 
p16 and p53 expression between KINs and SCCs.  
Immunostaining for p16 and p53 was performed on paraffin-embedded sections of 23 low-
grade KIN (LKIN) lesions, 28 high-grade KINs (HKINs) and 35 SCCs from 44 RTRs and 42 
immunocompetent controls (ICIs).  
In 74/86 lesions (86%) p53 was expressed and in 63/86(76%) lesions p16 expression was 
present.  Negativity for both p16 and p53 was found in 4/86 (5%) cases, while combined 
p53/p16 staining was most prevalent (55/86 lesions, 64%).  P16 staining proved independent 
of p53 expression (p=0.8), and immune status, sun exposure and histological diagnosis 
(LKIN-HKIN-SCC) had no influence on this independency. 
Transplantation was associated with p53 expression in SCCs (p=0.02; power = 34%) caused 
by higher prevalence of p53 negative SCCs in RTRs than in ICIs (30 versus 0%).  In HKINs, 
p16 was more frequently positive than in LKINs (p=0.003; power = 49%) and SCCs 
(p=0.03; power = 53%).  HKINs showed more frequent transepidermal p16 and p53 staining 
than LKIN lesions (p < 0.001;power  99%). 
This study demonstrates that in KIN lesions and cutaneous SCCs, p16 expression is 
independent of p53 expression, and immune status, sun exposure, and histological diagnosis 
have no influence on this independency.  Furthermore, HKIN lesions express significantly 
more p16 than LKINs and SCCs.  
 
Tumor suppressors in cutaneous carcinogenesis 45 
INTRODUCTION 
 
Based on epidemiological, clinical, histopathological, and molecular studies, keratinocytic 
intraepidermal neoplasia (KIN) is considered an early step in squamous cell carcinoma (SCC) 
development 38. Ultraviolet (UV) radiation is a prevailing factor implicated in the etiology of 
KIN and SCCs as evidenced by the high frequency of UV-related mutations in both the p53 
and p16 tumor suppressor genes 110,129,187,188. 
p16INK4A (p16) is encoded by the INK4a/CDKN2A gene located on chromosome 9p21163. P16 
is a cyclin-dependent kinase inhibitor that specifically blocks the activity of cyclin-dependent 
kinases (CDKs) CDK4 and CDK6.  By binding to CDK4, p16INK4A can inhibit the 
phosphorylation of pRB with subsequent inhibition of E2F release and arrest of the cell cycle 
in G1 phase and suppression of cell proliferation.  Functional or structural loss of p16, could 
therefore lead to cell cycle propagation of potential genetically damaged cells and subsequent 
risk of tumor development.  Links between the p16 and p53 pathways are present and 
mediated by p14ARF, which is formed by an alternative reading frame in the INK4a gene, 
which is shared by p16 and p14 42,163. Therefore, loss of the INK4a gene disrupts two cell 
control pathways, one through p16INK4A /CDK4/6/pRB and the other through p14ARF 
/MDM2/p53.  
P53 mutations are the most frequent genetic alteration in SCC of the skin with reported 
incidence of 63% in sporadic tumors and 48% in skin carcinomas of RTRs 129. The majority 
of mutations bear an UV-signature. 
UV-induced mutations of p16 have been reported in sporadic SCCs (24%)110,188 and SCCs of 
xeroderma pigmentosum patients (33%). In the latter, statistically significant associations 
were found between the frequency of mutations in p53 and p16 and between the frequency of 
mutations in p53 and in p14 187. These positive associations were not found for the sporadic 
skin carcinomas 188. Furthermore, experiments in cultured human keratinocytes have 
demonstrated different induction of both p16 and p53 by UVB radiation 37. All these data 
suggest that the p53 and p16 proteins are part of parallel pathways controlling cell cycle and 
response to UV DNA damage in keratinocytes. 
Immunocompromised patients, such as renal transplant recipients, have a markedly increased 
risk of developing KINs and SCCs of the skin, especially on sun exposed parts of the body 
11,63. In these patients, besides UV, immunosuppressive treatment and human papilloma virus 
(HPV) also are considered risk factors for the enhanced cutaneous carcinogenesis 43,63,212. The 
multiplicity of skin cancers in these patients and these cancers’ more aggressive behavior, 
with metastases in a considerable number of patients, suggest that the SCCs and their 
precursors in RTRs differ from those in immunocompetent individuals (ICIs) with regard to 
their clinicopathological behavior, which might be reflected in different expression of cell-
cycle-associated proteins. 
The aims of the present clinicopathological study were: (1) to assess a possible relation 
between two risk factors for cutaneous carcinogenesis (sun exposure and immune status) and 
the expression of p16 and p53 in patients with KIN and SCCs, (2) to assess whether the 
expression of p16 and p53 are statistically independent in SCCs and their precursors, and 3) 
to assess differences in p16 and p53 expression between KINs and SCCs.  
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MATERIALS AND METHODS 
 
Patients and histopathology 
For this retrospective study we retrieved formalin-fixed and paraffin-embedded skin 
excisions of 51 KIN lesions and 35 SCCs from 44 RTRs and 42 normal ICIs out of our 
archival material at the Department of Pathology, University Medical Center Nijmegen 
St.Radboud, Nijmegen, the Netherlands. 
Histology of all lesions was reviewed by the same dermatopathologist.  A KIN classification 
was applied to all dysplastic skin lesions according to the criteria for KIN grading proposed 
by Cockerell in 2000 38. In this grading system KIN I is histologically characterized by focal 
atypia of basal keratinocytes of the lower one third of the epidermis; KIN II lesions 
demonstrate (focal) atypia of keratinocytes in the lower two thirds of the epidermis (often 
with hyperkeratosis and sparing or some involvement of acrotrichia and acrosyringia and/or 
presence of acanthosis and/or basal budding).  KIN III lesions are characterized by a diffuse 
atypical keratinocytic proliferation involving the full thickness of the epidermis.  We 
considered KIN I and II to be low-grade KIN (LKIN), corresponding to actinic keratoses 
(AKs).  KIN III was considered to be high-grade intraepidermal neoplasia (HKIN), 
corresponding to Bowen’s disease or squamous cell carcinoma in situ 68. This separation was 
made because clinical behavior and, subsequently, treatment of AKs is generally different 
from Bowen’s disease. 
SCCs were classified according to their most poorly differentiated region and a 
subclassification in three categories of  well, moderately and poorly differentiated was used 
131. 
 
Immunohistochemistry 
Immunohistochemical analysis was performed on all lesions using a standard avidin-biotin-
peroxidase complex system with diaminobenzidine as the chromogen.  In brief, 4-μm-thick 
paraffin sections were deparaffinized, hydrated, and washed in phosphate buffered saline. 
The antibodies used, pretreatment and dilutions are listed in Table 1.  For p16 
immunostaining we used the p16INK4A Ab-4, clone 16PO4 or JC2 (Neomarkers, Fremont, 
CA).  With this antibody we have experience in (pre)malignant lesions of the uterine cervix 
with comparable results, as reported in literature 103,167. Furthermore, this is one of the few 
p16 antibodies with a known epitope (aa1-32 of p16), whereas the epitope has not yet been 
determined for most other p16 antibodies. 
After incubation with primary antibodies, sections were incubated for 30 minutes with 
biotinylated horse anti-mouse (1:200, Vector Laboratories, Burlingame, CA), followed by 45 
minutes’ incubation with avidin-biotin complex (1:50, Vector laboratories). 
Sections were counterstained with Mayer’s hematoxylin. 
 
 
Table 1.  Antibodies with used dilution, pretreatment, incubation time, and temperature. 
Antibody Antigen Source Dilution Pretreatment Temperature 
DO7 p53 Neomarkers, 
Fremont CA 
1:400 microwave 40C overnight 
P16INK4 Ab-4   
clone 16PO4 or JC2 
aa 1-32 of 
p16INK4a 
Neomarkers, 
Fremont CA 
1:100 microwave 40C overnight 
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Quantification of immunohistochemical results 
Immunoreactivity was scored semiquantitatively: 0  (negative), 1+ (10% of lesional cells 
positive), 2+ (10-50% of lesional cells positive), or 3+ (> 50% lesional cells positive). 
In addition, in positive-staining KIN lesions, localization of p16 and p53 immunoreactivity in 
the epidermal cell layers was assessed: 0 = only basal layer positivity, 1 = positivity confined 
to basal one third of epidermis, 2 = positivity confined to basal two thirds of epidermis, or 3 = 
transepidermal positive staining.  
Scoring was performed without knowledge of patient history. 
 
Statistics 
The association between the presence of p16- and p53-expression was assessed with 2 x 2 
contingency tables.  The presence of p16 and p53 expression is statistical independent if the 
conditional odds ratios between p16 and p53 expression do not differ significantly from 1.  
On the basis of the two presently studied risk factors (sun exposure and immune status), four 
risk groups were discerned,  and on the basis of the histological diagnosis, patients were 
divided in three groups  (LKIN, HKIN and SCC).  It may be possible that the association 
between the presence of p16 and p53 expression depends on the risk factors and/or the 
severity of the skin lesion.  Therefore, analyses of stratified 2 x 2 tables were performed.  The 
associations between the presence of p16 and p53 expression for the separate strata were 
tested with the Fisher’s exact test.  The Breslow-Day statistic was used to test whether the 
associations, defined in terms of conditional odds ratios, are equal for the different strata 
(testing the homogeneity of odds ratios).  The Mantel-Haenszel estimator was used as a 
common odds ratio for the several strata.  This estimator was used to test whether the 
estimated common odds ratio differed significantly from 1. If the Breslow-Day test for 
homogeneity of odds ratios and Mantel-Haenszel test for conditional independence resulted 
in P values > 0.05, we concluded that the presence of p16-expression is statistically 
independent on the expression of p53 and that this independency is not influenced by sun-
exposure and immune status or histological diagnosis.  
The differences between LKIN, HKIN, and SCC with regard to the extent of p53 and p16 
expression in relation to the risk factors were analyzed by means of I  X  J  two-way 
contingency tables. The same analyses were also used to assess the differences between well, 
moderately and poorly differentiated SCCs with regard to extent of p53 and p16 expression 
in relation to the two risk factors.  In these analysis significance was set at  P  0.05. 
The SPSS exact tests, available in SPSS 10.0 for Windows,  were used instead of the large-
sample approximations to obtain the exact P values.  Detailed information concerning the 
aforementioned statistical procedures is given in the literature2. 
Because of relatively small patient numbers, power analysis was performed using Power and 
Precision 2 (http://www.Power-Analysis.com).  Fisher’s exact method or the Casagrande and 
Pike method (approximation of Fisher’s exact test) was used to compute power for the 
Fisher’s exact tests performed. 
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RESULTS 
 
Patients 
Table 2 summarizes the data from all analyzed lesions. 
Lesions from the head and neck region, hands, and forearms were considered as sun-exposed: 
65 of the examined 86 lesions came from sun-exposed sites (75%), 18 cases (21%), from 
nonexposed sites; and in 3 cases, the localization was unknown (4%). 
 
Table 2.  Summary of cases. 
All cases n=86 M: F Age (mean±SD) Lesion type and number 
RTRs n=44 24:20 55.3±9.3 LKIN n=10 
HKIN n=14 
SCC n=20 
ICIs   n=42 21:21 72.5±11.4 LKIN n=13 
HKIN n=14 
SCC n=15 
 
Dependency of p16 expression on p53 expression in relation to the four combinations of 
the two studied risk factors (sun exposure and immune status) 
The frequencies of cases with regard to the expression of p16 and p53 in the 4 different risk 
categories are given in Table 3 for 83/86 lesions (of 3 lesions, localization and therefore sun 
exposure were unknown).  The Fisher’s exact test disclosed that in each of the four different 
risk groups the expression of p16 and p53 is statistically independent.  The Mantel-Haenszel 
test disclosed that the odds ratios in the four risk groups did not significantly differ from 1 (P 
= 0.82), and the Breslow-Day test disclosed that the four odd ratios for these risk groups did 
not differ significantly (P = 0.32).  
Therefore, the expression of p16 and p53 are conditionally independent and homogeneous for 
the four risk groups examined in this study.  
In RTRs, 10/44 (23%) cases were p53-/p16+, compared to 5/42 (12%) cases in ICIs and these 
differences were also not statistically different ( P = 0.26; power = 53%). 
 
Table 3.  The four expression patterns for p16 and p53 in relation to the 4 combinations of the 2 studied 
risk factors, transplantation status and sun exposure, in 83 of the 86 patients (in 3, specimen localization 
of the lesion was unknown).  
Risk factors P16-/p53- 
No. 
(percentage) 
P16-/p53+ 
No. 
(percentage) 
 
P16+/p53- 
No. 
(percentage) 
 
P16+/p53+ 
No. 
(percentage) 
 
Fisher test 
two-tailed  
p-value  
Power  
(Casagrande 
and Pike) 
Sun-/RTR-   
(N=9) 
1 (11%) 2 (22%) 0 6   (67%) 0.3 20% 
Sun-/RTR+  
(N=9) 
0 1 (11%) 2 (22%) 6   (67%) >0.9 48% 
Sun+/RTR-  
(N=32) 
1 (3%) 9 (28%) 5 (16%) 17 (53%) 0.6 61% 
Sun+/RTR+ 
(N=33) 
2 (6%) 7 (21%) 7 (21%) 17 (52%) >0.9 72% 
TOTAL        
(N=83) 
N=4 (5%) N=19 (23%) N=14(17%) N=46 (55%) 0.8 96% 
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Dependency of p16-expression on p53-expression in relation to histological diagnosis ( of 
LKIN, HKIN, and SCC) 
The frequencies of the 4 different expression patterns of p16 and p53 for patients with KIN 
and SSC are given in Table 4.  This table discloses that absence of both p16 and p53 was 
only present in 4/86 (5%) specimen, whereas combined expression of p53 and p16 was most 
prevalent in 48/86 (56%) cases. 
 
 
 
Table 4.  The expression patterns for p16 and p53 in relation to lesion type for the whole group of 86 
patients.  
Lesion type P16-/p53- 
No. 
(percentage) 
P16-/p53+ 
No. 
(percentage) 
P16+/p53- 
No. 
(percentage) 
P16+/p53+ 
No. 
(percentage) 
Fisher test 
two-tailed 
p-value 
Power 
(Casagrande 
and Pike) 
LKIN  
(N=23) 
2 (9%) 8 (35%) 5 (22%) 8  (35%) 0.4 20% 
HKIN  
(N=28) 
0 2 (7%) 6 (21%) 20 (71%) >0.9 68% 
SCC     
(N=35) 
2 (6%) 9 (26%) 4 (11%) 20 (57%) >0.9 76% 
TOTAL 
(N=86) 
N=4 (5%) N=19 (22%) N=15 (17%) N=48 (56%) 0.8 98% 
The Fisher’s exact test disclosed that in LKIN, HKIN and SCC the expression of p16 and p53 are 
statistically independent. 
 
The Fisher’s exact test disclosed that in low-grade KIN, high-grade KIN, and SCC, the 
expressions of p16 and p53 are statistically independent.  The Mantel-Haenszel test disclosed 
that the odds ratios in these three diagnostic groups did not significantly differ from 1 (P = 
0.6), and the Breslow-Day test disclosed that the three odd ratios for LKIN, HKIN, and SCC 
did not differ significantly (P = 0.62).  Therefore, the expression of p53 and p16 are 
conditionally independent and homogeneous for LKIN, HKIN, and SCCs (also see Fig.1 for 
illustration of immunohistochemical staining combinations for p16 and p53).  
 
 
The extensiveness of the p16 expression in KINs and SCCs 
P16 staining was cytoplasmic, or was both cytoplasmic and nuclear.  We considered both 
strong cytoplasmic staining as well as nuclear staining to be positive reaction, in analogue to 
previous studies on the uterine cervix 99,103,167. Normal epidermis showed only positive 
staining in melanocytes, with absent staining in keratinocytes (Fig.2A). 
In total, 63/86 (73%) lesions were p16 positive, and 23/86, negative (27%; Table 5).  In our 
series, none of the lesions showed exclusive nuclear staining.  The combined nuclear and 
cytoplasmic p16 staining was most prevalent and was present in 54 cases (63%).  Only nine 
cases (10%) showed exclusively cytoplasmic staining (three LKIN lesions and six SCCs). 
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FIGURE 1 
A-B: positive p53 (A) with absent p16INK4A (B) expression in KIN II of an immunocompetent control patient.  
P53 staining is restricted to the dysplastic basal two thirds of the epidermis. 
C-D: strong transepidermal expression of p53 (C, nuclear staining) and p16INK4A (D, nuclear and cytoplasmic) in 
a KIN 3 lesion (high grade KIN) of an immunocompetent patient. 
E- F: positive nuclear p53 (E) and absent p16 (F) staining in a squamous cell carcinoma of an 
immunocompetent individual. 
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FIGURE 2 
P16 expression patterns in normal skin (A) with only dendritic melanocytes staining positive; in LKIN of renal 
transplant recipient (RTR) showing more focal p16 staining in basal two thirds of the epidermis (B); and in 
HKIN of RTR with diffuse and strong, nuclear and cytoplasmic, transepidermal p16 staining, with sharp 
demarcation from normal skin (C-E), and in a SCC of RTR (F). 
 
Table 5.  P16 expression in LKIN, HKIN, and SCCs in the patient group as a whole.  
 LKIN  N=23 HKIN  N=28 SCC   N=35 Total  N=86 
P16 negative 10 (43%) 2   (7%) 11 (31%) 23 (27%) 
P16 cytopl positive 3   (13%) 0 6   (17%) 9   (10%) 
P16 combined nucl. & 
cytopl positive 
10 (43%) 26 (93%) 18 (51%) 54 (63%) 
Basal 1/3 5 0   
Basal 2/3 5  0   
transepidermal 3 26   
In KIN lesions further specified by location. As for p53  (Table 6), strongly significant more frequent 
transepidermal staining is present in HKIN compared to LKIN (P < 0.001). 
 
Figure 3, A-B, illustrates the percentage of p16-positive-stained lesional cells in LKIN, HKIN, 
and SCCs for RTRs and ICIs, respectively. Statistical analysis disclosed no significant 
differences between ICIs and RTRs concerning the frequencies of the four p16 staining 
A B
C D
E F
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categories for LKIN ( P = 0.22; power = 68%), HKIN (P = 0.46; power > 66%), and SCC (P = 
0.44; power = 74%).  
In fig.3E the extensiveness of p16 expression in well, moderately and poorly differentiated SCC, 
pooled over ICIs and RTRs, are given. The differences between the well, moderately and poorly 
differentiated tumors were not significant (p=0.20). 
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FIGURE 3 
Percentages of p16 (A, B) and p53 (C, D) positive lesional cells in LKIN, HKIN, and SCCs for the RTRs and the 
ICIs, respectively. 
In E and F the percentage of positive lesional cells for p16 and p53, respectively, are given in all combined SCCs 
divided in well, moderately and poorly differentiated tumors. 
 
Table 5 shows for KIN lesions the epidermal localization of p16 staining and discloses that 
HKIN lesions were more frequently positive than LKIN lesions (P = 0.003; power = 49%) 
and SCCs ( P = 0.03; power = 53%). Furthermore, strongly significant, more frequent 
transepidermal p16 staining was present in HKIN compared to LKIN (P < 0.001;power = 
100%); epidermal localization of p16 staining proved strongly correlated with KIN grade (r = 
0.83; P < 0.001; power = 100%). 
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In all p16 expressing HKIN lesions, a transepithelial expression was observed, whereas in 
only 3 of 13 LKIN lesions (23%) such an expression was found. The LKIN lesions with a 
transepithelial expression were morphologically classified as moderate dysplasia/KIN II. In 
HKIN lesions, p16 staining was continuously and diffuse present throughout all epidermal 
layers, with sharp demarcation between the normal and dysplastic epidermis (fig.2, C-E). 
 
The extensiveness of the p53-expression in KINs and SCCs 
P53 staining was nuclear. Normal epidermis showed only slight nuclear staining in a few 
scattered basal keratinocytes.  
In total, 74/86 lesions (86%) were p53 positive and 12/86 (14%) were p53 negative (Table 6). 
Percentages of p53-positive lesional cells in LKIN, HKIN, and SCCs for the RTRs and the ICIs, 
respectively, are illustrated in Figure 3, C-D. For LKIN and HKIN no significant differences 
were found between ICIs and RTRs with regard to the frequencies of the four p53-
immunostaining categories (P  0.65; power = 72% and 61% respectively). Only for SCCs was 
a significant difference in the prevalence of p53 positivity present between RTRs and ICIs (P 
= 0.02; power = 47%), due to a significantly higher frequency of SCC without p53 expression 
in RTR (6/20=30%) than in ICI (0/15=0%).  The extensiveness of p53 expression in SCC was 
highly associated with grade of the SCC. The percentage of SCCs with > 50% positive lesional 
cells increased with decrease in differentiation grade (Fig. 3F). In well, moderately and poorly 
differentiated SCCs respectively 14%, 68%, and 89% of the tumors showed >50% positive 
tumor cells. The prevalence of well, moderately and poorly differentiated SCCs in ICIs and 
RTRs was not significantly different (P = 0.26; power =66%). Therefore, the above-described 
significantly higher frequency of p53-negative SCCs in RTRs is not attributable to different 
prevalence of tumor grades between both groups. 
As for p16, in KIN lesions, strongly significant, more frequent transepidermal p53 staining was 
present in HKIN lesions compared to LKIN lesions (P < 0.001: Table 6; power = 99%). 
Transepithelial staining was observed in 22/28 (79%) of p53-positive HKIN, and in only 1/17 
(6%) of p53-positive LKIN lesions. Absence of p53 staining was exclusively found in LKIN, 
and p53 expression was positively correlated with KIN grade (r = 0.42; P < 0.001; power = 
43%). 
 
Table  6. P53 expression in LKIN, HKIN, and SCCs in the patient group as a whole, specified by location 
in KIN lesions.  
 LKIN 
N=23 
HKIN 
N=28 
SCC 
N=35 
Total 
N=86 
P53 negative 6 (26%) 0   (0%) 6 (17%) 12 (14%) 
P53 positive 17 (74%) 28 (100%) 29 (83%) 74 (86%) 
Basal layer 1 6   
Basal 1/3  8 0   
Basal 2/3  7 0   
Transepidermal 1 22   
Strongly significant more frequent transepidermal staining is present in HKIN compared to LKIN (P < 0.001). 
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DISCUSSION 
 
The present study is the first regarding immunohistochemical expression patterns of p16 in 
KIN and SCCs of RTRs. RTRs develop multiple HPV-induced warts, AKs and non 
melanoma skin cancers, especially on sun-exposed areas, which are directly related to the 
extent and duration of immunosuppression 16,26,82,86,94,210. In these immunosuppressed patients, 
it is thought that DNA repair and apoptotic mechanisms are abrogated by UV and HPVs and, 
along with the altered immune surveillance of these patients, might allow progression of 
benign HPV epidermal lesions to malignancy.  
In this study we show that both p16 as well as p53 are frequently overexpressed in KIN and 
SCCs of both RTRs and ICIs and that the expression of p16 is independent of p53 expression. 
This independency on the protein level parallels previous molecular findings in sporadic 
SCCs, in which p16 and p53 mutations proved to be independent events 188. Recently, it was 
also demonstrated that the p16 and the p53 protein were differently modulated by UV 
depending on the dose and regimen 37. These latter in vitro results strongly infer that both 
proteins are part of parallel pathways controlling response of keratinocytes to UV DNA 
damage. In our clinicopathological study, we found that the expression of p16 and p53 in skin 
lesions for sun exposed and non-sun exposed areas of the body did not differ, suggesting that 
the p16-p53 parallelism is not influenced by UV radiation.  
In addition, we found that p16 and p53 expression were conditional independent of RTR 
status. We found that combined p16-p53 expression was most prevalent (46/86 lesions, 56%). 
Together, these observations suggest that both p16 and p53 are strongly involved in 
epidermal carcinogenesis but that expression levels of both proteins are independent of 
etiologic factors (sun exposure and immune status). Therefore, RTRs seem to use comparable 
pathways in skin cancer development as ICIs despite differences in immune status, but their 
susceptibility and rate to develop SCCs might well be determined by the deficient immune 
system. 
Immune status was associated with p53 expression in SCCs (P = 0.02) because of a higher 
prevalence of p53-negative cases in RTRs compared to ICIs (30% versus 0%). Therefore, 
p53 seems differently involved in late stages of epidermal neoplasia in transplant recipients. 
Although in the present study, we did not perform PCR analysis for HPV status, one could 
speculate that the higher incidence of p53 negative tumors in RTRs suggests involvement of 
(oncogenic) HPV in the RTR group.  
In cervical lesions, p53 is inactivated due to the transforming activities of the E6 viral 
oncoprotein of the mucosal high-risk HPV types, for instance HPV16 99,192.  Overexpression 
of p16 in the (pre)malignant lesions of the uterine cervix is assumed to be the consequence of 
the inactivation of pRb by E7 of high-risk HPV types [Sano, 1998 #448}. So far, the 
knowledge on transforming properties of E6 and E7 of cutaneous HPV types is limited. In 
contrast to cervical cancer, in which high-risk HPV DNA becomes integrated in the host 
genome, in NMSCs containing presumed oncogenic HPV types, HPV integration is rare, and 
it was shown that E6 oncoprotein of, for instance, the cutaneous epidermodysplasia 
verruciformis-associated HPV38 could not degrade p53 protein 34,121. Surprisingly, HPV 38 
E6/E7-positive cells also did not express p16, in contrast to HPV 16 E6/E7-positive cells, 
whereas both HPV 38 and HPV 16 E7 had similar biological properties and both were able to 
inactivate pRb34. We were unable to demonstrate statistical linkage of the combined staining 
pattern with p53 negativity and p16 positivity (indicative of oncogenic HPV involvement) to 
the RTR population (P = 0.26). Therefore, based on the immunoexpression profiles for p53 
and p16 presently found, and because of the incomplete knowledge of the interactions of 
cutaneous E6 and E7 proteins with p53 and p16, the role of HPV in cutaneous carcinogenesis 
in RTRs remains speculative.  
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So far only a few studies have evaluated p16 immunoexpression in cutaneous SCCs and 
precursors. Hodges and Smoller 87 described p16 positivity in all 10 AKs, SCC in situ lesions, 
and SCCs studied, with the use of a different antibody (G175-405, Pharmingen, San Diego, 
CA) but a comparable scoring system, although cellular localization (either cytoplasmic 
and/or nuclear staining) was not further specified. Transepidermal staining was only present 
in SCC in situ, comparable to our results in HKINs. In contrast, we found statistically 
significant more p16 positivity in HKIN lesions (93%) than in LKIN and SCCs (57% and 
69% respectively, P = 0.003 and P = 0.03). Mortier et al. 140 found p16 expression in 66% of 
AKs and only 10% of SCCs, without specification of the used scoring method. In contrast to 
our data and those of Hodges and Smoller, those investigators also describe p16 expression in 
normal skin with the use of their antibody (G175-405, Pharmingen). 
Combined mutation analysis with immunohistochemistry for p16 so far was only performed 
by Chang et al. 35 , albeit on a very small number of SCCs (6 cases): two of six SCCs showed 
positive nuclear staining for p16 (anti-p16 antibody, C-20; Santa Cruz Biotechnology), and  
four of six SCCs were negative. In all cases, wild type p16 was present and no mutations 
could be demonstrated, implicating that immunohistochemical findings cannot directly be 
correlated to underlying molecular alterations. These conflicting results with respect to p16 
staining in SCCs of skin and precursors seem related to usage of different p16 antibodies, 
often-small patient numbers, and different immunohistochemical scoring methods.  The 
question arises as to what these different p16 antibodies actually recognize.  
In imitation of immunohistochemical studies on p16 expression in (pre)malignant lesions of 
the uterine cervix, we considered both nuclear and strong cytoplasmic p16 staining as a 
positive reaction 99,103,167.  Yet we have to admit that up to now, the significance of 
cytoplasmic p16 staining is still unclear, and conflicting data have been presented with 
respect to the specificity of cytoplasmic p16 staining in adenocarcinomas 71,178. In our series, 
none of the lesions showed exclusive nuclear staining: the combined nuclear and cytoplasmic 
p16 staining was most prevalent: 54 cases (63%) and only 9 cases (10%) showed exclusively 
cytoplasmic staining (3 LKIN lesions and 6 SCCs). When considering only the cases with 
combined staining to be p16 positive, statistical analysis disclosed no effects on the presented 
conclusions (data not shown). 
In conclusion, according to our data, squamous cell carcinogenesis in RTRs seems to occur 
along comparable pathways as in ICIs, with independent parallel involvement of both the p53 
and the p16 pathway. The present study demonstrates that p53 and p16 immunoexpression 
are conditionally independent of the two studied risk factors, transplantation status and sun 
exposure. The expression of p16 proved conditionally independent of the p53 expression in 
KIN and SCCs, and immune status and sun-exposition had no influence on this conditional 
independence.  Future studies combining immunohistochemistry and molecular data are 
needed to elucidate the exact role of p16 in epidermal carcinogenesis. 
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2.2 
 
 
P14 Expression and HPV in keratinocytic intraepidermal neoplasia (KIN) 
and cutaneous squamous cell carcinoma  
 
Abstract 
The tumor suppressor p14 forms a connection between the two main pathways governing cell 
growth, namely the p14-MDM2-p53 and p16-CDK4/6-RB pathway.  Previously, we found 
high-grade keratinocytic intraepidermal neoplasia (HKIN) lesions to frequently overexpress 
the tumor suppressor proteins p53 and p16.  The expression of p14 in KIN lesions has not 
been studied yet.  In skin tumors sun exposition, immune suppression and HPV are important 
etiological factors. 
Based on findings in cervical carcinogenesis, one could hypothesize that p14 and p16 would 
be overexpressed in HPV associated cases and based on in vitro studies inverse relations 
between p53 and p14 expression could be expected.  
The aims of this study were to assess 1)  whether the expression of p14, p16 and p53 are 
statistically independent in KINs and cutaneous squamous cell carcinomas (CSCCs), and 2) 
to assess a relation with etiological factors for cutaneous carcinogenesis (sun exposure and 
immune status), and 3) to determine the presence of mucosal HPV types in KINS and CSCCs.  
Immunostaining for p14, p16 and p53 was performed on paraffin embedded sections of 22 
low grade KIN (LKIN) lesions, 49 HKINs, and 34 CSCCs from 52 RTRs and 53 ICIs.  HPV 
detection was performed on consecutive sections using a short PCR fragment (SPF-LiPA) 
assay, allowing for the simultaneous detection, and typing of 25 mucosal HPV genotypes.  
P14 was expressed in a total of 42/105 lesions (40%).  In LKIN lesions 22% was p14 
positive, in HKINs 57%, and in CSCCs 50% of cases were p14 positive (p=0.05). P14 
expression proved independent of the expression of both p53 and p16, and immune status, 
sun-exposure and histological diagnosis had no influence on this independency. 
Only 2/105 specimens, both HKIN lesions in ICIs, contained HPV X and none of the 25 
known mucosal genotypes was detected.  Due to this low number of HPV positive cases no 
correlations with tumor suppressor protein expression could be studied. 
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INTRODUCTION  
 
Cell growth is controlled by two main pathways, one involving the retinoblastoma protein 
(pRb), regulating exit from the G1 phase of the cell cycle, and one involving the p53 protein 
that induces growth arrest or apoptosis in response to cellular stress or DNA damage.  
pRb is inactivated by phosphorylation, and inactivation of RB releases the E2F1 transcription 
factor from the RB complex.  This factor regulates the expression of many genes involved in 
entry and progression through the S phase of the cell cycle.  
Connections between the p53 and pRb pathways are provided by MDM2, by p21 and an 
additional important junction is provided by the INK4a-ARF locus located on human 
chromosome 9p21.  This locus, by alternative transcripts encodes for two proteins 
p16INK4a//p16 (exons 1, 2 and 3), and p14ARF /p14 (exons 1 and 2). 
Overexpression of p16 inhibits entry and progression into the S phase of the cell cycle by 
inhibition of  CDK4 and 6, thereby preventing phosphorylation of RB and release of E2F.  
Loss of p16 may allow excessive activity of CDKs, promoting RB phosphorylation and 
proliferation of tumor cells. 
Unlike p16, p14ARF (p14) does not bind to CDKs.  P14 interacts with MDM2 and sequesters 
MDM2 in the nucleolus and enables p53 stabilization.  P53 has an important function in cell 
cycle arrest and apoptosis.  Also E2F1-induced activation of p53 is mediated by p14, which is 
transcriptionally activated by E2F1 54,174.  This responsiveness of p14 to E2F1 makes p14 an 
important nexus between the pRB and p53 pathways.  The p14-E2F1 interplay enables the 
cell to sense oncogenic stimuli transduced through the RB-pathway, such as p16 inactivation.  
P14 is also induced by oncogenes such as myc and ras, and some viral oncogenes.  
Furthermore, p53 negatively regulates p14 creating a negative feedback loop  between p14 
and p53 193, which explains the reported  inverse correlation between p14 and p53 expression 
in human tumor cell lines 193.  
Therefore p14 plays a central role in cell cycle control, by integrating all kind of stimuli and 
by targeting at least two of the key pathways in control of cell cycle, namely the p14-MDM2-
p53 pathway and the p16-CDK4/6-RB pathway. 
Previously, we have studied the expression of p16 and p53 in (pre)malignant epidermal 
tumors of renal transplant recipients (RTRs) and immunocompetent individuals (ICIs) 18.  At 
present, there is only one study regarding p14 expression in skin tumors 32. 
From studies on cervical (pre)cancer, it is known that the three-tumor suppressors p53, p16 
and p14, are all influenced by the presence of HPV.  In cervical carcinogenesis, the E6 and 
E7 oncoproteins of high-risk HPV attribute to tumor development by inactivating p53 and 
Rb, leading to overexpression of p16 and p14 166.  In skin tumors of both RTRs and ICIs, the 
presence of HPV DNA is reported, including high-risk mucosal HPV types 89,164,173, although 
data on frequency and types found are conflicting.  We speculated that if high-risk mucosal 
HPV types indeed play a role in cutaneous carcinogenesis, comparable effects of HPV on 
expression of the tumor suppressors p14, p16, and p53 could be expected in skin tumors. 
Immunocompromised patients, such as renal transplant recipients, have a markedly increased 
risk to develop KINs and SCCs of the skin 11,63.  In these patients besides UV, also 
immunosuppressive treatment and Human Papilloma Virus (HPV), are considered risk 
factors for the enhanced cutaneous carcinogenesis 43,63,212.  The multiplicity of skin cancers in 
these patients and their more aggressive behavior with metastases in a considerable number 
of patients, suggest that the SCCs and their precursors in RTRs differ from those in ICIs with 
regard to their clinic pathological behavior which might be reflected in different expression 
of cell-cycle associated proteins. 
The aims of the present study were : 1) to assess whether the expression of p14 /p53, and p14 
/p16 are statistically independent in CSCCs and their precursors, and 2) to assess a possible 
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relation with risk factor for cutaneous carcinogenesis ( sun exposure and immune status), and 
3) to determine the presence of mucosal HPV types in order to clarify the role of (high risk) 
mucosal HPV types in skin carcinogenesis. 
 
MATERIALS AND METHODS 
 
Patients and histopathology 
For this retrospective study we retrieved 105 formalin fixed and paraffin embedded 
keratinocytic intraepidermal neoplasia (KIN) lesions and SCCs from immunocompetent 
individuals (ICIs) and renal transplant recipients (RTRs) out of our archival material at the 
Department of Pathology, Radboud University Nijmegen Medical Center, the Netherlands.  
Histology of all lesions was revised by the same dermatopathologist.  All dysplastic skin 
lesions were classified according to the proposed criteria for KIN grading by Cockerell in 
2000 38.  In this grading system KIN I is histologically characterized by focal atypia of basal 
keratinocytes of the lower one third of the epidermis; KIN II lesions demonstrate (focal) 
atypia of keratinocytes in the lower two thirds of the epidermis (often with hyperkeratosis 
and sparing or some involvement of acrotrichia and acrosyringia and/or presence of 
acanthosis and/or basal budding).  KIN III lesions are characterized by a diffuse atypical 
keratinocytic proliferation involving the full thickness of the epidermis.  We considered KIN 
I and II as low grade KIN (LKIN), corresponding to actinic keratoses (AKs).  KIN III was 
considered as high-grade intraepidermal neoplasia (HKIN), corresponding to Bowen disease 
or squamous cell carcinoma in situ.  This distinction was made since clinical behavior and 
subsequently treatment of actinic keratoses is generally different from Bowen’s disease. 
SCCs were classified according to their most poorly differentiated region and a sub 
classification in 3 categories of  “well”, “moderately” and “poorly” differentiated was used 
131. 
 
Immunohistochemistry 
For p14, p16 and p53 immunohistochemistry,  4μm thick paraffin sections were 
deparaffinized, hydrated and washed in buffered saline phosphate (PBS).  Microwave 
pretreatment consisted of 3 min. cooking in citrate buffer (0.01M, pH6.0) at 850 Watt, and 10 
min cooking at 180 Watt.  After preincubation with 20% normal goat serum for 10 min, 
sections were incubated with primary antibodies for 60 min at room temperature.  
For detection of p14, Ab-2, clone 14PO2 , lot no 850P203 (Neomarkers, Fremont, CA, USA; 
dilution 1:200) was used,; for p53, Ab-5 (DO-7), lot no 186p306 (Neomarkers, Fremont, CA, 
USA; dilution 1:200) was used and for p16,  we employed p16INK4A Ab-4, clone 16PO4 or 
JC2 , lot no 887P301 (Neomarkers, Fremont, CA, USA; dilution 1:500). 
After rinsing in PBS, 15 min post-antibody blocking (powervision plus) was performed 
followed by 30 min incubation with Poly-HRP-anti-mouse/rabbit/rat IgG (ready-to-use) (Kit 
Powervision and Poly-HRP-AntiMs/Rb/Rt IgG Biotin-free, one component ready-to-use, 
Immunologic, Duiven, the Netherlands, Code DPVO-999HRP, Lot.no. 30210-410).  For 
development, diaminobenzidine (DAB) was used as the chromogen. 
Sections were briefly counterstained with Mayer’s haematoxylin. 
Quantification of immunohistochemical results 
P16 and p53 immunoreactivity was scored semi-quantitatively as previously described 18, and  
the same method was applied for scoring  p14 immunoreactivity.  In brief, immunoreactivity 
was scored semi-quantitatively: 0  (negative), 1+ (up to 10% of lesional cells positive), 2+ 
(10-50% positive lesional cells), or 3+ (> 50% positive lesional cells).  In addition, in positive 
staining KIN lesions, localization of p16 and p53 immunoreactivity in the epidermal cell 
layers was assessed: 0= only basal layer positivity, 1=positivity confined to basal 1/3 of 
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epidermis, 2=positivity confined to basal 2/3 of epidermis or 3= transepidermal positive 
staining.  Scoring was performed without knowledge of patient history.  
 
HPV detection and genotyping by SPF10-LiPA  
A single 4-μm thick flanking tissue section obtained from the same tissue specimen as was 
used for the immunohistochemical staining, was put into a reaction tube and incubated 
overnight at 56˚C in 200 μl of 10 mM Tris-HCl with 1 mM EDTA, 0.2% Tween-20, and 
proteinase K (0.3mg/ml).  Proteinase K was inactivated by 10 min incubation at 100˚C.  The 
sample was centrifuged for 10 min at 11.000 rpm and 10 μl was directly used for PCR 
analysis.  A water blank control was processed with each batch of ten samples.  HPV 
detection was performed using a short PCR fragment (SPF10-PCR) assay 
104,134.  The SPF-
PCR system amplifies a 65 bp fragment of the L1 open reading frame, allowing for detection 
of at least 43 HPV types.  In case of positive PCR result, subsequent HPV genotyping was 
performed via a reverse hybridization line probe assay (LiPA), allowing for simultaneous 
typing of the following 25 genotypes of HPV 6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 
45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 70, and 74.  This combined SPF10-LiPA system for 
detection and genotyping of HPV has previously been described in detail134.  This HPV 
detection test is highly sensitive, specific, and reproducible and has been clinically validated 
104,134,165.  All specimens were processed separately to avoid cross-contamination. 
 
Statistics 
In this study, the data were analyzed by non-parametric statistical procedures because the 
Lilliefors test for normality disclosed that the percentage of p16, p14 and p53 expression 
were not Gaussian distributed.  
The association between the presence of p14- and p53-expression and between the presence 
of p14- and p16-expression was assessed with 2x2 contingency tables.  The presence of p14 
and p53 or p16 expression is statistical independent if the conditional odds ratios between 
p16- and p53-expression do not differ significantly from 1.  On the basis of the two presently 
studied risk factors (sun exposure and immune status) four risk groups were discerned, and 
on the basis of the histological diagnosis patients were divided in three groups  (LKIN, HKIN 
and SCC).  It may be possible that the association between the presence of p16- and p53-
expression depends on the risk factors and/or the severity of the skin lesion.  Therefore, 
analyses of stratified 2x2 tables were performed.  The associations between the presence of 
p16- and p53-expression for the separate strata were tested with the Fisher exact test.  The 
Breslow-Day statistic was used to test whether the associations, defined in terms of 
conditional odds ratios, are equal for the different strata (testing the homogeneity of odds 
ratios).  The Mantel-Haenszel estimator was used as a common odds ratio for the several 
strata.  This estimator was used to test whether the estimated common odds ratio differed 
significantly from 1.  If Breslow-Day test for homogeneity of odds ratios and Mantel-
Haenszel test for conditional independence resulted in p-values greater than 0.05, we 
conclude that the presence of p14-expression is statistically independent on the expression of 
p53 or p16 and that this independency is not influenced by sun-exposure and immune status 
or histological diagnosis.  
The difference between LKIN, HKIN, and SCC with regard to the extent of p14 expression 
was analyzed by means of I X J contingency tables.  In these analysis significance was set at 
p 0.05. 
The SPSS exact tests, available in SPSS 10.0 for Windows, were used to obtain the exact p-
values instead of the large-sample approximations for the p-values.  Detailed information 
concerning the afore mentioned statistical procedures are given in the literature2. 
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RESULTS 
 
Patients 
Table 1 summarizes the data from all analyzed lesions. 
Lesions from the head and neck region, hands, and forearms were considered as sun-exposed 
sites: 75 of the 105 examined lesions came from sun-exposed sites (71%), 30 cases from 
nonexposed sites (29%).  
 
 
Table 1.  Data of all analyzed lesions.  
 LKIN HKIN SCC Total 
ICI   6 (11%) 30 (58%) 16 (31%) 53 
RTR  16 (30%) 19 (36%) 18 (34%) 52 
Total 22 (21%) 49 (47%) 34 (32%) 105 
 
LKIN= low-grade keratinocytic intraepidermal neoplasia, HKIN= high-grade intraepidermal neoplasia, ICI= 
immunocompetent individual, RTR= renal transplant recipient. 
 
 
Dependency of p14 expression on p53 expression in relation to the four combinations of 
two studied risk factors (sun exposure and immune status) 
The frequencies of cases with regard to the expression of p14 and p53 in the 4 different risk 
categories are given in Table 2.  The Fisher’s exact test disclosed that in each of the four 
different groups the expression of p14 and p53 is statistically independent.  The Mantel-
Haenszel test disclosed that the odds ratios in the four risk groups did not significantly differ 
from 1 (p=0.1) and the Breslow-Day test disclosed that the four odds ratios for these risk 
groups did not differ significantly (p=0.7). 
Therefore the expression of p14 and p53 are conditionally independent and homogeneous for 
the 4 risk groups examined in this study.  
Single positivity (inverse relation between p14 and p53 expression) for one of the markers 
was present in 49/105 cases, while absence or presence of both markers was more prevalent 
and present in 56/105 cases.  Most of the lesions showed a p14-/p53+ pattern (42/105 
specimen, 40%).  Analysis of the 2x2 tables for each of the 4 risk categories disclosed that 
expression of p14 and p53 are not dependent (p>0.3). 
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Table 2.  The four expression patterns for p14 and p53 in relation to the 4 combinations of the 2 risk 
factors sun exposure and transplantation status, in all 105 lesions. 
Risk factors P14-/p53- 
Number (%) 
P14-/p53+ 
Number (%) 
P14+/p53- 
Number (%) 
P14+/p53+ 
Number (%) 
Fisher test two-tailed p- value 
Sun-/ICI 
N=14 
5 
(36%) 
6 
(43%) 
0 3 
(21%) 
0.3 
Sun-/RTR 
N=16 
4 
(25%) 
4 
(25%) 
2 
(13%) 
6 
(37%) 
0.6 
Sun+/ICI 
N=38 
4 
(11%) 
18 
(47%) 
1 
(2%) 
15 
(39%) 
0.4 
Sun+/RTR 
N=37 
8 
(22%) 
14 
(38%) 
4 
(11%) 
11 
(30%) 
0.7 
Total  
N=105 
21 
20% 
42 
(40%) 
7 
(7%) 
35 
(33%) 
 
 
 
Dependency of p14 expression on p16 expression in relation to the four combinations of 
two studied risk factors (sun exposure and immune status) 
The frequencies of cases with regard to the expression of p14 and p16 in the 4 different risk 
categories are given in Table 3.  As for p53, the Fisher’s exact test disclosed that in each of 
the four different groups the expression of p14 and p16 is statistically independent.  The 
Mantel-Haenszel test disclosed that the odds ratios in the four risk groups did not 
significantly differ from 1 (p=0.1) and the Breslow-Day test disclosed that the four odds 
ratios for these risk groups did not differ significantly (P=0.7). 
Therefore also the expression of p14 and p16 are conditionally independent and 
homogeneous for the 4 risk groups examined in this study.  
The combination of p14-/p16+ was most prevalent (41%), followed by double positivity for 
both markers.  Analysis of the 2x2 tables for each of the 4 risk categories disclosed that 
expression of p14 and p16 are not dependent (p>0.5). 
 
 
Table 3.  The four expression patterns for p14 and p16 in relation to the 4 combinations of the 2 risk 
factors sun exposure and transplantation status, in all 105 lesions. 
Risk factors P14-/p16- 
Number (%) 
P14-/p16+ 
Number (%) 
P14+/p16- 
Number (%) 
P14+/p16+ 
Number (%) 
Fisher test two-tailed p- 
value 
Sun-/ICI 
N=14 
2 (14%) 9 (64%) 0 3 (22%) >0.9 
Sun-/RTR 
N=16 
2 (12%) 6 (38%) 0 8 (50%) 0.5 
Sun+/ICI 
N=38 
8 (20%) 14 (37%) 4 (11%) 12 (32%) 0.5 
Sun+/RTR 
N=37 
8 (22%) 14 (38%) 3  (8%) 12 (32%) 0.5 
Total  
N=105 
20 (19%) 43 (41%) 7 (7%) 35 (33%)  
 
62  Chapter 2 
Dependency of p14 expression on p53 or p16 expression in relation to histological 
diagnosis of LKIN, HKIN and SCC 
The frequencies of the 4 different expression patterns of p14 and p53 for patients with KIN 
and SCCs are given in Table 4. 
 
Table 4.  The expression patterns for p14 and p53 in relation to the three diagnostic categories 
Diagnosis P14-/p53- 
Number (%) 
P14-/p53+ 
Number (%) 
P14+/p53- 
Number (%) 
P14+/p53+ 
Number (%) 
Fisher test two tailed 
p-value 
LKIN n=22 7 (32%) 11 (50%) 1 (4%) 3 (14%) >0.9 
HKIN n=49 11 (22%) 17 (35%) 3 (6%) 18 (37%) 0.07 
SCC n=34 3 (9%) 14 (41%) 3 (9%) 14 (41%) >0.9 
Total N=105 21 (20%) 42 (40%) 7 (7%) 35 (33%)  
 
The Fisher’s exact test disclosed that in LKIN, HKIN and SCCs, the expressions of p14 and 
p53, are statistically independent. 
The Mantel-Haenszel test disclosed that the odds ratios in these three diagnostic groups did 
not significantly differ from 1 (p=0.2), and the Breslow-Day test disclosed that the three odds 
ratios for LKIN, HKIN, and SCC did not differ significantly (p=0.5). 
Therefore , the expression of p14 and p53 are conditionally independent and homogeneous 
for LKIN, HKIN, and SCC. 
 
 
The frequencies of the 4 different expression patterns of p14 and p16 for patients with KIN 
and SCCs are given in Table 5. 
 
Table 5.  The expression patterns for p14 and p16 in relation to the three diagnostic categories. 
Diagnosis P14-/p16- 
Number (%) 
P14-/p16+ 
Number (%) 
P14+/p16- 
Number (%) 
P14+/p16+ 
Number (%) 
Fisher test two 
tailed 
p-value 
LKIN n=22 7 (32%) 11 (50%) 0 4 (18%) 0.3 
HKIN n=49 7 (14%) 21 (43%) 0 21 (43%) 0.02 
SCC n=34 6 (18%) 11 (32%) 7 (21%) 10 (29%) >0.9 
Total N=105 20 (19%) 43 (41%) 7 (7%) 35 (33%)  
 
The Fisher’s exact test disclosed that in LKIN and SCCs, the expressions of p14 and p16, are 
statistically independent.  In the HKIN group a weakly significant difference was present 
attributable to the strong correlation between p16 positivity and diagnosis of HKIN, see 
below. 
The Mantel-Haenszel test disclosed that the odds ratios in these three diagnostic groups did 
not significantly differ from 1 (p=0.1), and the Breslow-Day test disclosed that the three odds 
ratios for LKIN, HKIN, and SCC only differed weakly significant (p=0.04), mainly 
attributable to  HKIN lesions, as stated above. 
 
 
The extensiveness of p14 expression in KINs and SCCs 
Keratinocytes in normal skin were negative for p14.  In all cases p14 staining was nuclear, 
often in a dotted (“nucleolar”) pattern (Figure 1 ).  
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FIGURE 1. 
A.HE of a HKIN lesion, which showed strong transepithelial staining with p16  (B), p53 (C), and p14 (D).  As 
can be seen,  staining for p14 is much more difficult to discern in tissue sections when compared to p16 and p53  
using the same magnification.  E. High magnification of the same case showing typical nucleolar staining for 
p14 (400x). 
 
In total 42/105 (40%) cases were positive.  In LKIN lesions 22% was p14 positive, in HKINs 
57%, and in CSCCs 50% of cases were p14 positive.  These differences in presence of p14 
expression were weakly significant between the three diagnostic groups of LKIN, HKIN and 
SCC (Table 6). 
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Table 6.  p14 expression in LKIN, HKIN, and SCC in the patient group as a whole 
 LKIN HKIN SCC total p value (X sq) 
P14+ 4  (18%) 21 (43%) 17 (50%) 42 (40%) 
P14- 18 (82%) 28 (57%) 17 (50%) 63 (60%) 
0.05 
P16+ 15 (19%) 42 (54%) 21 (27%) 78 (74%) 
P16- 7 (26%) 7 (26%) 13 (48%) 27 (26%) 
0.04 
P53+ 14 (18%) 35 (46%) 28 (36%) 77 (73%) 
P53- 8 (29%) 14 (50%) 6 (21%) 28 (27%) 
0.3 
 
The percentage of positive lesional cells in LKIN, HKIN, and SCCs, for RTRs and ICIs 
respectively, are illustrated in Figure 2.  Statistical analysis disclosed no significant 
differences between ICIs and RTRs concerning the frequencies of the four-p14 staining 
categories for LKIN ( p=0.2), HKIN (p=0.8), and SCCs (p=0.9). 
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FIGURE 2 
Percentage of cases in the group of ICIs and RTRs showing absent p14 staining, less than 10% positive 
cells, between 10-50% positive cells, and >50% p14 positive cells. 
 
 
In general the number of p14 positive staining lesional in all three diagnostic categories was 
low.  
Only 7/105 cases showed more than 50% p14-positive lesional cells; 4 of these cases were 
HKIN lesions, and 3 were SCCs. 
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The extensiveness of p53 expression and p16 expression in KINs and SCCs 
We will only briefly report on findings with respect to p16 and p53 since results are 
comparable to previously described findings18. 
Normal skin showed only sporadic p53 staining in a few basal and suprabasal keratinocytes, 
and only p16 positivity in dendritic melanocytes. 
In total 78/105 (74%) cases were p16 positive, in 76 cases both cytoplasmic and nuclear 
staining was present; in 2 cases only cytoplasmic staining was seen.  There were a 
significantly higher number of p16 positive cases in the HKIN group.  
P53 positivity was always nuclear and present in 77/105 (73%) lesions.  There were no 
significant differences in number of p53 positive specimen between the three diagnostic 
groups. 
Statistical analysis disclosed no significant differences between ICIs and RTRs concerning 
the frequencies of the four-p16  staining categories for LKIN ( p=0.2), HKIN (p=0.6), and 
SCCs (p=0.7). 
For p53, only for SCCs there was a weak significant difference in the prevalence of p53 
positivity between RTRs and ICIs (p=0.05), due to higher frequency of p53 negative SCCs in 
RTRs, 33% (6/18 cases), than in ICIs (0/16 cases, 0%).  KIN grade correlated strongly with 
localization of p53 and p16 staining in the epidermal layers ( r>0.7, p<0.0001). 
 
HPV detection and typing 
Only 2/108 (1.9%) lesions contained HPV X DNA  in SPF10-LiPA.  Neither one of them 
contained one of the 25 known mucosal genotypes.  Both cases showed strong p16 staining 
(>95%), absent p14, and one case had low (15%) and the other case absent p53 staining.  Due 
to the low number of specimen containing HPV DNA, no correlations between tumor 
suppressor expression and HPV were calculated.  Both HPV containing specimen were 
HKIN lesions in ICIs. 
 
 
DISCUSSION 
 
The tumor suppressor p14 is thought to play a key role in cell cycle control, since p14 
connects the two main pathways governing cell growth, namely the p14-MDM2-p53 and 
p16-CDK4/6-RB pathway.  Both p14 and p16 both are products of one locus that has an 
unusual capacity to encode two structurally distinct proteins, the INK4a-ARF locus, and both 
have the potential to act as tumor suppressor and can be activated by oncogenes. 
Studies on cell lines transfected with a vector encoding the HPV E6 oncoprotein have 
reported inverse relations between p14 and p53 expression 158,193.  Immunohistochemical 
studies in cervical dysplasia and SCCs of the uterine cervix have reported overexpression of 
both p14 and p16 in HPV-associated cases.  In these cases p14 overexpression is attributed to 
functional inactivation of p53 by the E6 oncoprotein of high-risk HPV, and p16 
overexpression is attributed to inactivation of pRb by the E7 oncoprotein of high-risk HPV166. 
In cutaneous carcinogenesis, in which HPV is also implicated, one could hypothesize that 
p14 and p16 would be overexpressed in HPV associated cases.  In addition based on the 
above one could expect positive associations between p14 and p16 expression levels and 
inverse relations between p14 and p53 expression. 
However, in the present study of a series of 105 KIN lesions and CSCCs, we found the 
expression of p14 and p53, as well as the expression of p14 and p16,  to be independent.  
With respect to p14/p53 we found absence or presence of both markers more prevalent 
(56/105 cases) than single positivity (representing inverse relation) for one of the proteins.  
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Most cases (40%) showed a p14-/p53+ pattern.  With respect to p14/p16,  a p14-/p16+ 
pattern was most prevalent (41% of cases). 
Apparently, in skin neoplasia the relations between expressions of these tumor suppressors is 
different from what one would expect based on in vitro data and findings in cervical 
neoplasia.  The reasons for these discrepancies can be threefold.  
First, cutaneous carcinogenesis is probably more complex than cervical carcinogenesis, 
because in skin cancer besides HPV also sun exposition is implicated as a major etiological 
factor.  UV-induced mutations have been found in p53 and INK4a-ARF 19,129,187 and these 
mutations can affect protein expression. 
Secondly, oncogenic properties of HPV types implicated in cutaneous carcinogenesis seem 
different from those of high-risk HPV types in cervical carcinogenesis.  In cervical lesions, 
p53 is inactivated due to the transforming activities of the E6 viral oncoprotein of the 
mucosal high-risk HPV types, for instance HPV16 23.  So far, the knowledge on transforming 
properties of E6 and E7 of cutaneous HPV types is limited.  In contrast to cervical cancer, in 
which high-risk HPV DNA becomes integrated in the host genome, in NMSCs containing 
presumed oncogenic HPV types, HPV integration is rare, and it was shown that E6 
oncoprotein of, for instance, the cutaneous epidermodysplasia verruciformis-associated 
HPV38 could not degrade p53 protein 34,121.  Surprisingly, HPV 38 E6/E7-positive cells also 
did not express p16, in contrast to HPV 16 E6/E7-positive cells, whereas both HPV 38 and 
HPV 16 E7 had similar biological properties and both were able to inactivate pRb34.  
It is speculated that in skin carcinogenesis E6 mediated degradation of p53 is not as important 
as in cervical carcinogenesis, since in skin tumors p53 is already often silenced by UV-
induced p53 mutation 130.  
Finally, protein expression levels do not directly reflect changes on the molecular level.  For 
instance for p53 it is known that many of the mutations in the p53 coding region result in a 
structurally altered, inactive protein that is more stable than its wild type counterpart, 
resulting in higher levels of protein detectable by antibody.  The high prevalence of p53 
overexpression in our series, 77/105 cases (73%), could well reflect cases harboring p53 
mutations.  However, the reasons for overexpression of p14 and p16 in skin pre (cancer) still 
have to be established; previously in CSCCs inactivating molecular events (mutation or 
promotor methylation) were reported to have absent expression of p16 and p14 in 82% of 
cases 32.  At the moment the molecular events underlying p16 and p14 overexpression remain 
to be investigated; a previous study on mutation analysis of the CDKN2A gene in skin 
tumors, including 5 Bowen’s diseases (BDs) did not demonstrate mutations in any of the BDs 
169.  Nindl et al 141 studied overexpression of p16 and HPV presence in skin tumors, and found 
HPV DNA in all AKs (n=5), all SCCs (n=7), and all SCCs in situ (n=3) with overexpression 
of p16 in a part of the lesional cells of all these lesions.  In contrast normal skin (n=3), and 
warts (n=2) despite containing HPV in respectively 66% and 50% lacked p16 overexpression.  
The HPV types found were mucosal in 6 cases (twice in normal skin, BDs and SCCs each), 4 
times HPV type 16; 3 of these cases were p16 positive.  In 12 cases EV-associated HPV 
types were present all showing p16 positivity.  They suggest that HPV might be responsible 
for p16 positivity in skin (pre) cancers and less likely genetic alterations as mutation.  
However, we conclude that as long as its unknown what enhanced or absent protein 
expression reflects on the molecular level, it remains difficult to explain relations between 
expression of markers. 
Future studies including cutaneous and EV-associated HPV types with incorporation of 
molecular data are warranted to clarify the relation between expression of p14, p16, and p53 
and HPV infection.  
The present study showed  that expression pattern for p14/p53 and p14/p16 were conditional 
independent of immune status and sun exposure.  This suggests that skin cancer development 
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in RTRs and ICIs is comparable with respect to involvement of cell cycle associated proteins, 
despite differences in immune status and although there is a clear clinical difference in rate of 
tumor development between both groups. 
We could only demonstrate HPV X in 2/108 (1.9%) specimen, and none of the KIN lesions 
or CSCCs of RTRs and ICIs contained one of the known mucosal HPV types.  Due to this 
low prevalence of mucosal HPV types relations between presence of HPV and  expression 
levels of the three studied tumor suppressors could not be studied.  Data on frequencies of 
mucosal HPV types in skin tumors in literature are conflicting.  Previously de Jong-Tieben et 
al 43  also reported no mucosal HPV types in 96 epithelial skin tumors of RTRs by nested 
PCR.  They only found high frequencies of epidermodysplasia verruciformis (EV) HPV types 
(15, 19, 20,21, 23, 24, 25 and 38) in 80% of CSCCs and 93% of AKs. 
In contrast to our data and those of de Jong-Tieben et al 43, Soler et al 186 reported a high 
frequency of mucosal HPV types 6/11 with 30 out of 43 benign, premalignant and malignant 
cutaneous lesions of transplant recipients being HPV positive. Iftner et al and Shamanin et al 
also both reported presence of mucosal HPV types in NMSC.  Iftner et al 89 reported presence 
of high-risk mucosal HPV types in 18.2% (10/91 cases) of KIN lesions and in 20.9% (9/72 
cases) of CSCCs of ICIs.  Shamanin et al 173 only found high-risk HPV types in malignant 
skin tumors of RTRs, with malignant skin tumors of ICIs only containing low-risk mucosal 
HPV types.  We choose for a combined SPF-PCR-LiPA system for detection and genotyping 
of HPV since this HPV detection test is highly sensitive, specific, and reproducible and has 
been clinically validated 104,134,165.  Based on this solid technique we dare to conclude that our 
data do not support a role for mucosal HPV types in cutaneous carcinogenesis. 
With respect to p14 expression, in total 42/105 (40%) cases were positive.  In LKIN lesions 
22% was p14 positive, in HKINs 57%, and in CSCCs 50% of cases were p14 positive.  These 
differences in presence of p14 expression were weakly significant between the three 
diagnostic groups of LKIN, HKIN and SCC. 
So far only Brown et al studied p14 expression in 40 cutaneous SCCs, of which 30 were 
derived from immunosuppressed patients 32; they reported p14 expression in 18/40 cases 
(45%) of CSCCs, which is comparable to our finding of 50% p14-positive carcinomas. p14 
staining was not restricted to certain epidermal layers in KIN lesions.  This contrasts to 
already previously reported findings with respect to p16 and p53 staining 18.  The localization 
of these two markers significantly correlated with KIN grade, with higher KIN grades 
showing increase in epidermal staining extending from the basal layer to the surface.  
Therefore our data do not support a role for p14 immunohistochemistry in the diagnosis of 
epidermal skin tumors.   
P14 staining was generally difficult to discern in microscopical slides necessitating high 
magnification in order to see the weak nucleolar dotted or speckled staining with mostly low 
number of positive staining cells, in contrast to the much easier to discern and mostly 
stronger staining for p16 and p53.  
In conclusion, based on presented data p14 protein expression does not attribute to the 
diagnosis of epidermal neoplasia and mucosal HPV types do not play a role in these tumors.  
Expression of p14 and p53 and of p14 and p16 are independent in KIN lesions and CSCCs 
and these independencies are not influenced by sun exposure and immune status.  The 
reasons for overexpression of  p16 and p14 in especially HKIN lesions and CSCCs need 
further elucidation, which is also true for the role of non-mucosal HPV types.  
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2.3 
 
INK4A-ARF and p53 mutations in metastatic cutaneous 
squamous cell carcinoma  
Case report and archival study on the use of Ink4a-ARF and p53 mutation analysis in 
identification of the corresponding primary tumor 
 
Abstract 
So far histopathologic, immunohistochemical and molecular properties of metastatic 
cutaneous squamous cell carcinomas (CSCCs) are relatively unexplored.  In patients with 
multiple CSCCs, as for instance renal transplant recipients (RTRs), it might prove difficult to 
identify the primary tumor responsible for metastasis.  We report a case of a RTR with 
multiple CSCCs, one of which metastasized.  By using p53 and INK4a-ARF mutation analysis 
we identified the responsible primary tumor due to an identical mutation in exon 2 of the 
INK4a-ARF locus.  Archival study yielded 14 cases of metastatic CSCC (present case 
included).  In only 8/14 metastases, DNA quality was sufficient to perform PCR reactions.  In 
7 of /8 metastases either an INK4a-ARF (6 of 8 cases) and /or p53 (3 of 8 cases) mutation 
was present.  In 6  of 7 cases the corresponding primary could be identified by an identical 
mutation in p53 and/or INK4a-ARF. 
In conclusion, molecular analysis using a combination of p53 and INK4a-ARF mutation 
analysis can identify the corresponding primary skin tumor in case of CSCC metastases in 
the majority of cases.  This is facilitated by the high frequency of these mutations in 
metastatic CSCC when compared to frequency spectra reported in the literature in primary 
CSCCs.  The major limitation was formed by insufficient DNA quality in archival tissue. 
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INTRODUCTION 
 
With still improving graft and patient survival in renal transplant recipients (RTRs), 
nephrologists, dermatologists, and subsequently pathologists, are increasingly confronted 
with cutaneous complications in this patient group.  Of the latter, post-transplantation skin 
(pre) cancers are the most prevalent.  RTRs develop multiple warts, actinic keratoses (AKs), 
and non-melanoma skin cancers (NMSCs), especially on sun-exposed parts of the body.  Of 
these NMSCs, squamous cell carcinomas (SCCs) by far outnumber basal cell carcinomas 
(BCCs), in contrast to NMSCs in immunocompetents.  Cutaneous SCC (CSCC) is associated 
with a substantial risk of metastasis with reported rates of metastasis up to 5% 3 in the general 
population and between 5-10% in transplant patients 50. Once metastasized, the prognosis is 
poor in organ transplant recipients 125. 
So far, histopathologic, immunohistochemical and molecular properties of metastatic 
cutaneous SCCs are relatively unexplored 3,23,35,96,108. Of the first, especially large size (>2 cm 
in diameter) and depth >4 mm seem associated with metastasis 3,108. 
Especially in RTRs, there are often multiple CSCCs and it might prove difficult to identify 
the primary tumor responsible for the subsequent metastasis.  Previous studies in non-skin 
cancers have already demonstrated the value of the mutational status of p53 in separating or 
comparing primary and metastatic tumors in the case of multiple primary cancers 48,97. 
Molecular data have shown that P53 mutations are the most frequent genetic alteration in 
primary SCC of the skin with reported incidence of 50% in sporadic SCCs and 43% in SCCs 
of RTRs 129. More recently, mutations in the CDKN2A (INK4a-ARF) locus, which maps to 
chromosome 9p21163, were reported in primary CSCCs. This locus, by alternative transcripts 
encodes for two proteins p16INK4a (exons 1, 2 and 3), and p14ARF (exons 1 and 2).  
Mutations of p16 INK4a have been reported in up to 24% of cases in sporadic primary CSCCs 
110,188 and in 33% of CSCCs in xeroderma pigmentosum patients187.  
In this article we want to test the feasibility of using combined INK4a-ARF and p53 mutation 
analysis in identifying the corresponding primary skin SCC, especially in case of multiple 
primaries.  We illustrate this by means of a case report and an archival study. 
  
Case 
A female patient born in 1953 underwent a bilateral nephrectomy when she was 17 years of 
age (1970).  A renal transplantation was performed twice, in 1972 and in 1978 after a chronic 
vascular rejection of the first transplant.  
Immunosuppressive treatment consisted of Prednisone 2dd 5 mg and Azathioprine 1dd 
100mg. 
Since 1990, 18 years after the first renal transplant, she developed her first skin tumors.  In 
the beginning predominantly basal cell carcinomas, hyperkeratoses and keratoacanthomas.  
Since 1998 she progressively started to develop AKs, Bowen’s disease and SCCs, the latter at 
a rapidly inclining rate up till now, the end of 2003 (Figure1).  In 1996 chemopreventive 
therapy with acitretin was started in order to inhibit skin tumor development.  In July 2002, 
fine needle aspiration of an enlarged right supraclavicular lymph node demonstrated 
malignant cells consistent with squamous cell carcinoma metastasis.  
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FIGURE 1 
Since 1990, 18 years after the first renal transplantation, the patient began to develop skin tumors, first 
predominantly basal cell carcinomas (bcc), hyperkeratoses, and keratoacanthomas (KA).  Since 1998, she 
developed actinic keratoses, Bowen’s disease (taken together as keratinocytic intraepidermal neoplasia, KIN) 
and squamous cell carcinomas (SCCs), the latter at a rapidly inclining rate up till the end of 2003. 
vv=verruca vulgaris. 
 
In August 2002, a right-sided modified neck dissection (containing regions III-VI) was 
performed.  Only in region IV a solitary extranodal metastasis of SCC (Figure 2, A-B),  
measuring 2cm in diameter, was present with positive surgical margins.  The patient received 
postoperative radiotherapy.  Up till now, January 2004, patient is alive without evidence of 
metastases. 
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FIGURE 2 
A. Right cervical squamous cell carcinoma metastases of the presented case, developing in August 2002, 13 
months after the biopsy of the primary tumor located on the right clavicle.  No preexistent lymph node could be 
recognized.  In B more detailed picture of the tumor. 
C. Excision of the primary on the right clavicle, showing a superficial infiltrating moderately differentiated 
squamous cell carcinoma.  In the deeper dermis, scar tissue from the previous biopsy is seen (asterisk).  The 
black line indicates the tumor area which was scraped from the already HE stained slides in order to perform 
molecular analysis.  In D more detail of the tumor. 
 
 
Archival patient selection 
In the period between 1985 and the end of 2001, 14 metastases (13 nodal) from 14 different 
primary cutaneous SCCs from 12 patients, could be retrieved including the above-mentioned 
patient.  In the same time period the number of diagnosed primary CSCCs in our hospital 
numbered 1345.  
In 6 cases patients were renal transplant recipients (RTRs).  
The patient characteristics are summarized in Table 1. 
A B
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Table 1..  Patient characteristics. 
Patient  Metastatic 
tumor 
Sex RTR/ICI Age SCC 
metastasis 
Location 
candidate 
primary 
SCC 
Location LNN 
metastases 
Number of NMSCs 
before first CSCC 
metastasis 
1 I, case F Rtr 63 R clavicle R cervical 12 SCCs 
2 D M Rtr 53 R hand R axilla  13 SCCs 
3 E M Rtr 67 R hand R axilla 5 SCCs 
4 F1 
F2 
M Rtr 63 
63 
L arm 
R temple 
L axilla 
R parotic 
6 SCCs 
5 G M Rtr 67 R cheek R cervical 5 SCCs 
6 H M Rtr 52 R upper arm R axilla NA 
7 A1 
A2 
M Ici 79 
80 
L temple 
R ear 
L resp R 
cervical and 
parotic gland 
5 SCCs 
Multiple BCCs 
8 B M Ici 70 Chin Cervical 1 KA 
9 C M Ici 76 R ear R cervical and 
parotic gland  
0 
10 J M Ici 44 R neck R cervical 1 
11 K M Ici 86 L cheek L cervical 0 
12 L M Ici 80 R foot R inguinal NA 
 
 
MATERIALS AND METHODS 
 
For the DNA isolation about 3 sections of 10 μm per 1 cm2  formalin fixed paraffin-embedded 
tissue were manually microdissected from unstained sections to obtain a tumor cell 
percentage of at least 60%, using HE colored sections as a reference.  The sections were 
incubated in P-buffer (50mM Tris pH 8,5, 0.1 M NaCl, 1 mM EDTA, 0.5% Tween-20, 0.5% 
NP40, 20 mM DTT) for 15 minutes at 900C, 16 hours at 600C in the presence of 0.2 mg 
Proteinase K and 5 minutes at 950C.  Subsequently, DNA was extracted essentially as 
described by Miller 138. Depending on the DNA quality as determined in a control PCR, 0.1 to 
2 μl of the isolated DNA was used in all PCRs. PCR was performed with AmpliTaq Gold 
DNA Polymerase (Roche Applied Biosystems) using an optimized MgCl2 concentration 
(varying from 1 to 2 mM) in a MJ PTC 200 PCR cycler (Biozym).  Conditions were 1 min at 
920C, 1 min at 600C , 2 min at 720C for 45 (INK4a-ARF) or 40 (p53) cycles with 10 min 940C 
prior to and 10 min 720C after cycling.   
In each experiment a positive control and a control without template were included to 
monitor the efficiency of the PCR and the absence of cross-contamination.  After purification 
of the PCR products using a Qiaquick PCR purification kit (Qiagen), sequence analysis was 
performed using BigDye terminator version 2 of Applied Biosystems on an ABI 3730 
automatic sequencer (Applied Biosystems).  The amplicons allowed automatic sequence 
analysis of the complete exons and surrounding splice sites.  Since most exons are too large 
for efficient amplification of formalin fixed DNA,  for most exons overlapping PCR products 
were generated .  All primers used in the analysis of p53 contained either an M13 forward  or 
M13 reverse consensus sequence.  Sequence analysis of these PCR products was performed 
using M13 consensus primers.  For INK4a-ARF the primers that were used in the PCR were 
also used in the sequencing procedure.  All primers and sizes of the PCR products are listed 
in Table 2.  
The entire open reading frames of INK4a-ARF and exon 5 up to and including exon 8 of 
TP53 (encoding p53) were analyzed in DNA isolated from the metastases.  Mutations were 
confirmed on an independent PCR product.  Alterations that were also present in normal 
tissue of the patient were considered to be polymorphisms and were excluded from the 
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study.  The analysis of the primary tumors was restricted to the fragments containing the 
mutations identified in the metastases.  
 
 
Table 2..  Primers used in the analysis of INK4a-ARF and p53, and the size of their PCR products.   
 
INK4a-ARF (CDKN2A) 
exon Forward Reverse Size PCR 
product (bp) 
1B TCAGGGAAGGCGGGTGCGCG GCCGCGGGATGTGAACCAC 244 
1B CGCCGCGAGTGAGGGTTTT CACCGCGGTTATCTCCTCC 263 
1A GAGAGGGGGAGAGCAGGCAG GCACCTCCTCTACCCGACC 122 
1A GGAGCAGCATGGAGCCTTC AGTCGCCCGCCATCCC CTG 177 
2 AGCTTCCTTTCCGTCATGC GCAGCACCACCAGCGTGTC 202 
2 AGCCCAACTGCGCCGACCC CCAGGTCCACGGGCAGACG 146 
2 TGGACGTGCGCGATGCCTG GGAAGCTCTCAGGGTACAAATTC 188 
3 CGGTAGGGACGGCAAGAGAG GAGGGACCTTCGGTGACTGATG 162 
 
p53 (TP53) 1 
5 TCACTTGTGCCCTGACTT TCATGTGCTGTGACTGCTTG 179 
5 CAGCTGTGGGTTGATTCCAC GAGGAATCAGAGGCCTGG 196 
6 GAGACGACAGGGCTGGTT GAGACCCCAGTTGCAAAC 234 
7 CCAAGGCGCACTGGCCTC GAG GCAAGCAGAGGCTGG 249 
8 CCTTACTGCCTCTTGCTTC CCCCTTTCTTGCGGAGATTCTC 136 
8 TTGAGGTGCGTGTTTGTGCC TGAATC TGAGGCATAACT 181 
 
1. All forward primers contained the M13 consensus sequence TGT AAA ACG ACG GCC AGT at the 5’ end.  
All reverse primers contained the M13 consensus sequence CAG GAA ACA GCT ATG ACC. 
 
RESULTS 
 
Case 
At the moment of the right supraclavicular metastasis, the patient already had a history of 12 
cutaneous SCCs; located at the left hand/forearms (8 cases), right clavicle (1 case, once 
reexcised), left clavicle, and 2 cases on the right forearm.  Based on the drainage pattern, the 
right supraclavicular metastasis was most likely an in transit metastasis of the primary located 
on the skin of the right clavicle. 
Histopathological examination of this tumor was rather unremarkable.  In the previous 3 mm 
biopsy of this tumor performed in July 2001, tumor depth was 2.5 mm and the tumor was 
limited to the deep dermis.  In the excision 1 month later, only a small (-tumor diameter of 
8mm) moderately differentiated SCC with ulceration and an infiltrative growth pattern (Fig. 2 
C-D) was present.  Invasion depth was only 1 mm and the tumor was limited to the upper 
dermis.  The tumor involved the resection margin in this initial excision and was later 
reexcised (October 2001) with only little residual tumor and free margins this time (of 0.5 
mm focally).  Simultaneously with the SCC on the right clavicle the patient presented a much 
larger SCC on the left clavicle with tumor diameter of 2.5 cm and infiltration of 4.5 mm into 
the subcutaneous fat and this tumor was partially poorly differentiated.  Because of the more 
aggressive histopathological characteristics we decided to include this tumor in the molecular 
analysis together with the small primary on the right clavicle. 
The metastasis contained a mutation in exon 2 of the INK4a-ARF locus involving both p14 
(391^393 delCGCinsGA) and p16 (225^227delCGCinsGA).  No p53 mutation was detected.  
In the primary tumor on the right clavicle an identical mutation in the INK4a-ARF locus 
could be demonstrated.  The primary on the left clavicle contained a different mutation in 
exon 2 of the INK4a-ARF locus involving both p16 (155^178del) and p14 (321^344del). 
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Archival study 
In only 8 of 14 lymph node metastases DNA quality was sufficient to perform PCR reactions.  
In 7 of 8 metastases, mutations in either INK4a-ARF (6/8 cases) and/or p53 (3/8 cases) were 
detected (Table 3).  Patient and tumor numbering in table 3 corresponds to the numbering in 
table 1.  In 2 of 8 cases combined INK4a-ARF and p53 mutations were present.   
In 6 of 7 cases, the primary cutaneous SCC could be identified with certainty due to the 
presence of an identical mutation in primary and metastasis in either p53 and/or INK4a-ARF 
(Table 3).  This table also contains the available relevant histopathological data and clinical 
data of all tested cases.  In 4 cases the primary SCC was moderately differentiated, in 2 cases 
poorly differentiated.  Diameter of the tumors was between 8mm up to 8 cm.  Depth of the 
tumors varied from only 2.5 mm to deep invasion into the cortical bone.  In only 4 cases there 
was available clinical follow-up with 2 patients being death of disease.  
 
As can be read from the last column in Table 1, in the archival study, akin to the case report, 
5 patients (patient nos. 2, 3, 4, 5, and 7) had more than one previously diagnosed primary 
skin cancer before the metastasis developed.  Of these patients only in patient nos. 4, 5 and 7 
the DNA quality of the metastatic tumor was sufficient to perform molecular analysis for 
INK4a-ARF and p53 mutations.  
In patient no. 4 the metastasis contained no mutations.  Due to  absence of p53 and INK4A-
ARF mutations in the metastasis and our decision to restrict the analysis of the primary 
tumors to the fragments containing the mutations identified in the metastasis, none of the 
diagnosed CSCCs of this patient were tested.  
In patient no 5, the metastasis contained p53 and p14 mutations: we tested 2 possible primary 
tumors but could not demonstrate these mutations in either one of these tumors (Table 3).  
The metastasis was located in the right cervical lymph node (lnn), and the two tested 
primaries were located on the right cheek and ear respectively.  As can be read from table 1 
this patient had 5 previous SCCs: the other 3 tumors were less likely to have caused the right 
sided cervical lnn metastasis since they were all located on the left side of the face and 
therefore these tumors were not further tested. 
In patient no. 7 the metastasis contained a p16 mutation, which was confirmed in the most 
likely primary tumor located on the right ear, and hence no other CSCCs of this patient were 
tested (this patient had 5 previously diagnosed CSCCs, Table 1).  Furthermore the other 
previously diagnosed CSCCs in this patient were all located on the left side of the face, and 
were less likely to have caused the right parotic lnn metastasis based on lymph drainage. 
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 DISCUSSION 
 
The present case of an RTR with multiple CSCCs indeed illustrates that even a very small 
and histopathological unremarkable SCC can lead to metastasis.  Previously, Joseph et al. 
also demonstrated that in 34 of 695 metastasizing CSCCs, the majority of the primaries were 
small with 28 tumors measuring 1.5 cm or less96. The presented case and archival study of 
metastatic cutaneous SCCs in our institution, show that mutation analysis of both p53 and 
INK4a-ARF is very helpful in identifying primaries in case of metastatic CSCC.  The only 
drawback was the frequent insufficient quality of the DNA in archival paraffin embedded 
material, which led to loss of 6 of14 cases for further molecular analysis.  On the other hand, 
as illustrated by the presented case, even very little tumor tissue can be sufficient in 
identifying the primary.  In this particular case tumor tissue actually was scraped from 
already cut and HE stained slides.  
Seven of 8 tested metastases contained either an INK4a-ARF and/or p53 mutation that 
subsequently leads to the identification of the primary tumor in 6/7 cases.  This high 
prevalence of INK4a-ARF/p53 mutations in metastatic CSCCs makes this gene combination 
highly suitable for identification of primary SCCs of the skin.  
So far, only a few studies have addressed histopathologic, immunohistochemical and 
molecular characteristics of metastatic CSCCs.  However, in these studies, the supposed 
primary could not be linked with certainty to the metastasized tumor, due to lack of 
molecular tools3,23,35,96,108. 
Especially in the group of RTRs, molecular analysis could yield future important 
information on factors important for metastasis, since in this group SCCs are often multiple 
and histopathological characteristics are not always indicative of aggressive behavior as 
illustrated in this study by the presented case.  
In the literature, reported frequencies of p16 mutations in sporadic CSCCs vary from 15% 
(3/21 cases)110 to 19% (8/42 cases of CSCCs)187. P14 mutations in the sporadic CSCCs have a 
reported frequency of 17% (7/42 cases)187. In Xeroderma Pigmentosum (XP) patients, p16 
and p14 mutations both have a reported frequency of 33%  (6/18 cases) 187. In these patients, 
tumors often contained multiple mutations in p14, p16, and p53.  
In this archival study, with limited patient numbers, metastatic CSCCs were found to have 
p16 mutations in 63% (5/8 cases) of all cases.  P14 mutations were present in 38% of all 
cases (3/8 cases). 
Thus, the frequency of p16 mutations in metastases we found seems higher than those 
reported for primary CSCCs in both sporadic and XP-associated SCCs.  The metastases 
contained 50% INK4a-ARF mutations that could be attributed to UV-damage, comparable 
with XP-associated skin tumors.  Larger studies are needed to elucidate a potential role for 
p16 mutations in predicting metastatic potential of CSCCs. 
In the general population p53 mutations in primary SCC of the skin are reported in 19% (4/21 
sporadic SCCs)187 up to 50% (3/6 SCCs)129. In XP patients 44% (8/18 cases) of SCCs 
contained p53 mutations 187. In RTRs, McGregor reported ten p53 mutations in 9/21 (43%)  
SCCs of transplant recipients 129, while Bennett only reported p53 mutations in 2/25 SCCs of 
RTRs 10. In SCCs of epidermodysplasia verruciformis (EV) patients, 5 SCCs (62.5%) 
contained p53 mutations 147. 
In 3/8 metastases we detected a mutation in p53.  This frequency is fairly consistent with 
reported frequencies for p53 mutations in sporadic primary CSCCs and primary CSCCs in 
special patients groups.  In 1/3 metastasis, p53 mutation could be UV-induced.  
In conclusion, the present study shows that molecular analysis of p53 and INK4-ARF 
mutations can identify the primary CSCC responsible for the metastasis in the majority of 
cases.  This is facilitated by the high frequency of p53 and/or INK4a-ARF mutations we 
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found in metastatic CSCC, when compared to frequency spectrum reported in the literature in 
primary CSCCs.  The major limitation is formed by insufficient DNA quality in archival 
tissue.  
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RETINOID TREATMENT IN BENIGN 
AND (PRE) MALIGNANT EPIDERMAL 
TUMORS OF RTRS  
This chapter was based on the following publications : 
Retinoids strongly and selectively correlate with keratin K13 and not K19 
in cutaneous warts of renal transplant recipients  
Willeke A.M. Blokx, M.D1, Jurgen V.Smit, M.D.2, Elke M.G.J. de Jong, M.D., Ph.D.2, 
Monique M.G.M. Link1, Peter C.M. van de Kerkhof, M.D., Ph.D.2 , Dirk J. Ruiter, M.D., 
Ph.D.1 
Departments of Pathology1 and Dermatology2, University Medical Center St. Radboud, 
Nijmegen, the Netherlands 
Arch Dermatol 2002;138(1):61-5 
 
Acitretin treatment in (pre)malignant skin disorders of renal transplant 
recipient: histological and immunohistochemical effects 
Jurgen V.Smit, M.D.2, Ruud G.L. de Sévaux, M.D.3, Willeke A.M. Blokx, M.D1, Peter C.M. 
van de Kerkhof, M.D., Ph.D.2, Andries J.Hoitsma, M.D., Ph.D.3, Elke M.G.J. de Jong, M.D., 
Ph.D.2 
Departments of Pathology1, of Dermatology2, and of Nephrology3, University Medical Center 
St. Radboud, Nijmegen, the Netherlands3 
J Am Acad Dermatol 2004;50:189-96 
 
Immunohistochemical effects of temporary cessation of long-term acitretin 
treatment in keratinocytic intraepidermal neoplasia of renal transplant 
recipients 
Willeke A.M. Blokx, M.D1, Jurgen V. Smit, M.D.2, Peter C.M. de Wilde, D.M.D., Ph.D.1, Peter 
C.M. van de Kerkhof, M.D., Ph.D.2,  Dirk J. Ruiter, M.D., Ph.D.1, Elke M.G.J. de Jong, M.D., 
Ph.D.2 
Departments of Pathology1 and Dermatology2, University Medical Center St. Radboud, 
Nijmegen, the Netherlands 
Arch Dermatol 2003;139:671-73 
80  Chapter 3 
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Retinoids strongly and selectively correlate with keratin 13 and 
not keratin 19 expression in cutaneous warts of renal transplant 
recipients 
 
Abstract 
Objective To compare the expression of keratin (K)13 and K19 in cutaneous warts of renal 
transplant recipients (RTRs) and immunocompetent individuals (ICIs).  
Design Retrospective, nonrandomized immunohistochemical study.  
Patients  Specimens form cutaneous warts of RTRs and ICIs were retrieved from the archives 
of the Department of Pathology, University Medical Center St Radboud, Nijmegen, the 
Netherlands.  Twenty-one warts from RTRs and 21 from ICIs were examined.  Nine RTRs (10 
specimens) received either systemic acitretin or topical all-trans-retinoic acid, and their 
effect on both keratins was assessed. 
Main outcome measures Frequency and expression patterns of K13 and K19 in warts of 
RTRs vs. ICIs and the effect of retinoids. 
Results A significantly higher percentage of warts of RTRs expressed K13 compared with 
warts of ICIs (86% vs. 14%, respectively; P< 0.001).  In warts of RTRs, retinoid treatment 
correlated significantly with a particularly strong,  segmental  K13 expression pattern, which 
we termed zebroid.  Without use of  retinoids,  K13 was mostly restricted to suprabasal single 
cells.  Keratin 19 was absent in all warts of both patient groups.  
Conclusions   Retinoids  strongly correlate with  K13 in a characteristic zebroid pattern in 
warts of RTRs, making K13 a sensitive marker for  retinoid bioactivity in skin (lesions) of 
RTRs. 
In non-retinoid-treated RTRs, K13 is also frequently found in warts, but without the dramatic 
zebroid pattern noted with retinoid-treated warts. 
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INTRODUCTION 
 
Epithelial keratins comprise a heterogeneous group of acidic ( type I  ) and neutral-to-basic ( 
type II ) proteins.  As a general rule, they are coexpressed in specific pairings, each pair 
consisting of a type I and type II keratin.  For instance, in normal adult skin, keratin pairs 
K5/K14 and K1/K10 predominate in the basal layer and the suprabasal compartment, 
respectively 185.  
The type I keratins K13 and K19 are usually expressed separately in adult epithelia.  
Combined expression occurs only in fetal skin.  Both keratins are  thought to be absent in 
normal skin of adults except at certain body sites, such as the penile foreskin, which still 
contains K13.  Furthermore, K13 is abundantly present in adults in internal stratified epithelia 
and associated (with terminal differentiation ) with suprabasal expression 114,139,185,200. 
Expression of K19 in adults is found in simple epithelia, such as most glandular epithelia.  
In the past few years several murine and in vitro studies have demonstrated that vitamin A 
and its derivates ( retinoids ) are important regulators of epidermal differentiation and affect 
keratin gene expression.  In cultured keratinocytes, the induction of an embryonic type of 
differentiation by retinoids with reinduction of K13 and K19 expression has been well 
documented 106,107. In vivo topical application of retinoids on photo-aged human skin also 
showed induction of K13 162. 
Although retinoids are used as chemopreventive agents for inhibiting skin cancer in renal 
transplant recipients (RTRs)9,217, to the best of our knowledge there are no studies regarding 
the effects of retinoids on keratin expression in the skin or skin lesions of these patients. 
Renal transplant recipients develop multiple warts and skin neoplasms.  Immunosuppressive 
treatment, sun exposure, and viral infection with human papillomavirus are all implicated in 
the etiology of cutaneous tumorigenesis in RTRs6,30,149,171,210. The frequent simultaneous 
occurrence of warts and skin cancers in RTRs led us to the assumption that the verrucae or 
warts in RTRs might be more prone to become malignant than equivalent lesions in healthy 
immunocompetent individuals ( ICIs ).  The existence of high- and low-risk papillomas was 
previously shown in mice models of cutaneous carcinogenesis 218. Interestingly, these high-
risk papillomas expressed K13, which was absent in low-risk papillomas. 
The present study shows that  RTR-associated warts in contrast to warts in normal ICIs 
indeed show pronounced K13 expression.  This suggests that altered keratin expression may 
reflect an important molecular event inherent in the malignant degeneration of warts in 
RTRs.  Furthermore, this K13 expression in warts of RTRs  strongly  correlates with retinoid 
therapy, but,  in contrast to findings in animal studies and in cultured human keratinocytes 107, 
we could not demonstrate an effect of retinoids on K19 expression in these patients.  
Retinoid-related K13 expression in epithelial skin lesion of RTRs displays a highly 
characteristic pattern, which we termed zebroid, making K13 a useful marker for evaluating 
the effect of retinoid treatment in these patients. 
 
MATERIALS AND METHODS 
 
Tissues    
For this retrospective immunohistochemical study we retrieved formalin fixed and paraffin 
embedded skin excisions of warts from renal transplant recipients (21 excisions, 18 patients, 
average  age  50.8 years, mean duration of immunosuppression 16.4 years) and from  normal 
immunocompetent individuals (21 excisions, 19 patients, average age 33.3 years) out of our 
archival material at the department of Pathology, University Medical Center Nijmegen St. 
Radboud, the Netherlands.  
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Retinoid treatment 
Retinoids were only used by renal transplant recipients.  Of the 18 patients  with warts, 9 
patients (10 excisions) received retinoid treatment .  In 3 patients  (4 excisions)  topical all-
trans-retinoic acid (concentration 0.025-0.05 %)  was used and 6 patients received systemic 
acitretin ( dose at time of biopsy,  10-35 mg).  
Patients taking systemic acitretin participated in a clinical trial , unrelated to the present 
study, studying the effects of systemic retinoid on cutaneous carcinogenesis in RTRs. 
Inclusion criteria for this trial were either the presence of at least 1 squamous cell carcinoma 
(SCC) in the patient’s history or the presence of 10 or more actinic keratoses, with at least 1 
confirmed histologically.  Initially, most patients taking acitretin started with 30-35 mg/d, a 
dosage that prevented SCCs in RTRs in an earlier study9. However,  in a relatively large 
number of patients,  doses of acitretin had to be lowered because of  mucocutaneous adverse 
effects ( peeling of palms and soles and/or cheilitis ).  
Retinoid- and non-retinoid-treated patients showed no obvious differences with respect to 
duration, dosage, and type of immunosuppression,   all factors implied in the etiology of skin 
cancers in immunosuppressed patients (data not shown). 
 
Histopathology 
Histological examination of all studied lesions was revised according to World Health 
Organization definitions of verrucae 84. The verrucae  consisted predominantly of common 
warts or verrucae vulgares, with a smaller group of verrucae plana, especially in the ICIs, 
usually located on hands and feet.  Condyloma acuminata or anogenital warts were not 
included. 
 
Immunohistochemical analysis 
Immunohistochemical analysis was performed on all specimens by using standard avidin-
biotin-peroxidase complex system with either  diaminobenzidine (DAB) and/or  3-amino-9-
ethylcarbazole (AEC) as the chromogens.  In brief, 4-μm-thick paraffin sections were 
deparaffinized, hydrated and washed in buffered phosphate. 
For K13 staining, sections were cooked in buffered citrate ( 10mM, pH 6.0 ) in a microwave 
oven 2 times for 5 minutes each (600 Watt).  After a cooling down period of (at least ) 20 
minutes and preincubation with 20% normal horse serum for 15 minutes, the sections were 
incubated with undiluted primary antibody overnight at 4˚C.  We used two mouse 
monoclonal primary antibodies, 1C7 ( Immunoglobulin G2a ) and 2D7 ( Immunoglobulin 
G2b ), both recognizing K13 199. As a positive control, normal esophageal tissue was used.  
After incubation with primary antibodies, sections were incubated for  30 minutes with 
biotinylated horse anti-mouse (1: 200 dilution; Vector Laboratories, Burlingame, Calif ), 
followed by incubation for 45 minutes with avidin-biotin complex (1:50 dilution; Vector 
Laboratories).  For development with 3-amino-9-ethylcarbazole,  avidin-biotin complex 
concentrations were doubled.  
For K19 immunohistochemical analysis, ( mouse ) monoclonal antibody RCK 108 ( 
Biogenex, San Ramon, Calif/DAKO) was used.  Besides different pretreatment  (0.1% 
pronase for 10 minutes),the same procedure as for K13 was followed.  Eccrine ducts and 
sweat glands served as positive internal controls. 
Sections were counterstained with Mayer hematoxylin for 2 minutes. 
Immunoreactivity was scored as negative, slightly positive in a suprabasal single-cell pattern 
(< 10% of lesional keratinocytes positive ), or strongly positive in a suprabasal segmental 
columns pattern (zebroid pattern). 
Scoring was performed without knowledge of patient history and use of retinoid therapy.   
The Pearson 2  test was used for all statistical analyses, and significance was set at P<.05. 
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RESULTS 
 
General aspects of immunostaining for K13 and K19  
In all cases, immunostaining for K13 was restricted to the cytoplasm.  Slight variations in 
staining intensity were observed in lesional skin comparing  antibodies 1C7 and 2D7 with 
overall stronger staining with the 2D7 antibody.  Principally, however, the staining pattern of  
lesional skin with both antibodies was identical.  Normal esophagus was used as a positive 
control and showed strong diffuse suprabasal staining. 
Keratin 19 immunostaining was also localized in the cytoplasm.  Eccrine ducts and sweat 
glands, serving as internal controls, showed marked positivity. 
 
Expression of K13 and K19 in warts of RTRs vs. ICIs and effects of retinoid treatment 
There was a significant difference in K13 expression between warts of RTRs and warts of 
ICIs (P< .001 ).  A high percentage of warts of RTRs (86%, 18 cases) showed K13  
expression, whereas in benign warts of ICIs almost all lesions were negative except for  3 
(14%) of 21 with suprabasal single-cell positivity (Table 1 and Figure 1).  
 
 
 
Table 1.  K13-positive and K13-negative warts in RTRs and ICIs*. 
 Warts of RTRs 
21 lesions 
Warts of ICIs 
21 lesions 
K13 positive  18 
(86%) 
3 
(14%) 
K13 negative  3 
(14%) 
18 
(86%) 
*K13 indicates keratin 13; RTRs, renal transplant recipients; ICIs, immunocompetent 
individuals. 
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FIGURE 1 
A, Hematoxylin-eosin staining of a wart from a retinoid-treated renal transplant recipient (RTR)(original 
magnification x40).  B,  Immunohistochemical analysis of a wart from a retinoid-treated RTR for keratin (K)13 
(monoclonal antibody 2D7, with diaminobenzidine as the chromogen ) showing the particularly strong 3+ 
positive zebroid pattern of alternating suprabasal columns of K13-positive and K13-negative keratinocytes.  
This zebroid pattern was significantly correlated to retinoid treatment in RTRs (original magnification x40).  C 
and D, Wart of a retinoid-treated RTR showing uncoupled regulation of K13 and K19 expression by retinoids, 
with strong zebroid pattern K13 positivity (D), whereas K19 expression is absent (C).  The Arrows (C) point to 
K19-positive sweat glands, which serve as an internal control (original magnification x40).  E, Hematoxylin-
eosin staining of a wart from an immunocompetent individual (ICI).  F, Immunohistochemical analysis of a wart 
from an ICI for K13 (2D7, diaminobenzidine) showing suprabasal single-cell positivity (arrow).  This pattern of 
K13 expression was also typical of warts from non-retinoid-treated RTRs (original magnification x40).  G, In 
situ squamous cell carcinoma (ISSCC) of an RTR showing  K13 (2D7) expression partially centered around hair 
follicle structures (original magnification x40).  This staining pattern differs considerably from the retinoid 
therapy related zebroid K13 pattern. 
H, Perilesional skin in specimen from an ISSCC of an RTR receiving retinoid treatment.  Immunohistochemical 
analysis of K13 ( 2D7 ) shows the same zebroid pattern as in lesional skin of most warts of retinoid-treated 
RTRs (original magnification x40x). 
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This statistical difference in K13 positivity remained when we excluded retinoid treated 
patients; 82 % K13 positivity in non-retinoid-treated RTRs vs. 14%  in the controls (P<.001).  
Besides number of positive specimens,  the proportion of positive lesional cells also differed 
and was more pronounced in warts of RTRs: the 3 positive warts of ICIs showed only 
suprabasal single-cell positivity (Figure 2) ; in RTRs, half of the 18 positive warts also 
showed this single suprabasal cell positivity, whereas the other half showed strong positive 
staining in a remarkable pattern of segmental  positive suprabasal full epithelium thickness 
columns (zebroid pattern)( Figure 1B, D and Figure 2 ). This particular pattern was not linked 
to eccrine ducts or hair follicle structures; the latter actually seemed to be spared.  
 
FIGURE 2 
Keratin 13 expression patterns in warts of renal transplant recipients (RTRs) vs. immunocompetent individuals 
(ICIs). 
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This zebroid  pattern correlated with retinoid treatment ( topical and systemic ) when 
comparing retinoid-treated RTRs (warts and in situ SCCs) with non-retinoid-treated RTRs 
(Table 2)(P<.001). Only 1 patient without (anamnestically traceable) retinoid treatment 
exhibited the same K13 expression pattern.   
 
Table 2 Strong Keratin 13 (K13) positivity (zebroid pattern) and nonzebroid K13 positivity  vs. retinoid 
therapy in renal transplant recipients 
 
 Retinoid treated warts (No., %) 
n=10 
Non-retinoid treated warts (No., %) 
n=11 
K13  zebroid pattern 9 
(90% ) 
1 
(9%) 
K13  nonzebroid pattern 1 
(10%) 
10 
(91%) 
  
 
Most warts were superficially excised with no perilesional skin available.  In 1 retinoid-
treated RTR, the perilesional skin showed  K13 positivity comparable with the previously 
described zebroid pattern. 
All warts in both groups were negative for K19, with use of retinoids having no demonstrable 
effect on K19 expression ( Figure 1 C-D).  
 
COMMENT 
Data from numerous  animal and in vitro studies 55,79,106,107,202with cultured human 
keratinocytes have indicated that retinoids influence epidermal proliferation  and 
differentiation. Retinoids repressed expression of  differentiation-specific keratins (K1/K10) 
and strikingly reinduced K13 and K19 expression, two keratins that are only coexpressed in 
fetal skin but not normally present  in  epidermis of adults139,200. In contrast to these findings 
of coupled K13 and K19 induction by retinoids, Agarwal was the first to report uncoupled 
regulation of K13 and K19 expression in a human squamous cell carcinoma cell line1.  
Interestingly, our in vivo data with immunohistochemical evaluation of K13 and K19 
expression in warts of RTRs versus ICIs, showed that retinoids used as a chemoprotective 
agent in the transplant recipients for preventing skin cancer, also only strongly relate to K13 
and not K19 expression.  Our  finding of retinoid-related uncoupled K13 and K19 expression  
in these patients could be threefold.  First, the retinoid concentration  in our patients,  could 
be  sufficient to enhance K13 expression but not K19 expression.  Earlier findings in human 
epidermal cultures indeed showed stronger induction of K13 than of K19 by retinoids with 
already a marked increase of K13 in response to very low levels of retinoids, while for K19 
induction a higher threshold retinoid concentration was necessary106. Although in  a 
considerable number of our patients on systemic retinoids dosages had to be  lowered in the 
course of treatment because of severe mucocutaneous side effects,  also in  patients still 
receiving the higher dosages of acitretin no induction of K19 was found.  Second, response of 
keratinocytes to retinoids in vitro might not be representative for the  response in vivo and 
retinoids in humans in vivo might not induce an embryonic type of differentiation and only 
selectively induce K13.  In the only previously performed  in vivo study on effects of 
retinoids, in photo-aged skin, only K13 and not K19 expression was studied162. Finally, this 
differentiation towards “esophageal-type” of epithelium in contrast to so-called “embryonic-
type” of differentiation found in animals and in vitro, could be specific for skin and skin 
lesions in RTRs : earlier studies already showed that effects of  retinoids differed in normal 
keratinocytes when compared to diseased keratinocytes202. 
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Retinoid treatment significantly correlated with a specific pattern of K13 expression  in skin 
lesions of RTRs.  This pattern, which we termed zebroid because of alternating suprabasal 
columns of K-13 positive and K13-negative keratinocytes, is suggestive of a genetic 
mosaicism, reflecting clonal expansion of  genetically altered stem cells.  In warts and 
slightly dysplastic skin of RTRs,  segments of epidermis may contain keratinocytes with a 
genetic abnormality making them more susceptible to inductive actions of retinoids.  Future 
studies might unravel the underlying  genes that are involved in this process and whether, for 
instance, transforming ( transforming types of) human papillomavirus might play a role152. 
Interpretation of the biological impact of K13 expression in retinoid- and non-retinoid-treated 
warts of RTRs could be 2-fold.  The first interpretation relates the presence of K13 in skin to 
differentiation,  in parallel to internal squamous epithelia, in which K13 is restricted to  the 
suprabasal epithelial compartment and is associated with differentiation.  Retinoids, by 
inducing K13 expression or directing keratinocytes towards ( esophageal ) differentiation,  
might be chemopreventive by  “freezing” cells in this differentiated state and preventing them 
from ( further ) dedifferentiating.  Results of previous studies 57,106,189 of retinoid effects on 
epidermal keratinocytes have shown that in response to retinoid treatment, higher molecular 
weight keratins, typically encountered in squamous epithelia disappear, and synthesis of two 
new low molecular-weight keratins, a 40 – and 52-kD keratin, corresponding to  K19 and 
K13 respectively , is enhanced. In the absence of vitamin A , the opposite  occurs, with 
enhanced terminal epidermal type of differentiation 197 . Retinoid-induced esophageal-type 
differentiation could provide an explanation for the cosmetic improvement of lesional skin in 
these RTRs, who often had multiple hyperkeratoses before treatment:  esophageal epithelium 
is, in contrast to the keratinizing epidermis, a nonkeratinizing squamous epithelium.  By 
inducing non-keratinizing differentiation, retinoids could lower the number of hyperkeratotic 
skin lesions.  As an adverse effect, in normal skin the diminished cutaneous keratinization 
caused by retinoids leads to desquamation of palms and soles which usually show the most 
prominent keratinization.  On the lips, the outer cutaneous side becomes more vulnerable 
because of differentiation towards wet epithelium,  leading to cheilitis, another known 
adverse effect of acitretin treatment also present in our patients 9,80,217.  
The second interpretation relates the presence of K13 to a more dedifferentiated and 
potentially malignant phenotype.  Regarding cutaneous carcinogenesis, malignant 
transformation is heralded by a switch from production of high-molecular-weight keratins 
normally present in adult skin ( K1/K10 ) to low-molecular-weight keratins also characteristic 
of fetal skin and simple epithelia ( e.g. K8/K18 and K19 )185. Presence of K13,  a low-
molecular-weight embryonic keratin, would fit within this concept.  It is tempting to attribute 
relevance to the high frequency of K13 in warts of RTRs and to speculate that it may be 
related to the higher susceptibility of warts in these patients to become malignant.  This 
would be analogous to mouse models on skin carcinogenesis in which aberrant K13 
expression is a consistent finding in chemically  and v-Ha-ras-induced papillomas and 
squamous cell carcinomas142,194,218. In in situ SCC of RTRs and ICIs we indeed found frequent 
K13 expression in 75% and 45% of lesions, respectively (20 in situ SCC tested within each 
group, data not shown), which is in concert with this second hypothesis.  The pattern of K13 
expression  in in situ SCCs of both groups was different from the retinoid therapy-related 
K13 expression ( zebroid pattern, compare Figure 1 B, G).  Only 4 RTRs with in situ SCCs 
used retinoids, and in these patients the retinoid therapy-related zebroid K13 pattern was 
most pronounced or only present  in perilesional, slightly dysplastic skin (Figure 1H).  
When this latter interpretation would be applicable to retinoid-related  K13 expression,  use 
of retinoids  might actually be dangerous for these patients.  This is contradicted by studies of 
the long term safety of retinoid therapy,  since no increased incidence of skin cancer is 
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reported196. Studies of skin cancer chemoprophylaxis with retinoids in RTRs actually showed 
reduction in the skin cancer incidence9. 
In conclusion, this retrospective in vivo study of embryonic keratin expression in warts of 
RTRs, shows that retinoids strongly relate to K13 but not K19 expression.  By keeping 
keratinocytes in this esophageal-type differentiation retinoids might act chemo preventively.  
Retinoids correlate with a highly distinctive  and strong K13 expression, which we termed 
zebroid, making K13 a useful marker for evaluating retinoid treatment in these patients.  The 
alternating zebroid K13 pattern is suggestive of an underlying genetic mosaicism.  Even in 
the absence of retinoids, a significant higher percentage of K13 positivity is found in warts of 
RTRs compared with warts of ICIs.  Future prospective, randomized and well controlled 
studies need to establish the relevance of this finding and whether K13, in analogue to mouse 
models on skin carcinogenesis, might become a predictive marker for malignant progression.  
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3.2 
 
Acitretin treatment in (pre)malignant skin disorders of renal transplant  
recipients: histological and immunohistochemical effects  
 
 
 
Abstract 
Background: The incidence of (pre)malignant skin lesions after renal transplantation is 
high.  Acitretin treatment appears to decrease the number of new squamous cell carcinomas 
and ameliorates the aspect and reduces the number of actinic keratoses.  However, no 
histological and immunohistochemical studies have been performed to further substantiate 
these observations.  
Methods: In 33 renal transplant recipients, biopsies were taken before and after 3 months of 
treatment with acitretin in doses up to 0.4 mg/kg/day.  Histological and 
immunohistochemical parameters for dysplasia, epidermal thickness, proliferation, 
differentiation, apoptosis, and dermal inflammation were analyzed.  
Results: Following acitretin treatment, a significant reduction in epidermal thickness (P= 
.002) and a significant increase in normal differentiation parameter K10 (P= .02) was 
observed.  Epidermal proliferation did not change, nor did apoptosis, inflammation, 
keratinocytic epidermal neoplasia score, or transglutaminase staining.  At baseline in 8 
actinic keratoses a single cell expression pattern of K13 and/or K19 was found.  This  was 
associated with high levels of parameters indicative of high-risk lesions (P< .05).  After 
acitretin treatment, an increase in K13 (P= .006) and K19 (P= .05) was found, together with 
a change in expression towards a focal or band-like staining pattern.  
Conclusion: acitretin improves the aspect of actinic keratoses via alteration of 
keratinization, resulting in peeling of the stratum corneum.  No significant change in 
proliferation was found, which may explain for the rapid recurrence of actinic keratoses seen 
after cessation of acitretin treatment.  
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INTRODUCTION 
 
In renal transplant recipients (RTRs) receiving long-term immunosuppressive treatment, an 
increased incidence of several benign wart-like lesions and (pre)malignant conditions has 
been found.  The most frequently occurring (pre)malignant lesions are actinic keratosis (AK), 
Bowen’s disease, squamous cell carcinoma (SCC), keratoacanthoma, basal cell carcinoma, 
and porokeratosis 39,50. Major etiologic factors include previous sun exposure, the duration of 
immunosuppressive therapy, and human papillomavirus (HPV) infections 50,175. AKs are the 
lesions most frequently seen in this population and have been reported in up to 38% of these 
patients after 5 years follow-up, and even increase thereafter 6. The percentage of AKs that 
will convert into a SCC within one year varies between 0.25% and 16% depending on the 
number, sort and duration of risk factors present, especially the use of immunosuppressive 
drugs 76. 
AKs in RTRs usually are multiple and behave more aggressive when compared to identical 
lesions in non-immunocompromised individuals 208. Treatment modalities like surgical 
excision, cryotherapy, or topical fluorouracil, are often difficult to perform in view of the 
multiple localizations and involvement of large body areas.  Therefore, a systemic treatment 
preventing malignant transformation is urgently needed.  
Data obtained from 3 studies in RTRs where AKs were treated with systemic etretinate or its 
biologically active metabolite acitretin showed a significant decrease in the number and an 
improved aspect of the AKs 9,73,102 . In 5 studies it was mentioned that these systemic retinoids 
also decreased the number of SCCs 9,73,102,132,180 . However, only one of these studies was 
randomized and placebo-controlled 9. After cessation of systemic retinoid treatment a 
recurrence in the number and aspect of AKs 9,102 and in SCCs  was frequently seen 
9,73,102,132,180,208.   
Ideally, the criteria for improvement of AKs comprise both changes in clinical appearance 
and changes in relevant histopathologic and immunohistochemic features of the preneoplastic 
process.  Clinical improvement without improvement of dysplastic and proliferative 
characteristics may mask these premalignant keratoses and may mislead both patient and 
physician.  Apart from data on Langerhans cells 72,160, no histological and immunohistochemic 
studies investigating the effect of systemic retinoids on AKs in RTRs have been performed to 
strengthen or contradict the clinical impression.  
It is known that malignant transformation is represented by dedifferentiation, which is 
associated with a switch in synthesis of high molecular weight proteins, such as keratin 1 
(K1) and keratin 10 (K10), towards low molecular weight proteins, such as keratin 13 (K13) 
and keratin 19 (K19) 185. In normal human epidermis, these keratins are absent 139, but they 
can be expressed in SCCs 209. No information is available on the expression of these low-
molecular weight molecules in AKs. 
Therefore, in the present study we evaluated parameters for dysplasia, epidermal thickness, 
dermal infiltrate, epidermal proliferation, epidermal differentiation, and apoptosis, as well as 
parameters for dedifferentiation and retinoid-induced keratinization, the low molecular 
weight proteins K13 and K19 in AKs in RTRs. 
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MATERIALS AND METHODS 
 
Study design 
This study was conducted in adult RTRs with a stable graft function and a stable dose of 
immunosuppressive therapy.  Patients initiated treatment with acitretin 0.4 mg/kg/day, unless 
it was known from previous acitretin treatment that this dose was intolerable because of side 
effects.  In that case, the highest dose still tolerable by the patients was applied.  The duration 
of treatment was 12 weeks.  After this 12-week study period, patients remained on acitretin 
therapy for another 9 months for further clinical evaluation. 
Patients should have a history of at least one SCC of the skin and 10 AKs or 20 AKs if no 
previous SCC had occurred.  Exclusion criteria were: excessive alcohol intake, the use of 
anti-epileptic drugs, nephrotic syndrome, hypercholesterolemia (>9 mmol/l), 
hypertriglyceridemia (>10 mmol/l), elevated transaminase levels (ALT and/or AST more 
than twice the upper limit of normal) and pregnancy or pregnancy-wish.  The washout period 
for systemic retinoids was 3 months.  Topical retinoid treatment had to be discontinued at 
least 4 weeks before study enrollment to ensure an adequate epidermal turnover (in normal 
skin 2-3 weeks; in hyperproliferative disorders < 1 week 7) with respect to potential previous 
retinoid-associated effects by these agents. Medical Ethics Committee approval was obtained 
and all patients gave written informed consent prior to study enrollment.  
 
Biopsies and staining procedures 
Punch biopsy specimens of 4mm were taken under local anesthesia with xylocaine/1% 
adrenaline at baseline and after 3 months treatment.  Biopsy specimens were taken from AKs 
that were clinically identical at baseline and had the typical erythematous, scaling and mostly 
elevated aspect and from the same body region.  Suspicious lesions that were present at 
baseline or that newly formed during the study, were biopsied for diagnosis or, if necessary, 
surgically removed. 
Biopsy specimens were analyzed using standard histological techniques.  The following 
histological parameters were assessed: thickness of the lesions, total dermal infiltrate score 
(TDI), and keratinocytic epidermal neoplasia score (KIN) 38. 
The following immunohistochemical stainings were performed, using the avidin-biotin-
complex (ABC) staining method and indirect immunoperoxidase techniques: Ki-67 (MIB-1, 
epidermal proliferation), p53 (DO-7, apoptosis association), K10 (DE-K10, normal 
keratinization), K13 and K19 (1C7 and RCK108 respectively, retinoid-associated 
keratinization), K16 (LL025, hyperproliferation-associated keratinization) and 
transglutaminase (BT621, terminal differentiation).  Esophageal tissue, eccrine ducts, and 
sweat glands served as positive controls for K13 and 19 staining.  Further details on the 
immunohistochemical markers are provided in Table I. 
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Table 1.  Antibodies used in the study. 
antibody Specificity  Marker for Concentration Source 
MIB-1 Ki-67 Epidermal proliferation 1:50 Immunotech, Marseilles, France 
DE-K10 K10 Normal keratinization 1:100 Monosan, Uden, Netherlands 
1C7 K13 Retinoid-induced 
keratinization 
1:10 Monosan, Uden, Netherlands 
LL-025 K16 Hyperproliferation 
Associated 
Keratinization 
1:10 Novocastra lab. Ltd, Newcastle 
Upon Tyne, UK 
RCK108 K19 Retinoid-induced 
keratinization 
1:50 Monosan, Uden, Netherlands 
BT621 Transglutaminase Terminal differentiation 1:10 Biomedical Technologies Inc., 
Stoughton, Mass. 
DO-7 P53 Apoptosis 1:200 Dako, Glostrup, Denmark 
 
 
Histological and immunohistochemical scoring 
With respect to histological analysis, epidermal thickness (mm) was measured in the center 
of the AKs, and additionally assessed by counting the number of cell layers. TDI scores were 
performed by using a similar semi-quantitative score on a 5-point scale: 0 = no infiltrate, 1 = 
minimal infiltrate, 2 = moderate infiltrate, 3 = moderate-pronounced infiltrate, and 4 = 
pronounced infiltrate. KIN scores were assessed according to Cockerell’s criteria for 
keratinocytic epidermal neoplasia38. In brief, lesions were graded based on the degree and 
extent of dysplasia on a 4-point scale. 
Immunohistochemical scoring was based on methods previously published106 and occurred 
along the complete length of the slides, but only in the sections that showed typical 
histological signs of AKs. Transglutaminase scores were assessed in the center of the AKs as 
the ratio of BT621-positive epidermal cell layers divided by the total number of epidermal 
cell layers. Ki-67 and p53-positive keratinocytes (nuclei) were counted per millimeter length 
of section. For scoring of keratinization parameters K10, K13, and K16, the following semi-
quantitative scale was used: 0 = no staining, 1 = sporadic staining (single cell expression), 2 = 
minimal staining, 3 = moderate staining, 4 = moderate-pronounced staining, 5 = pronounced 
staining, 6 = whole epidermis stained. 
All histological and immunohistochemical scoring occurred under blinded conditions. 
Demographic and dosage-related results are expressed as means ± standard deviation (SD); 
histological and immunohistochemical results are expressed as means ± standard error of the 
mean (SEM) unless stated otherwise. 
 
Statistical analysis  
For the assessment of statistical significant differences before and after 12 weeks of treatment 
with respect to the histological and immunohistochemical parameters, a Wilcoxon matched 
pairs test was used. Assessment of statistical significant correlations between parameters was 
performed by calculating Spearman’s rank correlation. Differences between K13 and/or K19 
responders versus non-responders were analyzed by using the Mann-Whitney U test. A P 
value of < .05 was considered statistically significant. Calculations were performed using 
Statistica version 9.0 (StatSoft Inc, Tulsa, Okla). 
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RESULTS 
 
Demographics  
Demographic data are summarized in table 2. Thirty-three patients (15 men and 18 women) 
were included in this study. Most patients also participated in a randomized study focusing on 
the clinical effects of acitretin on AKs (de Sévaux et al, submitted for publication). The mean 
age was 53.6 ± 9.7 years. The follow-up period after renal transplantation was 16.4 ± 6.7 
years. Twenty-nine patients had a history of one or more SCCs, with a mean of 2.6 ± 2.8 
SCCs per patient (excluding keratoacanthomas). Maintenance immunosuppressive treatment 
consisted of prednisone plus azathioprine (25 patients), cyclosporine plus prednisone (6 
patients), mycophenolate mofetil plus prednisone (1 patient), and cyclosporin plus 
azathioprine (1 patient).  
 
Table 2. Demographic data 
 
 
Age (y)*         53.6 ± 9.7 
        
Sex (male : female)        15 : 18 
 
Years of immunosuppression*       16.4 ± 6.7 
 
Maintenance immunosuppression     
 
 Azathioprine / prednisone       25 
 
 Cyclosporine / prednisone       6 
 
 Mycophenolate mofetil / prednisone     1 
 
 Cyclosporine / azathioprine       1 
Number of previous SCCs (No./patient)        
 
 All previous SCCs       2.6 ± 2.8 
 
 During year before study       1.0 ± 1.3 
 
Previous systemic retinoid use 
 
 Within 1 yr before study       0 
 
 More than 1 yr before study      3 
 
Previous local retinoid treatment       7  
       
 
* Values are given as mean ± SD 
 
 
Dosage 
Except for two patients who started with a lower dose (0.2mg/kg/d) due to previous 
intolerability of higher acitretin doses, the remaining 31 patients initiated treatment with 
acitretin 0.4 mg/kg/d. Most of these patients could not tolerate the starting dose of 0.4 
mg/kg/d because of mucocutaneous side effects (mostly cheilitis, intensive peeling, and eye 
irritation/conjunctivitis). Therefore, all patients received the maximum dose of acitretin that 
94  Chapter 3 
 
 
was still tolerated. The starting dose was 39.8 ± 8.6 mg/day (0.38 ± 0.07 mg/kg/d). At the end 
of the 12-week treatment period, the mean dose had been reduced to 20.2 ± 9.6 mg/d (0.26 ± 
0.13 mg/kg/d).  
 
Histologic results  
Biopsy specimens taken at baseline and after 12 weeks of treatment with acitretin were 
available in 32 out of 33 patients. One patient withdrew from the study because of severe 
mucocutaneous side effects after 8 weeks of treatment. In 28 baseline samples a typical 
actinic keratosis was found; in 2 samples, only hyperkeratosis without dysplasia was seen; in 
1, actinic keratosis had already progressed to a SCC; and 1 hyperkeratotic lesion appeared to 
be a common wart. One biopsy was not intact and was therefore excluded from evaluation. 
Therefore, 27 pairs of biopsies taken before and after acitretin treatment could be used for 
histological and immunohistochemical analysis.  
On histological examination, a mean reduction in epidermal thickness of 44.0% (P< .01) was 
found after acitretin treatment. This reduction was completely caused by a decrease in 
stratum corneum thickness; no significant reduction could be seen in the other strata (Figure 
1). 
 
 
 
FIGURE 1:  
Epidermal thickness as the sum score of stratum corneum thickness and thickness of the other strata in 
millimeter at baseline and after 12 weeks treatment with acitretin (mean ± SEM) (* P < .01; N=27). 
 
At baseline, minimal to moderate TDI scores were found in 85% of the AKs, whereas the 
remaining 15% demonstrated a moderate-pronounced TDI. The infiltrates were localized 
perivascular and in the upper dermis. After 12 weeks of treatment, no significant alterations 
were seen in TDI scores (Figure 2).  
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FIGURE 2:  
Semi-quantitative scores for keratinocytic intraepidermal neoplasia (KIN), total dermal infiltrate (TDI), and 
keratins K10, K13, K16, and K19 at baseline and after 12 weeks treatment with acitretin (mean ± SEM) (* P < 
.01; **P  .05; N=27) 
 
 
The KIN score, a scoring system for dysplasia, did not change significantly during the study 
period. Before treatment the KIN score was 1.7 ± 0.2 versus 1.3 ± 0.2 after treatment (Figure 
2).  
  
 
Immunohistochemical results 
At baseline, in most AKs the epidermal proliferation parameter Ki-67 revealed numerous 
proliferating cells mostly in the basal cell layer, but also to a variable extent depending on 
KIN score in the suprabasal regions of the epidermis. Ki-67 expression was restricted to the 
nuclei and featured a rather homogenous staining pattern in the horizontal plane of the 
epidermis. Treatment with acitretin did not lead to a significant alteration in the number of 
Ki-67-positive keratinocytes (Figure 3). In 13 patients, an increase in Ki-67-positive cells 
could be demonstrated, whereas in 14 patients a decrease in this number was found after 
acitretin treatment. 
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FIGURE 3: 
Ki-67 and p53 scores as the number of positive stained cells per mm length of section of the slides at baseline 
and after 12 weeks treatment with acitretin (mean ± SEM) (N=27). 
 
Apoptosis-associated p53 protein at baseline was mostly observed in the basal and lower 
suprabasal cell layers of the epidermis, but in some AKs p53 expression throughout all 
epidermal cell layers was seen. Expression of P53 basically followed the pattern of Ki-67. 
However, incomplete staining areas for p53 were often observed, whereas the corresponding 
Ki-67 staining in a consecutive slide was continuous along the complete length of the slide. 
Overall, the number of p53 positive cells was also much higher than the number of Ki-67-
positive cells. Statistical analysis revealed no significant change in p53 staining after acitretin 
treatment (Figure 3). 
Changes in the different parameters of keratinization are depicted in figure 2. Epidermal 
differentiation parameters at baseline showed the following patterns. Normal differentiation-
associated K10 expression was only seen in the suprabasal compartment. Its staining pattern 
was less when compared to normal skin and often showed unstained foci. After acitretin 
treatment, a significant increase in K10 expression was found with a more complete staining 
pattern (P= .02). 
Hyperproliferation-associated K16 was expressed in the suprabasal compartment of all AKs. 
Expression was moderate to pronounced, with staining of all suprabasal cell layers. Most 
intense staining for K16 was observed suprabasally in the hypertrophic center of AKs directly 
below the stratum corneum. The degree of K16 expression before and after acitretin treatment 
was similar. 
In the untreated AKs, terminal differentiation-associated transglutaminase staining was seen 
in the stratum granulosum and stratum spinosum. The number of positive cell layers varied 
among the AKs from 1 to 15. In addition, also in individual AKs differences could be seen in 
the number of positive cell layers. In general, in the interpapillary areas the number of 
positive cell layers was the highest. No significant changes in transglutaminase scores could 
be detected after acitretin treatment.  
 
Keratin 13 and keratin 19 
At baseline, K13 expression was found in 8 patients and this was localized in the suprabasal 
cell layers of the AKs. The staining pattern in these sections was always sporadic with single 
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cell expression mostly scattered in the epidermis. After acitretin treatment K13 expression 
was found in 14 patients featuring increased expression in the suprabasal regions of the 
epidermis. No K13 staining was observed in the basal cell compartment. This increase in K13 
expression (in number and score) after acitretin treatment was significant (P< .01). In Figure 
4, K13 expression is shown in a non-retinoid treated actinic keratosis and in an acitretin-
treated actinic keratosis. 
 
FIGURE 4:  
A, K13 expression (1C7) in tissue samples of a non-retinoid treated actinic keratosis (single cell expression; 
X200) and (B) of an acitretin-treated actinic keratosis (increased expression; X200). 
 
At baseline, in 4 patients K19 expression was found. Its grade of expression varied from 
sporadic to minimal, with typical single cell expression mainly located in the suprabasal 
compartment. After acitretin treatment K19 could be detected in 10 AKs. After treatment 
K19 was primarily located in the basal cell layers with minimal expression in the suprabasal 
compartment. The expression of K19 increased (P= .05) from single cell to continuous 
staining (Figure 5).  
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FIGURE 5:  
A, K19 expression (RCK108) in tissue samples of a non-retinoid treated actinic keratosis (single cell expression; 
X200) and (B) in an acitretin-treated actinic keratosis increased expression (X200). 
 
None of the patients who showed K19 expression at baseline, and only 2 out of 8 patients 
who showed K13 at baseline, had previously used retinoids. 
 
Correlations 
In the baseline samples, a significant positive correlation was found between Ki-67 and p53 
(R=0.61; P = .001), between Ki-67 and KIN score (R=0.50; P= .013) and between KIN and 
p53 score (R=0.48; P= .02).  
Because of the unexpected finding of K13 and K19 expression in some of the samples at 
baseline, we looked at correlations between K13/K19 and parameters positively correlated 
with malignant transformation, including epidermal proliferation ( Ki-67 ) 146,177 , (mutant) 
p53 expression 146,177 , and KIN score 38, as it has been suggested that the presence of low-
molecular weight proteins in human skin can be a sign of malignant transformation. In 
addition, we looked at a correlation between K13/K19 and the frequency of newly formed 
SCCs in the year before study participation. 
With respect to K13 expression at baseline, significant positive correlations were found with 
Ki-67 (R=0.41; P= .036) and with the number of SCCs that each patient had developed in the 
12 months immediately before treatment (R=0.43; P= .024).  
For K19, a similar positive correlation with Ki-67 (R=0.56; P= .003) was found in the 
baseline samples as well as significant positive correlations with p53 (R=0.56; P= .002) and 
KIN score (R=0.53; P= .007). No statistical significant correlation between baseline K13 and 
K19 expression was found. 
In order to assess whether induction of K13 and K19 in AKs by acitretin are correlated with 
each other, we compared K13 scores with K19 scores in patients who had at least grade 2 
expressions in either K13 or K19 ( N=10) with patients who were both K13 and K19 negative 
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(N=8) after acitretin treatment. Grade 1 (single cell) expression was excluded because this 
was also seen in untreated biopsies. After this correction for single cell expression in 
acitretin-treated AKs, a statistical significant correlation (R=0.49; P= .039) between K13 and 
K19 could be demonstrated in these 18 patients. 
 
DISCUSSION 
 
From previous studies it is known that retinoids can improve the aspect of AKs by reducing 
its roughness 9,73,102. Our data indicate that this clinical improvement is caused by a decrease in 
thickness of the stratum corneum, whereas the other strata remain unchanged with respect to 
thickness or the number of cell layers. Other histological parameters (TDI, KIN) did not 
change significantly. With respect to immunohistochemical data, we have demonstrated 
alterations in K10, K13, and K19, but no effect on K16, transglutaminase, epidermal 
proliferation, and p53 expression. These results are in contrast to psoriasis, where a 12-week 
treatment period with systemic acitretin in a similar dose led to significant reduction in 
epidermal proliferation, transglutaminase, K16, and dermal inflammation in a group of 10 
patients112. 
In general, retinoids are known to alter normal differentiation of the cornifying epidermis 
towards an esophageal-type of differentiation by stimulating the synthesis of low molecular 
weight keratins, such as K13, that are normally present in internal squamous epithelia, but not 
in adult human skin 57,106. 
In studies with cultured keratinocytes, coupled induction of K13 and K19 by retinoids has 
been described 106,107. With respect to in vivo studies, K13 expression was induced by topical 
application of all-trans-retinoic acid (ATRA) on photoaged human skin 162 and by systemic 
treatment in warts in RTRs 20. To our knowledge, no in vivo studies have been performed that 
report an induction of K19 by retinoids. The present study in AKs in RTRs also demonstrates 
that induction of K13 by acitretin is correlated with K19 induction, although, in contrast to 
fetal skin, expression of both parameters was seen uncoupled. Uncoupled expression of K13 
and K19 has been reported previously in a human SCC cell line 1 and in warts in RTRs 20. 
Our data also suggest that induction of K13 in AKs by acitretin is more frequently seen than 
induction of K19. Earlier findings in human epidermal cultures indeed showed stronger 
induction of K13 than of K19 by retinoids106.  
Apart from the induction of K13 and K19 by acitretin, in the present study we found evidence 
that K13 expression in non-retinoid-treated AKs is correlated with higher epidermal 
proliferation, higher (mutant) p53 protein expression, and a higher degree of dysplasia. 
Therefore, these data indicate that assessment of K13 and K19 in non-retinoid treated AKs 
may provide further information on the risk of malignant transformation and thus may be of 
interest for the identification of high-risk lesions.  
It is intriguing that retinoid treatment induces keratins that are correlated with malignant 
transformation and on the other hand cause a reduction in skin cancer incidence 9,73,102,132,160,180. 
Therefore, it is likely that, with respect to K13 and K19 expression, we deal with 
epiphenomena, related to two distinct pathways: malignant transformation associated 
dedifferentiation and retinoid-associated keratinization. 
KIN scores based on histological criteria did not always correlate well with the clinical 
picture in this group of RTRs. While all 27 baseline biopsies were taken from typical AKs 
with evident erythematosquamous hallmarks, suggesting a grade II to III KIN score, in 2 
biopsies no dysplasia (KIN 0), and in 10 biopsies a KIN grade I was found. Therefore, in 
RTRs, who often have numerous erythematosquamous and hypertrophic AKs, the directly 
visible clinical hallmarks of these lesions may not always reflect the grade of dysplasia in the 
epidermis of these lesions. 
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Combining clinical, histological, and immunohistochemical data, it can be concluded that 
treatment with systemic acitretin improves AKs probably via alteration of the keratinization 
process of the keratinocytes, leading to peeling of the hypertrophic stratum corneum of these 
lesions and clinically resulting in softening of the skin. No significant decrease in 
proliferation and dysplasia was found, which might be the explanation why recurrence of 
AKs is normally seen after cessation of acitretin treatment. Expression of low-molecular-
weight keratins K13 and/or K19 in non-retinoid treated AKs is correlated with parameters 
that are indicative for high-risk AKs. Therefore, K13 and K19 may provide two new 
diagnostic parameters for assessment of AKs at particular risk for transformation into a SCC. 
 
 
Retinoid treatment of skin cancer in renal transplant recipients 101 
3.3 
 
Immunohistochemical effects of temporary cessation of long-term 
acitretin treatment in keratinocytic intraepidermal neoplasia of 
renal transplant recipients  
 
 
Abstract 
Objectives: to study effects of temporary cessation of systemic acitretin treatment in renal 
transplant recipients (RTRs). 
Design: prospective, non-randomized clinical and immunohistochemical study. 
Setting: University hospital. 
Patients and methods: 9 RTRs on systemic acitretin (mean duration 2.3±0.6 yrs; mean 
dosage 18.3±9.9mg) were asked to interrupt their treatment for three months. Patients gave 
written informed consent. Patients were seen at intervals of 6 weeks, starting at the moment 
of acitretin interruption. Each visit epidermal lesions were counted; erythema and 
desquamation of normal skin and AKs were recorded and induration of AKs, a visual 
analogue score (VAS) for patient’s contentedness was performed, and clinical comparable 
AKs were biopsied.  
Main outcome measurements:  
1.establish change in numbers of skin lesions and skin (pre) cancers after acitretin 
interruption; 
2.compare expression of keratin 13 (K13), MIB-1, p53 and p16INK4A in KIN lesions of RTRs, 
with and without acitretin; 
Results: After 3 months, the number of warts was significantly increased (p=0.02) and AKs 
were more indurated (p=0.02). VAS score reduced significantly already after 6 weeks 
(p=0.04), and strongly after 12 weeks (p=0.004). We could not demonstrate a significant 
increase in number of AKs (p=0.09) or SCCs (p=0.3). 
After 6 and 12 weeks, a significant decrease of  K13 expression was found (p=0.03 and 
p=0.02 respectively);  zebroid K13 expression also decreased but this reduction was not 
significant (5/9 cases at the start vs. 1/9 cases after 6 and 12 weeks ; p=0.10). No alteration 
in expression of cell cycle associated markers was found.  
Conclusions:  Acitretin withdrawal in RTRs leads to  
1.clinical deterioration within 3 months, without significant increase in skin (pre) cancer, 
and  
2.significant reduction of aberrant K13 expression, without alteration in expression of cell-
cycle-associated markers.  
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INTRODUCTION 
 
Retinoids, synthetic vitamin A analogues, interfere with epidermal growth and 
differentiation. These effects of retinoids on proliferation and differentiation make retinoids 
of interest in the treatment of hyperproliferative skin diseases, such as psoriasis, disorders of 
keratinisation and as an anti-tumor drug 197. 
Renal transplant recipients (RTRs) in general develop multiple warts, actinic keratoses (AKs) 
and non-melanoma skin cancers (NMSCs), especially on sun-exposed parts of the body24,26,117, 
which lead to a major co-morbidity. In the past two decades, systemic treatment with 
retinoids has shown to be promising in chemoprevention of actinic keratoses (AKs) and 
squamous cell carcinoma (SCC)118, also in RTRs 9,73,132,180,203. 
Several studies suggested a beneficial effect of systemic retinoid treatment, with either 
etretinate or acitretin, with prevention of SSCs and reduction of the incidence of keratotic 
lesions in RTRs with NMSC in their history or severe lesions 9,73,118,180,203 
However, after stopping the retinoid treatment the beneficial effect disappeared, with report 
of relapses varying from 4-12 months after discontinuation of retinoid therapy 9,46,118,203. 
Therefore, some have recommended continuous treatment 132.  
How retinoids exert their chemopreventive effect is so far unknown. Recently, we 
demonstrated that retinoids alter differentiation in almost 90% of warts of RTRs, with 
induction of keratin 13 (K13) expression 20, a keratin normally not present in the adult 
epidermis 28. A specific zebroid K13 expression pattern, proved indicative of retinoid 
bioactivity in skin of these patients. Whether comparable K13 expression patterns are present 
in retinoid treated KIN lesions of RTRs remains to be established. 
In addition, in view of the clinical efficacy of retinoids in NMSCs in RTRs, it is feasible that 
retinoids interfere with cell cycle associated proteins. Thus far, effects of retinoids on 
expression of cell cycle associated markers in KIN lesions of RTRs have not been published. 
The most current and so far best documented cell cycle associated marker for intraepithelial 
neoplasia (especially in neoplasia of the uterine cervix) is the proliferation marker, MIB-1 
70,127 .In AKs of both immunocompetent individuals and RTRs frequent overexpression of the 
p53 tumor suppressor is reported 66,120. Recent data show that besides the p53 pathway, also 
the pathway involving the tumor suppressor p16INK4A is involved in skin carcinogenesis 188; in 
high grade KIN lesions of both RTRs and immunocompetent  individuals we found frequent 
p16INK4A overexpression (own data, manuscript in preparation). 
The present prospective study was designed to study the effects of 3 months withdrawal of 
long term acitretin treatment on clinical skin condition and skin (pre) cancer development in 
RTRs, and assess effects on histology and immunohistochemical expression of the three 
biomarkers MIB-1, p53 and p16INK4A in KIN lesions of RTRs. Furthermore, we examined 
whether K13 expression in acitretin treated KIN lesions showed comparable expression 
pattern as previously found in warts during retinoid treatment, and if K13 expression reduced 
after acitretin withdrawal. 
 
MATERIALS AND METHODS 
 
Patients  
RTRs on systemic acitretin (mean duration of acitretin treatment 2.3+/-0.6yr; mean dosage 
18.3+/-9.9 mg/day ) were asked to interrupt their treatment for 3 months.  
Initially, 11 out of 16 approached patients agreed to participate and in all cases written 
informed consent was obtained. However, one female withdrew after the first visit due to 
interfering breast cancer and 1 patient withdrew because of progression of AKs and SCCs, 6 
weeks after the start of the study.  
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The characteristics of the remaining 9 patients (3 males, 6 females) that finally completed the 
3-month study period, including data on previous retinoid therapy and type and duration of 
immunosuppression are listed in Table 1.  
 
Table 1. Characteristics of the 9 participating patients; M=male; F=female; yrs=years; A=azathioprine; 
P=prednisolone; S=sirolimus;  AK=actinic keratoses. 
patient Age 
(yrs) 
sex Duration 
imm.suppress. 
(yrs) 
Type 
imm.suppression 
Dosage 
acitretin at 
T0(mg/day) 
Dosage 
acitretin  
at T0 
(mg/kg) 
Duration of acitretin 
treatment(yrs) 
1  65 M 33 AP 20 0.24  2.9 
2  60 F 6 AP 35 0.30 2.9 
3  53 F 27 P+S 20 0.29 2.8 
4  64 M 8 AP 10 
 
0.20 1.5 
5  64 F 24 AP 15 0.16 2.6 
6 48 F 22 AP 15 0.15 2.6 
7  60 M 21 AP 15 0.19 2.3 
8  51 F 26 C 25 
 
0.26 1.9 
9  60 F 13 AP 10 0.13 1.5 
Mean 
(±SD) 
58.3  20 (±9.1)  18.3 (±9.9) 0.21(±0.06) 2.3 (±0.6) 
 
 
Design of the study  
During the 3-month study period the patients were seen at three defined moments, with 
intervals of 6 weeks in between each visit. At time T0 the study started and on this day 
systemic acitretin was stopped. Control visits were respectively 6 (T1), and 12 (T2) weeks 
after acitretin stop. 
At each visit all warts and actinic keratoses in each patient were counted and scored by the 
same dermatological investigator, familiar with this type of patients and their skin lesions. 
Erythema and desquamation of lesional and non-lesional skin and induration of lesional skin 
were judged, using a scale of 0-3 (0=absent, 1= minimal, 2=moderate, 3=severe). 
Patients were asked to give a subjective judgment of their skin condition using a visual 
analogue score (VAS), with a scale from 0-10 (0=very discontented, 10=very satisfied). At 
the end of each visit a 6 mm skin biopsy was taken; it was attempted to biopsy clinically 
identical (at baseline defined) actinic keratoses from the same location in all three sessions, 
preferentially from the forearm.  
Of each participating RTR, the number of biopsied AKs, Bowen’s diseases (BDs) and SCCs 
during the 3-month study period was compared with the number of lesions, which had 
occurred in the last 3 months with retinoid treatment. 
 
Histopathology and immunohistochemistry 
A KIN (keratinocytic intraepidermal neoplasia)-classification was assigned to all skin 
biopsies 38,216.  
Immunohistochemical analysis was performed on all lesions using standard avidin-biotin-
peroxidase complex system with diaminobenzidine (DAB) as the chromogen. In brief, 4-
micron thick paraffin sections were deparaffinized, hydrated, and washed in buffered saline 
phosphate. 
The monoclonal antibodies used, the antigen they recognise, and pretreatment and dilutions 
are listed in Table 2.  
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Table 2. Antibodies with the recognized antigens, used dilution, pretreatment, incubation time and 
temperature.  
antibody antigen Source dilution pretreatment Incubation time and 
temperature 
DO7  P53  Neomarkers 1:400 microwave 40C overnight 
P16INK4A/MTS1, Ab-4, 
16PO4 
P16INK4A  Neomarkers 1:100 microwave 40C overnight 
MIB-1 Ki-67 Progen 1:100 microwave 40C overnight 
2D7 (IgG2b) Keratin 13 G. van Muyen 1:1 microwave 40C overnight 
 
 
After incubation with primary antibodies, sections were incubated for 30 minutes with (a 1: 
200 dilution of) biotinylated horse anti-mouse (Vector laboratories, Burlingham, CA), 
followed by 45 min. incubation with (a 1:50 dilution of) avidin-biotin complex (Vector 
laboratories, Burlingham, CA). 
Sections were counterstained with Mayer’s haematoxylin. 
Immunoreactivity was scored semi-quantitatively for all applied immunohistochemical 
markers, in the following manner:   
MIB-1 and p53  : for both staining was nuclear. Staining was scored as previously published 
by Keating et al. in cervical neoplasia 99: 0= only basal layer positivity, 1=positivity confined 
to basal 1/3 of epidermis, 2=positivity confined to basal 2/3 of epidermis or 3= 
transepidermal positive staining). 
K13  :  staining was cytoplasmic. Scoring was performed as described previously 20; 
0=negative staining, 1= suprabasal single cell positivity, 2= zebroid pattern.  
P16INK4 :staining was both nuclear and cytoplasmic. Staining was scored as for MIB-1 and 
p53. 
Scoring of immunostaining was performed without knowledge of patient history. 
 
Statistics 
The Lilliefors test for normality disclosed that the data were not-Gaussian distributed. 
Therefore, non-parametric statistical procedures were used to analyze the data. Since the 
small series of patients included in this study the exact significance level is given or an 
unbiased estimate of exact significance level, calculated by repeatedly sampling (= Monte 
Carlo method).  
The relations between the grade of KIN and expression of K13, MIB1, p53 and p16INK4A were 
assessed with both rank correlation analysis and the Jonckheere-Terpstra test, a distribution-
free test for ordered alternatives (Hollander and Wolfe). 
In this study a before-after-design 176 was used to study the effect of cessation of retinoid 
treatment on some clinical and immunohistochemical parameters. If a significant effect was 
present after 6 weeks (T1) it will be further mentioned a short-term effect. If a significant 
effect was present after 13 weeks (T2) it will be further mentioned a long-term effect.  
A partial rank correlation analysis controlled for KIN grade was used to assess the effect of 
retinoid treatment cessation on the KIN-grade dependent immunohistochemical features.  
For the KIN-grade independent immunohistochemical features and clinical parameters the 
following statistical procedures were used to analyze the treatment cessation effect.  
Two planned pair wise comparisons (T1 versus T0 and T2 versus T0) were used to study the 
short and long term effects.  The Wilcoxon matched-pairs signed-rank test and McNemar test 
were used for these pair wise comparisons. The latter test was used for the dichotomous 
dependent variables. With a limited number of planned pair wise comparisons the Bonferroni 
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adjustment of the Type I error rate can be omitted 176. Because there is a definite expectation 
about the direction of the therapy cessation effect, a directional (one-tailed) alternative 
hypothesis was used. 
All statistical analyses were performed with SPSS 10.0 for Windows. 
 
RESULTS 
 
Clinical effects of interruption of systemic acitretin 
The number of counted warts and AKs at each control visit is listed in Table 3. Only for the 
number of warts a significant increase was seen after 3 months when compared to the start of 
the study (p=0.02); for AKs no significant differences in number of lesions were found. 
Desquamation of clinically normal and lesional skin did not significantly alter during the 3-
month study period (Table 3). Erythema of normal skin reduced significantly already after 6 
weeks (p=0.03): induration of AKs increased significantly only in the first 6 weeks after 
acitretin withdrawal (p=0.004): after 3 months this increased induration was no longer 
significant when compared to the start of the study.  
The mean VAS-score of all patients at each visit is listed in table 3; already after 6 weeks of 
acitretin VAS score is significantly reduced (p=0.04), and after 12 weeks this effect is 
strongly significant (p=0.004). 
During the 3-month study period, patients developed 7 new AKs, 2 BDs, 5 SSCs and 1 basal 
cell carcinoma (BCC), compared to 2 new AKs and 2 SCCs in the 3 months pre-study period 
while still on acitretin therapy; differences were not significant, neither for the number of 
AKs (p=0.09), nor for the number of SCCs (p=0.3). However, numbers are small and follow-
up is relatively short. 
 
 
Table 3. T0=start of the study; T1=6 weeks after acitretin withdrawal; T2=12 weeks after acitretin 
withdrawal;p1=p value T0-T1(week0-6); p2=p value T0-T2(week 0-12);  SEM=standard error of mean; 
AKs= actinic keratoses; VAS=visual analogue score. Figures in bold indicating statistically significant 
findings. 
 
parameter T0 
mean±SEM 
T1 
mean±SEM 
T2 
mean±SEM 
P1 P2 
number of warts 1.6±0.8 1.9±1.0 2.7±1.1 0.5 0.02 
number of AKs 129.6±36.4 108.1±26.7 109.6±25.4 0.1 0.2 
Erythema of perilesional normal skin 0.9±0.3 0.2±0.2 0.2±0.2 0.03 0.03 
Desquamation of perilesional normal skin 0.6±0.2 0.3±0.2 0.3±0.2 0.3 0.3 
Erythema AK 1.9±0.4 1.7±0.3 1.7±0.3 0.4 0.4 
Desquamation AK 1.1±0.3 2.00±0.3 1.6±0.4 0.05 0.3 
Induration AK 0.9±0.2 2.0±0.2 1.9±0.3 0.004 0.05 
VAS 5.6±0.7 4.4±0.7 3.1±0.6 0.04 0.004 
 
 
Histopathologic and immunohistochemical effects of interruption of systemic acitretin 
Since immunohistochemical parameters can be dependent of KIN grade, we had to take this 
into account while studying the effects of cessation of acitretin. In total 27 biopsies, 3 of each 
participating RTR were processed for histology and immunohistochemistry. Of each patient 
three biopsied were taken at T0, T1, and T2 that came from clinically comparable lesions, 
which on histological examination sometimes varied in KIN grade. In 8 patients in all visits 
either KIN 1 or 2 was biopsied, in 1 patient each control visit a KIN 3 lesion was biopsied. A 
correlation analysis showed that MIB-1 score strongly correlated with KIN grade (r=1). All 
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KIN 1 lesions showed a 1+ MIB-1 score, all KIN 2 lesions a 2+ and all KIN3 lesions a 3+ 
MIB-1 score. The p53 expression was weakly correlated with KIN grade (r=0.5, p=0.01). 
Expression of both p16 and K13 were not significantly correlated with KIN grade (r=0.33, 
p=0.10 and r=-0.03, p=0.90 respectively).  
When taken the KIN grade into account, we found no significant correlation between the 
biopsy number and the expression of MIB-1, p53 and p16INK4A. Therefore, in this small patient 
group no influence of acitretin withdrawal on expression of these three biomarkers could be 
demonstrated. However, a negative correlation between K13 expression and the time of 
biopsy (r=-0.50, p=0.01) was present. 
K13 expression decreased significantly from 1.44±0.24 to 0.33±0.24 after 12 weeks (p=0.02), 
when comparing K13 negative versus K13 positive cases. At the start of the study 90% of 
KIN lesions were K13 positive, after 6 weeks 33% and after 12 weeks 22% (Figure 1A).  If 
we only considered zebroid expression, there was clearly a trend towards decrease of K13 
expression after acitretin withdrawal (p=0.10): at the start of the study zebroid K13 
expression was found in 5/9 patients (56%), while after 6 weeks and 12 weeks of acitretin 
withdrawal  zebroid K13 expression was only  present in 1/9 patients (11%, Figure 1 B). The 
patient at 6 and 12 weeks with zebroid K13 expression was not the same patient.  
 
A B 
  
 
FIGURE 1: 
Expression of keratin 13 (K13) in keratinocytic intraepidermal neoplasia lesions of renal transplant recipients at 
baseline(T0), 6 weeks (T1), and 12 weeks (T2) after withdrawal. of acitretin therapy.  
A, Keratin 13-positive vs. K13-negative cases. Keratin 13 expression decreased significantly 12 weeks after 
withdrawal of acitretin therapy (P =0.02). 
B, Keratin 13-positive cases subdivided into cases having suprabasal single cell (SSC) expression or zebroid 
K13 expression. The latter pattern was previously found to be correlated with retinoid treatment 20. For zebroid 
K13 expression, a decreasing trend was present, with zebroid K13 expression being present in 5 (56%) of 9 
patients at T0, and only in 1 patient (11%) after 6 weeks and 12 weeks (P = 0.10). 
 
 
Histopathology of the skin biopsies at the start of the study with a zebroid K13 pattern, 
revealed in the areas of immunohistochemical K13 expression often compact 
hyperorthokeratosis, hypergranulosis, acanthosis and swelling with focally cytoplasmic 
vacuolization of the keratinocytes when compared to the K13 negative adjacent epithelium 
(fig. 2). These are known histological changes following topical and systemic retinoid 
treatment 56. The transition with the K13 negative epithelium was mostly sharp and abrupt.  
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FIGURE 2: 
A, Keratinocytic intraepidermal neoplasia (KIN) lesion of a renal transplant recipient, with biopsy specimen 
obtained at the start of the study (first day of acitretin withdrawal). Findings are consistent with KIN 1. An 
abrupt transition from normal to lesional skin with hyperorthokeratosis and acanthosis is seen; a slightly 
disordered epidermal structure with atypia in the basal one third of the epithelium is present (hematoxylin-eosin, 
original magnification / 100). 
B,.MIB-1 shows positive nuclear staining in the basal  one-third layer of the epidermis (arrow). Findings are 
consistent with KIN 1 (MIB-1, immunohistochemical analysis by using standard avidin-biotin-peroxidase 
complex system with diaminobenzidine, original magnification / 100).  
C, In lesional skin, a zebroid keratin 13 (K13) expression pattern is present with alternating columns of K13-
positive and K13-negative cells  (K13, immunohistochemical analysis by using standard avidin-biotin-
peroxidase complex system with diaminobenzidine, original magnification / 100). 
 
 
 
DISCUSSION 
 
The present study shows that 3 months cessation of systemic acitretin treatment is followed 
by reduction of aberrant differentiation in KIN lesions of RTRs with significant decrease of 
K13 expression. Expression of the proliferation marker MIB-1, and of cell-cycle-associated 
proteins p53 and p16, all often found overexpressed in KIN120,146 (p16, own data), were not 
altered on acitretin withdrawal. These data suggest that retinoids in RTRs exert their effect by 
inducing aberrant terminal differentiation (induction of K13, normally present suprabasal in 
internal stratified squamous epithelia, like the esophagus 185) and not by decreasing 
proliferation or influencing tumor suppressors in cutaneous carcinogenesis. Previously, we 
found a particular zebroid K13 expression pattern related to retinoid treatment in warts of 
RTRs which we postulated to be indicative of retinoid bioactivity in warts of these RTRs 20; 
almost 90% of warts in RTRs showed this typical zebroid K13 pattern in case of retinoid 
treatment.  
In the present study, concerned with KIN  lesions, we found a much lower percentage of 
zebroid K13 pattern at the start of the study, than would be expected from the previous 
findings in warts; only 5/9 patients (56%) on acitretin showed zebroid K13 expression. This 
zebroid K13 expression markedly reduced on acitretin withdrawal, with only 1/9 patients 
(11%) displaying this zebroid K13 pattern after 6 and 12 weeks, as we already anticipated 
based on the previously found correlation between zebroid K13 expression and retinoid 
treatment in warts. This marked reduction, however, proved not significant (p=0.1), probably 
due to the small number of patients. When combining the two patterns of K13 expression, the 
decrease in K13 expression reached significance after 6 and 12 weeks of acitretin withdrawal 
(p=0.03 and p=0.02 respectively). 
The lower frequency of zebroid K13 expression presently found in KIN lesions when 
compared to warts, might be attributable to the dysplastic changes in KIN with genetic 
alterations that might interfere with the retinoid receptor or interactions with the retinoid 
receptor or alterations in keratin gene regulation ( e.g. K13) that would otherwise have been 
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transcriptionally induced. Indeed, recently Xu et al. found progressive decrease in nuclear 
retinoid receptors during skin squamous carcinogenesis 215. On the other hand in warts, 
(transforming) types of human papillomavirus, might increase the sensitivity of keratinocytes 
to retinoid effects 152. Future research on warts and AKs within one patient during acitretin 
treatment might elucidate whether there is an interlesional variation in retinoid susceptibility. 
In parallel to the immunohistochemical decrease in K13 expression, clinical progression of 
skin lesions was seen with significant increase in warts (p=0.02). We could not demonstrate a 
significant increase in number of AKs and SCCs when acitretin treatment was interrupted for 
3 months. This could be caused by the relatively small number of patients and the short study 
period. The latter possibility is supported by the previous studies by Bouwes Bavinck27, 
where a relapse of new skin cancers occurred between 3 and 6 months after acitretin 
withdrawal, and by Shuttleworth180, who described the development of further lesions 6 
months after etretinate cessation.  
VAS score also significantly decreased in the 3 months study period,  reflecting a reduction 
in contentment of the patients with their skin condition.  
Already after 6 weeks of acitretin withdrawal, erythema of normal perilesional skin 
diminished significantly, as could be expected since erythema is a well-known adverse effect 
of topical and oral retinoid treatment 118. After 3 months a trend towards increased induration 
of AKs was present; since we found no significant concomitant increase in SCCs, induration 
seems more likely due to increased hyperkeratosis (in the absence of retinoids) instead of 
infiltrative growth. Retinoids could have an antihyperkeratotic, by induction of aberrant 
suprabasal K13 expression causing terminal differentiation towards internal non-keratinizing 
stratified squamous epithelia 185. This diminished hyperkeratosis with retinoids leads to better 
cosmetic appearance of the skin, important for patient’s contentment. Increased induration in 
the absence of  retinoids could make it more difficult for the clinician to differentiate AKs 
from invasive lesions (masking effect), necessitating more frequent biopsies in these RTRs, 
which are already subject to frequent skin biopsies. 
So far, effects of systemic retinoids on epidermal proliferation in RTRs were only studied by 
means of 3H thymidine labeling index; Shuttleworth et al. 180 found a significant increase in 
the labeling indices after 6 months of systemic etretinate treatment in normal sun-exposed 
skin, but not in sun protected skin in 6 RTRs; effects on dysplastic skin were not assessed. 
Besides Gibson et al., who found no significant differences in histological features of SCCs 
73, no other studies on chemoprevention by systemic retinoids in RTRs 27,160,203 included 
histological  or immunohistochemical evaluation of retinoid effects on skin lesions, to study 
for instance effects on proliferation or differentiation. 
In the present study, clinical comparable AKs were biopsied, which on histological 
examination sometimes varied in KIN grade. When taken the KIN grade into account, we 
found no significant correlation between the time of biopsy and the expression of MIB-1, p53 
and p16INK4A. Therefore in this small patient group no influence of acitretin withdrawal on 
expression of these three biomarkers could be demonstrated. 
In conclusion, this study demonstrates that 3 months cessation of systemic acitretin therapy in 
RTRs, leads to significant reduction of aberrant K13 expression, without alteration in 
expression of proliferation and cell-cycle associated markers (MIB-1, p53, p16INK4A), in KIN 
lesions of RTRs. Therefore, our data imply that if retinoids in RTRs exert an anti-neoplastic 
effect, it is by modifying differentiation (K13 expression).  
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SUMMARY, SUPPLEMENTARY 
DISCUSSION AND FUTURE 
PERSPECTIVES  
 
 
 
The central theme of this thesis is the role of cell- cycle associated proteins, especially tumor 
suppressor proteins p53, p16, and p14, in the pathogenesis of skin cancer focused on renal 
transplant recipients.  The objective was to gain a deeper understanding of the role of 
etiological factors in skin cancer development in these patients. 
The second aim was to study feasibility of p53 and INK4a-ARF mutation analysis in 
determination of primary skin cancer in case of metastasis. 
The third objective was to investigate the mode of action of retinoids in skin cancer 
prevention in renal transplant recipients. 
The first 2 objectives were dealt with in chapter 2, the third in chapter 3. 
In this chapter the results of the performed studies will be briefly summarized and discussed.
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Tumor suppressors p53, p16 and p14 in cutaneous carcinogenesis; 
the influence of sun-exposure, transplantation and human 
papillomavirus (HPV)1 
 
Sun exposition is a major etiological factor in the development of cutaneous squamous cell 
carcinoma (CSCC) and its precursors, keratinocytic intraepidermal neoplasia (KIN).  
Previous studies have demonstrated UV-related mutations in the tumor suppressor gene TP53 
in these epidermal (pre) malignant lesions.  More recently also UV-related mutations in the 
CDKN2A (INK4A-ARF) locus, which encodes for two tumor suppressor proteins p16 and 
p14, were found in epidermal neoplasia. 
In immunocompetent individuals (ICIs), KIN lesions and CSCCs frequently show 
overexpression of the tumor suppressor proteins p53 and p16.  Expression of p14 in skin 
(pre) malignancies is so far hardly studied. 
Renal transplant recipients (RTRs) are known for developing large numbers of skin tumors, 
especially SCCs, which start to develop several years post-transplantation and with time their 
number tends to increase exponentially.  These SCCs are often preceded and accompanied by 
large numbers of cutaneous warts and hyperkeratoses.  The latter histological often represent 
KIN lesions and therefore are preneoplastic.  All these skin lesions develop on sun-exposed 
sites, are more frequent in patients in warmer climates, and are more frequent in patients with 
a past history of high sun-exposure.  These data suggest that also in RTRs sun-exposure 
forms a major causal factor in cutaneous carcinogenesis.  Previous studies have reported UV-
related p53 mutations in CSCCs of RTRs (most often low patient numbers tested with a wide 
range in prevalence of p53 mutations varying from 8-43%).  Also p53 overexpression in (pre) 
malignant skin tumors in these patients has been reported, sometimes with comparable 
findings as in the general population.  Others reported more frequent p53 overexpression in 
skin lesions of RTRs. 
Data on p16 and p14 mutations and expression of these two proteins in skin (pre) 
malignancies in RTRs are currently lacking.  At the moment there is only one study 
performed in immunosuppressed patients that were not further specified. 
Because RTRs develop skin cancer at an increased rate and with a much higher frequency 
when compared to the general population, and because the CSCCs in these RTRs tend to 
behave more aggressively, there seem to be additional factors besides UV in this patient 
group that attribute to this enhanced cutaneous carcinogenesis.  One can think of the immune 
suppressive treatment in these RTRs, which creates a state of decreased immune surveillance 
and insufficient eradication of precancerous lesions.  In addition immunosuppression could 
increase the susceptibility for infection with oncogenic viruses.  In skin tumors the mostly 
likely candidate oncogenic virus would be the Human Papiloma Virus (HPV), since skin 
tumors in RTRs are often accompanied by (HPV-induced) warts and histological KIN lesions 
and CSCCs in these patients are reported to contain viral features known to be caused by 
HPV such as koilocytosis and verrucous architecture. 
In carcinoma of the uterine cervix and precursors, the role of high-risk mucosal types HPV 
has already been established.  In these tumors integration of high risk HPV-DNA in the host 
genome leads to enhanced expression of the E6 and E7 oncoproteins.  The E6 oncoprotein 
leads to inactivation of p53 and E7 causes functional activation of pRb, thereby disrupting the 
two major pathways important for cell cycle control, the p14-p53-MDM2- and the p16-
CDK4/6-Rb pathway, causing malignant progression and enhanced cell proliferation. 
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At present the role of HPV in cutaneous carcinogenesis remains to be established.  In contrast 
to cervical (pre) cancer, in skin cancer integration of HPV is rare.  Additionally, in vitro 
studies have shown that the role of the oncoprotein E6 of presumed oncogenic HPV types in 
cutaneous carcinogenesis seems different from that in cervical cancer being unable to 
promote p53 degradation but instead might promote proteolysis of another pro-apoptotic 
protein, named bak. 
In chapter 2 the research aims were to assess the influence of risk factors for cutaneous 
carcinogenesis (sun exposure, HPV, and immune status) in RTRs compared to ICIs, and to 
explore whether molecular tools aid in identifying the correct primary cutaneous squamous 
cell carcinoma in case of metastases in patients with multiple primary skin cancers.  
For this purpose, immunoexpression of the tumor suppressor proteins p53, p16, and p14, in 
KIN lesions and CSCCs of RTRs were compared with expression profiles in ICIs.  .  By 
comparing profiles with data in the literature on profiles in HPV induced cervical neoplasia 
the role of HPV in skin cancer development of these patients might become clearer.  In 
addition PCR for mucosal HPV types was performed and related to the expression of these 
markers. 
Finally, p53 and INK4a-ARF mutation analysis of primary tumors and their metastases were 
performed in order to determine usefulness of this mutation analysis in identifying primary 
CSCCs in case of metastases and multiple primary CSCCs. 
In 2.1 it was shown that overexpression of both p53 and p16 is frequently present in skin 
(pre) malignancies: in 74/86 lesions (86%) p53 was expressed and in 63/86(76%) lesions p16 
expression was present.  Negativity for both p16 and p53 was found in 4/86 (5%) cases, 
while combined p53/p16 staining was most prevalent (55/86 lesions, 64%).  P16 staining 
proved independent of p53 expression (p=0.8), and immune status, sun exposure and 
histological diagnosis (LKIN-HKIN-SCC) had no influence on this independency. 
The study in 2.2 showed P14 expression in a total of 42/105 KIN lesions and CSCCs (40%).  
P14 staining was generally more difficult to detect in slides when compared to p16 or p53 
staining due to often low number of positive lesional cells and nucleolar staining pattern. 
P14 expression proved independent of the expression of both p53 and p16, and immune 
status, sun-exposure and histological diagnosis had no influence on this independency. 
Together, these observations suggest that p16, p53, and p14 are all involved in epidermal 
carcinogenesis but that expression levels of these three proteins are independent of etiologic 
factors (sun exposure and immune status).  Therefore, RTRs seem to use comparable 
pathways in skin cancer development as ICIs despite differences in immune status, but their 
susceptibility and rate to develop SCCs might well be determined by the deficient immune 
system. 
Transplantation was associated with p53 expression in SCCs (p=0.02; power = 34%) caused 
by higher prevalence of p53 negative SCCs in RTRs than in ICIs (30 versus 0%).  This 
suggests that in advanced stages of epidermal neoplasia in RTRs, p53 is differently involved 
when compared to ICIs, which might be attributable to HPV (since in cervical cancer high-
risk HPV causes p53 inactivation). 
Furthermore, the study in 2.1 showed that in high-grade KIN lesions (HKINs), p16 was more 
frequently positive than in low-grade KIN lesions (LKINs) (p=0.003; power = 49%) and 
SCCs (p=0.03; power = 53%).  HKINs showed more frequent transepidermal p16 and p53 
staining than LKIN lesions (p < 0.001;power >= 99%).  These results with respect to strong 
and transepithelial p16 overexpression in HKIN are comparable to previous findings reported 
in literature, especially with respect to squamous cell carcinoma in situ.  
The strong p16 overexpression in HKIN lesions could be caused by upregulation of wild type 
p16 or it could be due to p16 mutation, in analogue to p53 overexpression, which is often 
caused by p53 mutation.  Previous limited research on p16 immune-expression and correlates 
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with underlying molecular changes in skin (pre) malignancies have not shown a clear cut 
correlation between p16 expression pattern and underlying molecular changes.  In one study 
in CSCCs in 64% of cases there was concordance between the presence/absence of p16 
protein expression and genetic results (mutation, methylation).  In 70% of tumors with 
biallelic events, p16 protein expression was absent.  In chapter 2.3 besides mutation analysis 
we performed immunohistochemistry for p53, p16 and p14 on the metastasized CSCCs.  In 
this limited number of cases 5 out of 8 cases contained a p53 mutation, of which 2 showed 
strong (>50% + tumor cells) p53 immune expression, and 2 were p53 negative.  P16 mutation 
was present in 5/8 cases, of which 2 tumors showed more than 10% positive lesional cells 
with 3 cases having absent p16 expression.  Of the 3 p14-mutated carcinomas, one was strong 
p14 positive and 2 were p14 negative.  These data were not further shown in the article. 
Future studies regarding the exact role of these tumor suppressors in skin malignancies 
should combine analysis of protein expression patterns with molecular data.  It would be 
interesting to study the role of p16 in the progression of HKIN into CSCCs since in 
carcinomas decrease of p16 expression is noted compared to HKINs. 
In the archival study described in chapter 2.3 metastatic CSCCs were found to have p16 
mutations in 63% (5/8 cases) of all cases.  P14 mutations were present in 38% of all cases 
(3/8 cases).  Although the patient number is limited, the frequency of p16 mutations in 
metastases we found is higher than that reported for primary CSCCs in both sporadic and 
xeroderma pigmentosum-associated SCCs (15-33%).  Larger studies are needed to elucidate 
a potential role for p16 mutations in predicting metastatic potential of CSCCs. Maybe p16 
mutation is predictive of a more aggressive behavior of the tumor with higher risk for 
metastasis. 
In chapter 2.3 we found that mutation analysis of p53 and INK4a-ARF was useful in 
identifying the responsible primary tumor in case of metastasis and multiple primary CSCCs.  
In 7 of /8 metastases (88%) either an INK4a-ARF (6 of 8 cases) and /or p53 (3 of 8 cases) 
mutation was present.  In 6 of 7 cases the corresponding primary could be identified by an 
identical mutation in p53 and/or INK4a-ARF.  In the future this type of mutation analysis in 
patients with multiple CSCCs could attribute to correct identification of primaries responsible 
for metastasis, after which comparison (histological, clinical, molecular and array techniques) 
of these tumors with matched non-metastasizing cases might yield risk factors or a risk 
profile for metastatic behavior.  This study furthermore showed the relevance of optimal 
histological processing and if possible freezing tumor tissue for research in a department of 
pathology.  In 6 out of 14 cases of metastasized CSCC, the DNA quality of paraffin 
embedded tissue was insufficient to perform PCR reactions. 
Finally, in chapter 2.2 detection of mucosal HPV was performed in KIN lesions and CSCCs 
using a short PCR fragment (SPF-LiPA) assay, which allows simultaneous detection and 
typing of 25 mucosal HPV genotypes.  Only 2/105 specimens, both HKIN lesions in ICIs, 
contained HPV X and none of the 25 known mucosal genotypes was detected.  Due to this 
low number of HPV containing cases, no relation between presence of HPV and expression 
of the proteins p53, p16, and p14 could be determined.  We conclude that our data do not 
support a role for mucosal HPV types in cutaneous carcinogenesis.  Future studies including 
cutaneous HPV types, especially epidermodysplasia verruciformis associated HPV types 
which are presumed to be oncogenic, in relation to expression of the three oncoproteins 
(together with molecular analysis) studied in this chapter are of interest in order to further 
elucidate the exact mechanisms by which these HPV types could be involved in skin cancer.  
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Retinoid treatment of benign and (pre)malignant epidermal 
tumors of renal transplant recipients 
 
Several studies have demonstrated a beneficial effect of systemic retinoid treatment with 
either acitretin or etrinitate with respect to chemoprevention of skin(pre)malignancies in renal 
transplant recipients (RTRs). Since these patients often have multiple KIN lesions and 
CSCCs, which affect large areas of the body surface, systemic treatment is  an important 
treatment modality.  A number of studies showed that the effect of retinoid treatment was 
only temporarily with even rebound and enhanced tumor development after therapy 
cessation. 
In none of the studies concerned with systemic retinoid treatment in RTRs, histology of 
(peri)lesional skin or immunohistochemistry with markers for  instance proliferation (MIB-
1/Ki-67) or markers for apoptosis and cell-cycle associated proteins (p53/p16) were 
performed to elucidate the chemopreventive action of retinoids. 
Since retinoids seem to decrease skin tumor development, one could hypothesize that 
retinoids influence differentiation and/or proliferation and/or apoptosis of keratinocytes. 
Data from animal and in vitro studies with cultured human keratinocytes have indicated that 
retinoids repressed expression of  epidermal differentiation-specific keratins (K1/K10) and 
strikingly reinduced expression of two lower molecular weight keratins, corresponding to 
K13 and K19 respectively. Since these two keratins are coexpressed in fetal skin, this type of 
retinoid-induced differentiation is also termed embryonic differentiation. Furthermore 
retinoids in vitro increase the keratins K4, K15 and the hyperproliferative keratins K6/K16. 
Keratinocytes in vivo, when exposed to topical retinoids in healthy volunteers, displayed an 
increase in K13 and K6/16 synthesis, but no alterations in K1/10 and K14 expression. 
Interestingly, in contrast to normal keratinocytes, in psoriatic skin systemic retinoid treatment 
seems to reverse the altered enhanced K6/16 in psoriasis, with restoration of suprabasal 
K1/10 expression.  
This illustrates that retinoid response of keratinocytes in vivo and in vitro do not always 
correlate and that normal keratinocytes respond differently to retinoid than diseased 
keratinocytes. 
In skin (pre) malignancies, as in psoriasis keratinocytes are diseased or dysplastic. The 
response of the dysplastic or malignant keratinocytes in vivo to retinoid treatment with 
respect to markers for keratinisation was not studied previously. 
In chapter 3.1 we describe the results of a retrospective nonrandomized 
immunohistochemical study to study the effects of retinoids on the expression of keratin 
(K)13 and K19 in 21 cutaneous warts of renal transplant recipients (RTRs) and 
immunocompetent individuals (ICIs).  
Nine RTRs (10 specimens) received either systemic acitretin or topical all-trans-retinoic acid 
treatment at the time of biopsy.  A significantly higher percentage of warts of RTRs 
expressed K13 compared with warts of ICIs (86% vs. 14%, respectively; P< 0.001). In warts 
of RTRs, retinoid treatment correlated significantly with a particularly strong,  segmental  
K13 expression pattern, which we termed zebroid. Without use of  retinoids,  K13 was 
mostly restricted to suprabasal single cells.  Keratin 19 was absent in all warts of both patient 
groups.  
Since retinoids strongly correlated with  K13 in a characteristic zebroid pattern in warts of 
RTRs, we concluded that K13 is a sensitive marker for  retinoid bioactivity in skin (lesions) 
of RTRs. 
In non-retinoid-treated RTRs, K13 is also frequently found in warts, but without the dramatic 
zebroid pattern noted with retinoid-treated warts. Maybe this single cell expression of K13 in 
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warts of RTRs has a different biological meaning and is indicative of a more malignant 
phenotype. Thus far, immunohistochemical studies in skin (pre)malignancies indicated that 
cutaneous malignant transformation was heralded by a switch from production of larger MW 
keratins normally present in the epidermis (K1/10) to smaller MW keratins (K8,18 and 19) 
characteristic of fetal skin and simple epithelia and that the extent of shift correlates with the 
histological grade of the tumor. K13 expression was reported to be absent in (pre)malignant 
epidermal tumors. In the study reported in 3.1 we also studied 20 cases of squamous cell 
carcinoma in situ ( SCCIS or Bowen’s disease) and we found K13 expression in 75% and 
45% of lesions in RTRs and ICIs, respectively. This further supports that K13 expression also 
might reflect presence of  a more malignant phenotype. In these SCCIS the perilesional skin 
in 3 of 4 retinoid treated RTRs the same zebroid K13 expression as in retinoid treated warts. 
This retinoid related zebroid K13 pattern was clearly different and distinguishable also in 
SCCIS. 
In chapter 3.2 we describe the results of a histological and immunohistochemical study 
regarding the effects of systemic acitretin treatment on actinic keratoses in 33 RTRs. 
Following acitretin treatment, a significant reduction in epidermal thickness (P= .002) and a 
significant increase in normal differentiation parameter K10 (P= .02) was observed. After 
acitretin treatment, an increase in K13 (P= .006) and K19 (P= .05) was found. This K13 
expression was located suprabasal and band like (zebroid), while K19 was expressed in the 
basal epidermal layer. As in the study in warts in chapter 3.1 expression of K13 and K19 
were uncoupled. Epidermal proliferation did not change, nor did apoptosis, inflammation, 
keratinocytic epidermal neoplasia score, or transglutaminase staining. At baseline in 8 actinic 
keratoses a single cell expression pattern of K13 and/or K19 was found, correlated with 
higher epidermal proliferation (Ki-67). Baseline K13 expression also correlated with higher 
incidence of SCCs before retinoid treatment. These findings with respect to spontaneous 
(non-retinoid-induced) K13 expression in AKs, could in analogue to spontaneous K13 
expression in warts of RTRs, be a reflection of the more malignant phenotype of AKs in 
RTRs. 
It was concluded that acitretin improves the aspect of actinic keratoses via alteration of 
keratinization, resulting in peeling of the stratum corneum. No significant change in 
proliferation was found, which may explain for the rapid recurrence of actinic keratoses seen 
after cessation of acitretin treatment.  
The accompanying randomized clinical study 45 (not published in this thesis), 26 RTRs were 
treated with oral acitretin during 1 year,  demonstrated a significant improvement of AKs 
with respect to thickness of the lesions ( p< 0.01). In addition there was an almost 50% 
reduction in the number of AKs , while the number of malignant tumors was comparable to 
the number in the year before the study. 
In chapter 3.3  a prospective non-randomized clinical and immunohistochemical study was 
performed to evaluate effects of temporary cessation of systemic acitretin treatment in renal 
transplant recipients (RTRs). We used K13 as a marker for retinoid bioactivity based on the 
findings in 3.1 and evaluated effects of acitretin cessation on expression of cell-cycle 
associated proteins MIB-1, p53 and p16. Previous studies reported a temporarily effect of 
retinoid treatment with a rebound and increase in skin tumors after cessation of systemic 
retinoid treatment. Therefore the number of (pre)cancers before, during and after treatment 
were compared. Since retinoid treatment has considerable side-effects, this stop-study with 
the help of K13, might help in establishing an optimal interval for intermittent retinoid 
treatment. Nine RTRs on systemic acitretin (mean duration 2.3±0.6 yrs; mean dosage 
18.3±9.9mg) were asked to interrupt their treatment for three months. Patients gave written 
informed consent. Patients were seen at intervals of 6 weeks, starting at the moment of 
acitretin interruption. Each visit epidermal lesions were counted; erythema and desquamation 
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of normal skin and AK were recorded and induration of AKs, a visual analogue score (VAS) 
for patient’s contentedness was performed, and clinical comparable AKs were biopsied.  
After 6 and 12 weeks, a significant decrease of  K13 expression was found (p=0.03 and 
p=0.02 respectively);  zebroid K13 expression also decreased but this reduction was not 
significant (5/9 cases at the start vs. 1/9 cases after 6 and 12 weeks ; p=0.10). Cessation of 
acitretin treatment had no influence on expression of the markers MIB-1, p53, and p16. These 
results suggest that retinoids exert their effect by alteration of differentiation without effects 
on proliferation or effects on tumor suppressor protein expression. The lower percentage of 
zebroid K13 expression in AKs, 56%,  compared to warts, 90%(chapter 3.1), during retinoid 
treatment might be caused by dysplastic changes in KIN lesions with decrease in retinoid 
receptors or altered retinoid receptor interactions and/or alterations in keratinocyt gene 
regulation in dysplastic keratinocytes. 
Future studies combining immunohistochemistry for K13 and  retinoid receptors could 
answer this question. Previously it was shown that retinoid receptors decreased with 
progression of cutaneous tumors. In addition, study of K13 expression within one patient of 
both benign and (pre)malignant skin lesions during retinoid treatment, can yield information 
on interlesional differences in retinoid sensitivity of skin lesions. 
This “stop”-study demonstrated a significant increase in the number of warts after 3 months 
of retinoid cessation (p=0.02), but there was no significant increase in number of AKs 
(p=0.09) or SCCs (p=0.3). This supports the above mentioned assumption that warts or 
benign skin lesions contain more retinoid receptors when compared to (pre)malignant skin 
tumors. Patients were significantly less satisfied with the cosmetically aspects of their skin 
and AKs were more indurated (p=0.02). The latter can readily be explained by increase in 
hyperkeratosis in the absence of retinoids. The study in 3.1 demonstrated that retinoids act 
anti-hyperkeratotic by induction of K13 expression, which leads to a non-keratinizing type of 
squamous differentiation. When retinoids are stopped this antihyperkeratotic effect will 
diminish. 
All three studies indicate that K13 expression can be related to two different and independent 
mechanisms, dependent on the expression pattern present: zebroid or retinoid-associated 
keratinisation versus single cell positivity or associated with malignant transformation. In 
none of the studies a clinical anticarcinogenic effect of retinoids could be demonstrated, 
although a cosmetic improvement was evident. 
Future randomized studies case controlled studies with histology and immunohistochemistry 
over a longer time period and in large patient groups is needed to elucidate whether retinoid 
treatment is truly anticarcinogenic. 
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Samenvatting en conclusies 
 
Tumorsuppressor eiwitten p53, p16 en p14 in cutane 
carcinogenese ; invloed van zonexpositie, transplantatie en HPV 
 
Zonexpositie is een belangrijke oorzakelijke factor in het ontstaan van huidkanker, in casu 
plaveiselcel carcinoom (PCC), en voorstadia hiervan, die we keratinocytaire intraepidermale 
neoplasie (KIN) noemen. Uit onderzoek is gebleken dat in deze (pre)maligniteiten vaak 
ultraviolet (UV)-gerelateerde mutaties voorkomen van het p53  tumor-suppressor gen. Meer 
recent werden ook UV-gerelateerde mutaties aangetoond van het CDKN2A (INK4a-ARF) 
locus dat codeert voor de tumorsuppressor eiwitten p16 en p14. 
In immuuncompetente patiënten bleken KIN laesies en plaveiselcel carcinomen van de huid 
frequent overexpressie te tonen van de tumorsuppressor eiwitten p53 en p16. Naar p14 
expressie in huid(pre)maligniteiten werd vooralsnog nauwelijks onderzoek verricht. 
Niertransplantatie-patiënten ontwikkelen frequent huidcarcinomen, met name plaveiselcel 
carcinomen, die veelal pas een aantal jaren na transplantatie beginnen te ontstaan en veelal 
vanaf dat moment exponentieel in aantal toenemen. Deze carcinomen worden veelal vooraf 
gegaan, dan wel begeleid, door toegenomen aantal wratten en hyperkeratosen. Deze laatste 
blijken histologisch veelal te berusten op KIN laesies. Al deze laesies worden met name 
gezien op zonblootgestelde lichaamsdelen, komen meer voor bij patiënten in zonnige 
klimaten, en zijn frequenter bij patiënten meer zonexpositie in het verleden. Dit suggereert 
ook bij niertransplantatiepatiënten derhalve een grote rol voor zonexpositie bij het ontstaan 
van huid(pre)maligniteiten. Eerdere studies hebben aangetoond dat ook in plaveiselcel 
carcinomen van de huid bij niertransplantatiepatiënten UV-gerelateerde p53 mutaties 
voorkomen ( aantal patiënten dat onderzocht werd is veelal beperkt met veel variatie in 
gevonden frequenties van p53 mutaties, variërend van 8-43%). Ook p53 overexpressie in 
huid(pre)maligniteiten van deze patiënten is beschreven; soms worden vergelijkbare 
bevindingen gemeld met de normale populatie, echter een aantal onderzoeken vinden 
frequenter p53 overexpressie in huidlaesies bij niertransplantatiepatiënten. 
Onderzoek naar p16 - en p14 mutaties en -eiwitexpressie in huid(pre)maligniteiten in de 
specifieke subgroep van niertransplantatiepatiënten ontbreekt dusver ( er is slechts 1 studie  
verricht in patiënten met immuunsuppressie die niet nader omschreven zijn). 
Omdat niertransplantatiepatiënten in een versneld tempo en in veel hogere frequentie 
huidmaligniteiten ontwikkelen in vergelijking tot de normale populatie en deze 
huidmaligniteiten zich bovendien vaker agressief gedragen, lijken er bij deze patiënten naast 
zonexpositie nog additionele factoren bij het ontstaan en het beloop van huidtumoren 
aanwezig. Hierbij moet dan met name gedacht worden aan de immuun suppressie waarbij de 
gedachte is dat deze leidt tot verminderde tumorafweer en tevens kan leiden tot verhoogde 
infectiekans met (oncogene) virussen. Hiervoor zou in de huid het humaan papilloma virus 
(HPV) in aanmerking komen, aangezien de huidtumoren bij deze patiënten klinisch vaak 
begeleid worden door (gelijktijdig) voorkomen van (door HPV-geinduceerde) wratten en 
histologisch frequent in huid(pre)maligniteiten van deze patiënten nog virale kenmerken 
(bekend van HPV zoals koilocytose, en verruceuze bouw) worden herkend. 
In baarmoederhalscarcinoom en voorstadia hiervan, is de rol van hoog risico HPV in het 
ontstaan middels vele onderzoeken reeds vast komen te staan. Hier blijkt integratie van hoog 
risico HPV-DNA in het gastheergenoom te leiden tot inactivatie van p53 en overexpressie 
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van p16 en ook p14.  De oncoproteinen E6 en E7 van hoog risico HPV typen spelen hierbij 
een grote rol. 
De rol van HPV in het ontstaan van huidcarcinoom is nog onopgehelderd. In tegenstelling tot 
baarmoederhalscarcinoom, is in huidcarcinoom integratie van HPV zeldzaam. Verder heeft in 
vitro onderzoek aangetoond dat het oncoproteine E6 van veronderstelde hoogrisico typen 
HPV voor het ontstaan van huidkanker, zoals epidermodysplasia verruciformis geassocieerde 
HPV typen,  apoptose zou remmen in een p53-onafhankelijke manier namelijk door 
stimuleren van proteolyse van het anti-apoptotisch eiwit bak. 
In hoofdstuk 2 werd gekeken of er verschillen zijn in effecten van zonexpositie, 
immuunstatus en HPV bij het ontstaan van huidmaligniteiten in niertransplantatiepatiënten 
ten opzichte van de normale populatie. Daartoe werden immuunhistochemische studies 
verricht naar de expressie van p53, p16 en p14 in keratinocytaire intraepidermale neoplasie 
(KIN) laesies en plaveiselcel carcinomen van niertransplantatiepatiënten en vergeleken met 
die in normale immuuncompetente personen. Verder was een onderzoeksvraagstelling of 
moleculair onderzoek naar mutaties behulpzaam is bij het identificeren van een 
metastaserend huidcarcinoom als een patiënt meerdere primaire huidtumoren heeft. 
Het onderzoek in 2.1 toonde aan dat zowel p53 als p16 overexpressie frequent aanwezig is in 
huid(pre)maligniteiten, in respectievelijk 86% van huidlaesies werd p53 overexpressie 
gevonden en in 76% p16 overexpressie. Gecombineerde p53/p16 overexpressie was het 
meest frequent, 64%. P16 en p53 expressie bleken onafhankelijk van elkaar (p = 0 .8). 
Immuunstatus (wel of geen transplantatie), zonexpositie en histologische diagnose hadden 
geen invloed op deze onafhankelijkheid.  
Het onderzoek in 2.2  toonde P14 expressie in 42 van de 105 (40%) onderzochte 
huid(pre)maligniteiten. P14 expressie was hierbij veel lastiger te detecteren in coupes dan 
expressie van p16 en p53, omdat meestal slechts weinig cellen positief waren voor p14. Ook 
expressie van p14 en p53 en van p14 en p16 bleken onafhankelijk van elkaar. Ook hier had 
immuunstatus en zonexpositie geen invloed op deze onafhankelijkheid (p=0.1).  
Dit suggereert dat de 2 belangrijke paden betrokken bij de controle van de celcyclus, 
respectievelijk de routing via p16/CDK4-6/pRb  en die via p14/MDM2/p53, beide betrokken 
zijn in cutane carcinogenese en dat bij niertransplantatiepatiënten dezelfde paden betrokken 
zijn als bij immuuncompetente personen. De hogere snelheid waarmee 
niertransplantatiepatiënten echter tumoren ontwikkelen zou evenwel toch goed bepaald 
kunnen worden door hun deficiënte immuunsysteem. Getransplanteerd zijn bleek 
geassocieerd met p53 expressie in plaveiselcel carcinomen (P = .02): plaveiselcel carcinomen 
van niertransplantatiepatiënten waren vaker p53 negatief (hoofdstuk 2.1 en 2.2). Dit kan 
betekenen dat in gevorderde stadia van epidermale neoplasie bij niertransplantatiepatiënten, 
p53  anders betrokken is dan bij immuuncompetenten, waarbij er mogelijk een rol zou 
kunnen zijn voor (hoog risico?) HPV ( uit cervixcarcinoom is namelijk zoals boven 
beschreven bekend dat hoog risico HPV inactivatie van p53 geeft). 
Verder bleek in de studie in hoofdstuk 2.1 dat hooggradige dysplasieën ( Hooggradige KIN 
laesies, HKINs) vaker p16 positief waren dan laaggradige KIN laesies (LKINs) en 
plaveiselcel carcinomen (p 0.03). En HKINs tonen vaker transepidermale p16 en p53 
expressie dan LKINs ( P < .001). De resultaten tav hoge en transepitheliale p16 overexpressie 
in hooggradige dysplasie/HKIN zijn vergelijkbaar met bevindingen eerder gemeld in de 
literatuur, met name tav plaveiselcel carcinoom in situ laesies. 
Een verklaring voor de hoge p16 overexpressie in HKIN, zou opregulatie van wild type p16 
kunnen zijn of  eventueel zoals veelal voor p53 overexpressie geldt p16 mutatie. Eerder 
relatief beperkt onderzoek naar p16 immuunexpressie en onderliggende moleculaire 
veranderingen in huid(pre)maligniteiten heeft voor alsnog geen duidelijke correlatie laten 
zien tussen p16 expressie patronen en onderliggende moleculaire veranderingen. Beperkt 
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werk dat wij zelf hebben gedaan in de studie van de gemetastaseerde plaveiselcel carcinomen 
in hoofdstuk 2.3 van dit proefschrift bevestigt de bevindingen in de  literatuur. In deze groep 
van 8 gemetastaseerde plaveiselcel carcinomen van de huid was er geen correlatie 
aantoonbaar tussen aan/afwezigheid van p53/p16 of p14 mutatie en aan/afwezigheid van 
immuunexpressie voor deze markers. In 5/8 gevallen was er p53 mutatie aantoonbaar: 3/5 
gemuteerde tumoren toonden p53 overexpressie, waarvan 2 sterk (>50% positieve 
tumorcellen), terwijl 2/5 p53-immuunnegatief waren. P16 mutatie was aanwezig in 5/8 
gevallen, waarbij 2 tumoren p16 expressie toonden ( > 10% tumorcellen positief), echter 3 
tumoren bleken p16 negatief. Van de 3 p14-gemuteerde tumoren, was 1 sterk positief voor 
p14, echter 2 tumoren waren p14 negatief (data verder niet beschreven). 
Toekomstig onderzoek naar de exacte rol van deze tumor suppressor eiwitten in 
huidmaligniteiten zou meer licht op expressie patronen en onderliggende moleculaire 
veranderingen kunnen werpen. O.a. zou het interessant zijn te onderzoeken wat de rol van 
p16 is bij overgang van HKIN/plaveiselcel carcinoom in situ naar invasief plaveiselcel 
carcinoom, aangezien hier weer afname van p16 overexpressie wordt gezien. 
In hoofdstuk 2.3 bleek verder dat de frequentie van p16 mutaties in naar de lymfklier 
gemetastaseerd plaveiselcel carcinoom van de huid zeer hoog is in vergelijking tot 
frequenties in de normale populatie, zij het dat onze onderzoeksgroep wel beperkt was (n=8). 
In de gemetastaseerde carcinomen vonden wij een frequentie van 63% p16 mutaties, terwijl 
gerapporteerde frequenties van p16 mutaties in de literatuur in sporadische niet 
gemetastaseerde huidcarcinomen variëren van 15-19%. Aanvullende klinisch-pathologische 
studies naar het voorkomen van p16 mutaties in gemetastaseerde versus niet-gemetastaseerde 
in grotere patiënten groepen zou zinvol zijn. Mogelijk is p16 mutatie een predictor voor meer 
agressief beloop en hogere metastaseringskans. 
Hoofdstuk 2.3 wordt aangetoond dat mutatieanalyse van p53 en INK4a-ARF behulpzaam is 
in de identificatie van primaire huidtumoren in geval van metastasering, aangezien de 
mutatiefrequentie van beide genen in (gemetastaseerde ) huidcarcinomen hoog is, namelijk 
88% (7/8 gevallen). In 6/7 (86%) gevallen waren wij in staat met zekerheid de primaire tumor 
vast te stellen die verantwoordelijk was voor de metastase. In de toekomst zou dit type 
mutatieanalyse bij patiënten met multipele huidtumoren een goede bijdrage kunnen leveren 
aan zekere identificatie van primaire tumoren, waarna aanvullende vergelijkend onderzoek 
(histopathologisch, klinisch, moleculair, array technieken) tussen wel en niet gemetastaseerde 
tumoren, risicofactoren c.q. een risicoprofiel voor metastaserend gedrag zou kunnen 
opleveren. Deze studie toont overigens ook het belang van goede histologische bewerking 
met invriezen van tumormateriaal op de afdeling pathologie. In 6/14 gevallen was geen 
gevroren tumorweefsel aanwezig en bleek paraffine ingebed materiaal van onvoldoende 
DNA kwaliteit om PCR reacties te verrichten. 
In hoofdstuk 2.2 werd tot slot nog  HPV detectie verricht op de 105 huid(pre)maligniteiten 
waarop tevens immuunexpressie van p14, p16 en p53 was bepaald. De HPV bepaling werd 
verricht op aansluitende weefselcoupes met behulp van een short PCR fragment (SPF-LiPA) 
assay, waarbij tegelijkertijd 25 mucosale HPV typen gedetecteerd en getypeerd kunnen 
worden.  In slechts 2 van de 105 gevallen werd HPV gevonden; beide gevallen betrof het een 
HKIN laesie van een immuuncompetent persoon; in beide gevallen betrof het een HPV type 
X, en bleek het geen bekend mucosaal type HPV te zijn. Helaas kon door dit lage aantal HPV 
positieve casus geen relatie tussen aanwezigheid van HPV en eiwitexpressie van p14, p15 en 
p53 bestudeerd worden. Uit dit onderzoek concluderen wij wel dat onze data geen aanwijzing 
bieden dat mucosale HPV typen een rol spelen bij cutane carcinogenese. Toekomstig 
onderzoek met inclusie van cutane HPV typen en met name Epidermodysplasia verruciformis 
geassocieerde HPV typen zou interessant zijn, zeker ook in relatie tot de expressie van de 3 
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tumor suppressor eiwitten p53, p16 en p14 aangevuld met moleculair onderzoek zoals 
mutatieanalyse en onderzoek naar promotor methylering.  
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Retinoid behandeling van benigne en (pre)maligne epidermale 
tumoren bij niertransplantatiepatiënten 
 
Diverse studies hebben een gunstig effect beschreven van systemische retinoiden behandeling 
met acitretine of etrenitaat, in de preventie van huid(pre)maligniteiten bij 
niertransplantatiepatiënten. Systemische behandeling is met name in deze groep van 
niertransplantatiepatiënten een belangrijke therapievorm, in verband met het grote aantal 
(pre)maligniteiten in deze patiënten groep. Een aantal studies geven aan dat het effect van 
deze behandeling wel tijdelijk is met wederom toename van huidtumoren na het stoppen van 
deze therapie.  
In geen van deze studies met systemische retinoidbehandeling bij niertransplantatiepatiënten 
werd histologisch onderzoek verricht van (peri)lesionale huid, dan wel immuunhistochemisch 
onderzoek verricht naar markers voor keratinisatie, proliferatie (MIB-1/Ki-67) of markers 
voor apoptose en cel-cyclus-geassocieerde eiwitten (p53, p16) ten einde meer zicht te krijgen 
op het chemopreventieve werkingsmechanisme van retinoiden. 
Aangezien retinoiden ontstaan van huidkanker en voorstadia hiervan zouden remmen, lijkt 
het aannemelijk dat zij invloed hebben op de differentiatie en/of proliferatie snelheid van 
keratinocyten en/of op de mate waarin keratinocyten in apoptose gaan. 
Uit dierexperimenteel onderzoek en in vitro studies is reeds bekend dat retinoiden 
keratinisatie en differentiatie van keratinocyten beïnvloeden, waarbij keratines die gezien 
worden tijdens normale epidermale differentiatie, namelijk K1 en K10, worden onderdrukt en 
embryonale keratines, K13 en K19 worden geïnduceerd; ook expressie van 
hyperproliferatieve keratines K6/16 nam toe in keratinocyt-kweken. In vivo onderzoek in 
gezonde vrijwilligers met topicale retinoiden liet ook een toename van K13 en K6/16 
expressie zien. Bij psoriasispatiënten werd echter afname van K6/16 gezien en herstel van 
normale keratines gezien. Derhalve lijkt de respons op retinoiden van keratinocyten in vitro 
en in vivo te variëren en afhankelijk te zijn van de toestand waarin deze keratinocyten 
verkeren ( normale/zieke keratinocyten).  Ook in (pre)maligniteiten hebben we te maken met 
afwijkende cq dysplastische/maligne keratinocyten en de respons van deze dysplastische en 
maligne cellen in vivo op retinoiden tav keratinisatie is voor alsnog niet eerder 
immuunhistochemisch onderzocht. 
In hoofdstuk 3.1 staan de resultaten beschreven van een retrospectieve niet gerandomiseerde 
immuunhistochemische studie naar de effecten van retinoiden op de expressie van keratines 
13 en 19 in 21 wratten van niertransplantatiepatiënten en immuuncompetente individuen. 
Van de niertransplantatiepatiënten gebruikten 9 patiënten systemische of lokale 
retinoidtherapie ten tijde van het biopt.  In de wratten afkomstig van 
niertransplantatiepatiënten werd een significant hoger percentage K13 positieve wratten 
gezien (86%) t.o.v. de wratten in de normale populatie (14%, P<0.001). Hierbij lieten de 
wratten in geval van retinoidtherapie een typisch zebroid patroon zien met sterke K13 
expressie in segmentale positieve suprabasale kolommen. Wratten waarbij geen retinoiden 
therapie was gebruikt toonden alleen positiviteit in suprabasale solitaire cellen (single cell 
expressie). Keratine K19 expressie werd in geen enkele wrat van beide groepen gezien, ook 
niet na retinoidbehandeling. I.v.m. de sterke correlatie tussen zebroide K13 expressie en 
retinoidtherapie, blijkt uit deze studie dat K13 als goede marker te gebruiken is voor de 
biologische activiteit van retinoiden in de huid(laesies) van niertransplantatiepatiënten. 
Mogelijk heeft de meer frequente single cell expressie van K13 in niet-retinoid behandelde 
wratten van niertransplantatie patiënten ook een biologische betekenis: mogelijk duidt dit op 
een meer maligne fenotype. Uit eerder onderzoek is namelijk gebleken dat bij maligne 
transformatie in cutane carcinogenese, er een switch plaats vind van hoogmoleculaire 
Samenvatting en Conclusies 121 
keratines die normaal in de epidermis voorkomen (K1/10) naar laagmoleculaire keratines. 
K13 is een laagmoleculair keratine; echter aanwezigheid van K13 in (pre)maligne huidlaesies 
was tot nu toe niet eerder beschreven. In deze zelfde studie onderzochten wij ook 20 
plaveiselcel carcinoom in situ (M.Bowen) laesies in beide patiënten groepen en vonden wel 
degelijk K13 expressie in 75% en 45% van deze laesies bij respectievelijk de 
niertransplantatiepatiënten en immuuncompetenten. Dit steunt de hypothese van een meer 
maligne fenotype van wratten bij niertransplantatiepatiënten. Bij deze carcinoom in situ 
laesies toonde de perilesionale huid in 3 van de 4 met retinoiden-behandelde 
niertransplantatiepatiënten ook zebroide K13 expressie. Het retinoid-geassocieerde K13-
patroon bleef duidelijk anders en goed herkenbaar. 
In hoofdstuk 3.2 staan de resultaten van een studie naar de histologische en 
immuunhistochemische effecten van systemische acitretine behandeling op actinische 
keratosen van 33 niertransplantatiepatiënten. Histologisch werd een significante reductie van 
epidermale dikte (p= 0.002) gezien, als gevolg van afname van de stratum corneum dikte. 
Immuunhistochemisch werd alleen significante toename cq herstel van K10 expressie gezien 
(P= 0.02) en inductie van K13 (p=0.006) en K19 (p= 0.05) gezien. De K13 expressie werd 
suprabasaal gevonden met een meer bandvormig aankleuringspatroon, en de K19 expressie 
met name basaal. Dus net als in wratten was er ontkoppeling van K13 en K19 expressie. 
Epidermale proliferatie (Ki-67), apoptose (p53), hyperproliferatie geassocieerde keratine 
(K16), terminale differentiatie (transglutaminase), en dermale ontsteking bleven onveranderd. 
Onbehandelde aktinische keratosen toonden deels K13 en K19 expressie echter in een meer 
single cell expressie patroon, waarbij beiden correleerden met een hogere epidermale 
proliferatie (Ki-67). Baseline K13 expressie bleek ook te correleren met een hogere 
plaveiselcelcarcinoom incidentie voor retinoidtherapie. Deze bevindingen omtrent spontane 
K13 expressie in onbehandelde aktinische keratosen, zouden parallel aan  de bovenstaand 
beschreven spontane (niet-retinoid-geinduceerde) K13 expressie in wratten  van 
nierrecipiënten kunnen duiden op een meer maligne fenotype van de aktinische keratose. 
In de bij dit onderzoek horende gerandomiseerde klinische studie 45 (niet in dit proefschrift 
gepubliceerd), werden 26 nierrecipiënten gedurende 1 jaar behandeld met oraal acitretine, 
waarbij klinisch een significante verbetering van de actinische keratosen werd gezien tav de 
dikte van de laesies (P<0.01). Tevens was er een klinisch een bijna 50% afname van het 
aantal aktinische keratosen, maar het aantal maligne tumoren tijdens het jaar van behandeling 
was gelijk aan het aantal in het jaar vooraf aan de studie.  
In hoofdstuk 3.3 staat een prospectieve niet gerandomiseerde  immuunhistochemische studie 
beschreven waarin we met behulp van K13 als marker van retinoidactiviteit (op basis van de 
studie in 4.1) gekeken hebben of stoppen van retinoidtherapie (systemisch acitretine) invloed 
had op de expressie van celcyclusgeassocieerde eiwitten MIB-1, p53 en p16. Volgens eerdere 
gepubliceerde studies zouden  de effecten van retinoidtherapie tijdelijk zijn met rebound 
effect en toename van tumoren na staken van de therapie, die mogelijk ook zijn weerslag 
heeft op markerexpressie in huidlaesies van patiënten. In verband met bijwerkingen van 
retinoidtherapie zou intermitterende therapie een goed optie kunnen zijn, en deze studie met 
gebruik van retinoid-geassocieerde K13 expressie als marker van retinoidactiviteit in de huid 
zou mogelijk tevens een aanknopingspunt kunnen geven over de lengte van het toe te passen 
interval van stoppen. Klinische effecten werden gedurende de 3 maanden stop geregistreerd. 
Bij 9 nierrecipiënten werden biopten van klinisch vergelijkbare aktinische keratosen genomen 
bij start van de studie (waarop systemische acitretine behandeling werd stop gezet), en na 
resp. 6 en 12 weken staken van retinoid therapie.  
Deze “stop”-studie toonde aan dat staken van acitretine therapie, leidt tot reductie van 
abnormale differentiatie in KIN laesies van niertransplantatiepatiënten met significante 
afname van K13 expressie. Staken van acitretine therapie had geen invloed op expressie van 
122  Chapter 4 
de markers MIB-1, p53 en p16. Dit suggereert dat retinoiden hun effect hebben middels 
verandering van differentiatie, zonder proliferatie of tumorsuppressor expressie te 
beïnvloeden. 
Een zebroid K13 patroon werd in 56% van de KIN laesies aangetroffen bij start van de studie 
met een dalende trend gedurende de 3 maanden studie periode (11%, 1/9 patiënten). Het 
lagere percentage KIN laesies met zebroide K13 expressie tijdens retinoidtherapie ten 
opzichte van wratten in de studie in hoofdstuk 4.1 (56% vs. 90%) zou  veroorzaakt kunnen 
worden door dysplastische veranderingen in de KIN laesies met afname van 
retinoidreceptoren of veranderde receptor interacties en/of veranderingen in keratine gen 
regulatie in dysplastische keratinocyten. 
Toekomstig onderzoek in biopten naar gecombineerde aanwezigheid van (zebroide) K13 
expressie en aanwezigheid van retinoidreceptoren in huidlaesies zou hierop mogelijk een 
antwoord kunnen geven. Eerder onderzoek naar retinoidreceptoren heeft al aangetoond dat 
deze af zouden nemen bij progressie van cutane tumoren. Ook onderzoek naar bijvoorbeeld 
K13 expressie binnen 1 patiënt ten tijde van retinoidbehandeling met zowel benigne als (pre) 
maligne huidlaesies kan zinvolle informatie opleveren over interlesionale verschillen in 
retinoid gevoeligheid van huidlaesies. 
In deze studie werd binnen de 3 maanden therapie stop een significante toename van wratten 
gezien, maar geen significante toename van (pre)maligne huidlaesies. Dit steunt 
bovenstaande veronderstelling met meer retinoidreceptoren in wratten ten opzichte van 
actinische keratosen. Patiënten waren ook significant minder tevreden over de cosmetische 
aspecten van de huid. Induratie van aktinische keratosen nam toe. Dit kan zeer goed verklaard 
worden door toename van hyperkeratose zonder retinoiden. Retinoiden werken namelijk door 
inductie van K13 antihyperkeratotisch doordat ze een niet verhoornende plaveiselcellige 
differentiatie induceren, en staken van medicatie geeft dan weer toegenomen keratinisatie. 
Alle 3 de studies duiden erop dat K13 expressie gerelateerd kan zijn aan twee onafhankelijke 
mechanismen, afhankelijk van het type expressie patroon: zebroid cq retinoid-geassocieerde 
keratinisatie versus single cell expressie cq duidend op maligne transformatie. 
In geen van de studies kon een evident anticarcinogeen effect van retinoiden worden 
aangetoond. Wel was er een cosmetische verbetering van de huid onder invloed van 
retinoidtherapie. 
Toekomstige studies, gerandomiseerd en gecontroleerd met histologie en 
immuunhistochemie, gedurende lange tijd en in grotere groepen van 
niertransplantatiepatiënten zullen meer uitsluitsel moeten geven omtrent een daadwerkelijk 
anticarcinogeen effect van retinoidtherapie.  
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Toen ik bijna 10 jaar geleden solliciteerde bij de afdeling Pathologie op de vacature van 
assistent in opleiding vanuit mijn kraambed, waren er 5 vacatures, waarbij de keuze was voor 
een zgn. AGIKO constructie, een aanstelling gekoppeld aan promotieonderzoek, ofwel een 
aanstelling als louter assistent pathologie. De keuze was voor mij toen gemakkelijk, namelijk 
geen onderzoek voor deze dame.  Gaandeweg de opleiding had ik al snel door dat ik een  
grote voorliefde had voor het gebied van de dermatopathologie. Professor van Haelst was 
degene die destijds dit vakgebied in het Radboud Ziekenhuis met een zekere haatliefde 
verhouding bedreef, altijd zeer accuraat beschrijvend en met wel overwogen conclusies. 
Wetenschappelijk onderzoek kwam voor mij pas later in beeld, aanvankelijk min of meer als 
must aangezien ik althans deels “academisch” wilde blijven werken. Wat begon als must 
werd later meer een lust; ik begon het onderzoek leuk te vinden. Het bleek creatiever dan de 
patiëntenzorg, met innovatieve ideeën die je kon uitwerken, zolang echter de financiële 
situatie het toeliet, want ik had geen project en moest bij elk ideetje weer ergens wat 
centen/en later euro’s zien los te peuteren en hopen dat ik analytische ondersteuning kreeg. 
De eerste 2 jaar heb ik regelmatig zelf met veel plezier trouwens ook  in het lab gestaan voor 
het kleuren van immuno’s en later het doen van PCR reacties. Daardoor heb ik veel respect 
en bewondering gekregen voor het werk van analisten ( die kunnen dit toch echt veel beter 
dan ik) en denk ik bovendien beter inzicht in het werken van en op zo’n lab. 
Bij het tot stand komen van dit proefschrift zijn vele mensen op verschillende manieren van 
belang geweest. Echter hoewel ik met veel liefde en plezier werk, zal dit toch altijd op de 2e 
plaats komen en wil ik beginnen met de mensen uit mijn privé omgeving te bedanken en 
vervolgens alle anderen. 
 
Een van de belangrijkste personen voor mij is natuurlijk mijn vriendman Harold, die altijd als 
belangrijke spil mede ons gezin met inmiddels een kwartet van kinderen, draaiend houdt. Die 
daarnaast bovendien altijd degene was die als pispaaltje fungeerde als het weer eens tegenzat 
en dat wonderbaarlijk genoeg met niet afnemende liefde bleef beantwoorden. Daarnaast 
leverde hij ook zeker een belangrijke wetenschappelijke bijdrage aan het tot stand komen van 
dit boekje door altijd mijn artikelen kritisch te lezen en door zijn onmisbare 
computerondersteuning. Dankzij hem werd ik van een computer nerd, langzaam een iets 
mindere nerd. Onze kindjes en grote gezamenlijke liefdes Jop (11), Ruth (9), Zoë (6) en 
recent de afsluiter in de rij Norah (1) zorgden en zorgen voor veel afleiding en de nodige 
relativiteit tav werk en onderzoek. Als vrouw kan je niet rustig werken als het thuisfront niet 
goed draait en dankzij onze oppas Door die reeds 10 jaar lang met veel toewijding ons gezin 
en onze was mede draaiend houdt was en ben ik in staat om te werken zoals ik heb gewerkt 
en nog vele jaren hoop door te werken. 
Pap. Mam, ook jullie stonden altijd klaar als er weer eens  geklust moest worden in onze 
money pitt, of als er weer eens een kinderopvangprobleem was. Datzelfde geldt voor mijn 
lieve zus Lenneke die zeer veel credit heeft opgebouwd en nog kan rekenen op vele jaren 
oppas van onze zijde nu ze zelf haar eerste dochter Sam heeft gekregen.  
Prof.Dr.D.J.Ruiter, Dirk (mocht ik zeggen vanaf mijn pathologenschap ca 3 jaar geleden 
waar ik overigens zeer aan moest wennen), mijn promotor, was degene die mij de kans bood 
om de dermatopathologie op academisch niveau te blijven beoefenen. Als onderzoeker in hart 
en nieren moest dat wel begeleid worden met een onderzoek en promotie. Jouw werksnelheid 
is echt bewonderenswaardig, evenals de workload die je kan verzetten en daar heb ik veel 
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bewondering voor. Niet zeuren, maar doen, hopelijk heb ik dat ook goed van jou mee 
gekregen. Daarnaast heb je een grote kennis op het gebied van melanocytaire laesies, die ik 
mezelf nu eigen aan het maken ben met jouw steun sinds jij begin 2004 decaan bent 
geworden. Jouw kennis op allerlei gebieden is zeer divers, en ook in het onderzoek in dit 
proefschrift hoewel dat niet primair jouw aandachtsveld was, is deze zeker zeer goed van pas 
gekomen. Jij zag ook direct het belang van goede samenwerking met de afdeling 
dermatologie zonder welke dit proefschrift er niet was geweest. Je stimuleert ook de 
zelfredzaamheid die je in het begin als onderzoeker soms wat hopeloos maakt ( uitspraken 
van jou : dat moet anders, maar hoe ? dat stond er dan niet bij. Of “it’s your baby” wat in 
mijn geval soms ook letterlijk zo was), maar uiteindelijk ervoor zorgt dat je een vrijwel 
zelfstandig onderzoeker wordt althans dat hoop ik dat ik ben geworden. Dank voor je 
expertise op zeer breed gebied. 
Prof.Dr.P.C.M. van de Kerkhof, Peter, mijn andere promotor, en in een aantal opzichten 
tegenpool en daardoor goed tegenwicht van Dirk. Door jouw enthousiasme (“ dit artikel is 
werkelijk fantastisch”) werd samenwerken met jouw afdeling heel plezierig en constructief 
niet alleen op het gebied van onderzoek maar ook op het gebied van patiëntenzorg, met een 
12 uur bespreking die nu wekelijks goed loopt en een dermatopathologie-stage die goed 
draait.  Ik bewonder ook bijzonder jouw sociale gaven, en de gelijkwaardige manier waarop 
je met anderen en ook met mij omgaat/ging, waardoor er volgens mij in jullie staf ook zoveel 
amicaliteit is naast toch ook veel respect voor elkaars kunnen en zijn. Je commentaar op 
artikelen was altijd snel, kort en bondig en constructief en je was altijd bereid om actief te 
participeren. Ik weet nog dat je voor het eerste artikel in de Archives over retinoiden in 
wratten zelf nog een patiënt thuis hebt opgebeld of hij echt geen retinoiden gebruikt had of 
crèmes en je een heel verhaal over scheerschuim moest aanhoren. Dank je voor je 
dermatologische kijk en grote expertise, inzet en zeer plezierige samenwerking. 
Dr.E.M.G.J. de Jong, Elke, in het begin was onze samenwerking enigszins met horten en 
stoten in verband met jouw zwangerschap en bijbehorend verlof dat viel vrij kort na de start 
van ons gezamenlijke onderzoek. Jurgen Smit en Peter van de kerkhof vingen echter samen 
de gang van zaken goed op en zo konden we toch vrij snel al de eerste resultaten 
neerschrijven. Later hebben wij de draad samen weer opgepakt en ik vond het erg plezierig 
dat jij ondanks jouw drukke bezetting altijd tijd probeerde vrij te maken voor zoveel mogelijk 
een reguliere afspraak om de 1 a 2 weken. Ik vond je als mens bijzonder plezierig in de 
omgang en je hebt de gave om mensen te sturen zonder erg op de voorgrond te staan. 
Daarnaast ben je een bijzonder goed en kundig dermatoloog want ook op het vlak van 
patiëntenzorg kwam ik je natuurlijk vaak tegen. De samenwerking met jou en jullie afdeling 
heeft voor mij veel meerwaarde gehad en bijgedragen aan mijn toegenomen, zij het nog 
steeds beperkte kennis van de dermatologie.   
Dr. P.C.M. de Wilde, Peter, mijn statistische steun en toeverlaat. Jouw bijdrage aan het tot 
stand komen van dit proefschrift was aanzienlijk. Jij was een zeer kritisch coauteur ( soms 
bijna te), en jouw zeer secure aanpak bood een goed tegenwicht aan mijn over 1 dag ijs gaan, 
zodat de stukken die wij samen produceerden uiteindelijk goed gefundeerd, maar toch niet te 
laat de pers bereikten. Als collega patholoog “next door”, heb ik je ook zeer gewaardeerd en 
zijn we in de loop der jaren vanuit mijn perspectief althans meer vrienden dan collegae 
geworden. Dat laatste mede door onze gedeelde liefde voor drank en spijs. Hoewel ik op het 
gebied van de vinologie ongetwijfeld een heidense barbaar ben in jouw ogen, want de witte 
wijnen laat ik staan. Hopelijk zullen we in de toekomst veel blijven samenwerken op het 
gebied van onderzoek en diagnostiek, want samen coupes kijken is iets wat we in de loop der 
jaren regelmatig deden en waaruit jouw grote kennis van de orale pathologie bleek, waarvan 
ik graag deelgenoot werd/word. Als tegenprestatie kijk ik dan graag naar  naevi of baso’s die 
de kaakchirurg per ongeluk mee verwijdert. 
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Dr. J.V. Smit, Jurgen, dankzij de samenwerking met jou kwamen de eerste publicaties snel 
van de grond. Jij bent inmiddels al toegetreden tot het gezelschap van doktoren middels je 
mooie proefschrift op 14 april 2003. Gelukkig kon ik daaraan ook een bescheiden bijdrage 
leveren. Ik vond het leuk om de patiënten poli’s die jij deed van de patiënten die deels 
studieobject waren van dit proefschrift bij te wonen bij de start van mijn onderzoek zodat ik 
een beter kader kreeg van de huidproblematiek bij niertransplantatiepatiënten. Ik weet dat je 
nu een zware periode privé doormaakt, maar hopelijk komen jullie daar goed doorheen. 
Mijn collega-pathologen in het CWZ, Marcel, Ewout, Carla, Erik, Anne en Ineke wil ik 
hartelijk bedanken voor de steun en interesse bij het tot stand komen van dit proefschrift. 
Veel van de artikelen zijn tot stand gekomen tussen de bedrijven door en ook in CWZ tijd 
heb ik heel wat zinnen op papier gezet. Vanaf september ga ik de efficiëntie uit de periferie 
echt wel missen, maar hopelijk kan ik er wat van meenemen naar de academie. Jullie 
collegialiteit hoop ik te behouden ook al is de afstand nu iets groter geworden. Saskia zal naar 
mijn idee de dermatopathologie in het CWZ zeer adequaat gaan overnemen. 
Veel analisten uit het Radboud, maar ook uit het CWZ (hier met name Ingrid en onder 
toeziend oog van de mijns inziens uitstekende en altijd tot medewerking bereid zijnde 
hoofdanalist Henk de Haard), hebben bijgedragen door het snijden van coupes en kleuren van 
deze, waarvoor mijn grote dank. Speciaal wil ik Monique Link bedanken en later Sabine 
Aalders, die veel van het uitstekende immuunhistochemisch werk hebben verricht voor de 
diverse publicaties. Dank ook aan Monique voor het bijbrengen van de basics van de 
immuunhistochemie zodat ik deels mijn eigen coupes kon kleuren. Ook speciale dank aan 
Marian van Dijk die monnikenwerk heeft verricht bij het tot stand komen van een goed 
lopende PCR voor INK4a-ARF mutaties. Dank aan Riki Willems voor de leerzame stage op 
het moleculaire lab. Dat viel erg tegen om zelf te doen. Petje af voor jullie expertise. 
Arie Maat dank voor het altijd probleemloos vers verwerken, splitsen en vriezen, van de 
huidjes voor het onderzoek van Jurgen en mij. En daarnaast ook voor de wekelijkse keek op 
de week op vrijdagmiddag als je met mij mee terugreed en –rijdt naar ons mooie land van 
Maas en Waal. 
Willem Melchers, dank aan jouw virlogische bijdrage aan het artikel over p14 en HPV, en 
dank voor de eindsprint die jij nog even hebt ingezet mede op verzoek van Han van Krieken 
(waarvoor dank Han) zodat ik het manuscript in mijn zwangerschapverlof van Norah kon 
afronden. 
Marjolein Ligtenberg ben ik veel dank verschuldigd bij het tot stand komen van het artikel 
over p53 en INK4a-ARF mutaties. Dankzij jouw bijdrage werd het uiteindelijk een 
uitstekende publicatie. 
Dank ook aan het alle secretaressen zowel op het CWZ als in het Radboud die voor mij 
ontelbare coupes en/of blokjes uit het archief hebben gelicht ( later hielp ook Wim Jansen 
hieraan mee) en/of mijn artikelen met veel zorg opstuurden. 
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Willeke Blokx werd geboren op 30 juni 1967 te Den Dungen. Van 1979 tot 1985 doorliep zij 
het Gymnasium Beekvliet te St. Michielsgestel. Na 2 jaar opleiding fysiotherapie aan de 
S.U.P.A. te Utrecht, ving zij aan met de studie geneeskunde aan de Rijksuniversiteit Utrecht. 
Zij behaalde haar doctoraalexamen cum laude in 1991. Van 1991 tot 1994 volgde zij haar co-
schappen waaronder een keuzeco-schap pathologie  in het AZU. Op 29 juli 1994 behaalde zij 
haar artsexamen. Na de geboorte van haar eerste zoon Jop, begon zij in februari 1995 aan 
haar opleiding tot patholoog op  de afdeling pathologie van het Universitair Medisch 
Centrum St. Radboud, met als afdelingshoofd en toenmalige opleider Prof.Dr.D.J.Ruiter. In 
het CWZ te Nijmegen volgde zij van 1-12-1997 tot 1-10-1998 de B-opleiding pathologie, 
met als opleider Dr.E.Schaafsma. Op 21 november 2000 voltooide zij de opleiding 
pathologie. Vanaf 1 december 2000 tot en met heden is zij werkzaam voor 2 dagen per week 
als klinisch patholoog in het CWZ te Nijmegen. Daarnaast werkte zij tezelfdertijd 2 dagen 
per week in het UMC St.Radboud, eerst vanaf 1 december 2000 tot 1 december 2002 als 
artsonderzoeker en vanaf 1 december 2002 als staflid bij de vakgroep pathologie. In de 
academische dagen werkte zij aan de onderzoeken welke geleid hebben tot dit proefschrift 
met daarnaast verrichten van patiëntenzorg met als aandachtsveld de dermatopathologie. 
Inmiddels is zij inmiddels tevens moeder van 4 kinderen (Jop, Ruth, Zoë en Norah) en 
vervult zij naast haar werkzaamheden hierboven samen met haar manvriend Harold van Rijen 
een zeer gelukkig co-ouderschap. 
Per 1 september 2005 zal zij geheel werkzaam worden in het UMC St.Radboud als chef de 
clinique op de afdeling pathologie, met nog steeds het geliefde aandachtsveld van 
dermatopathologie en onderzoek op dit gebied. 
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